FEED Validator

Congratulations!

This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

• line 40, column 0: description should not contain decoding attribute [help]

  					<description><![CDATA[<div style="margin-bottom:20px;"><img width="1200 ...
  

• line 40, column 0: description should not contain fetchpriority attribute [help]

  					<description><![CDATA[<div style="margin-bottom:20px;"><img width="1200 ...
  

• line 40, column 0: description should not contain sizes attribute [help]

  					<description><![CDATA[<div style="margin-bottom:20px;"><img width="1200 ...
  

• line 41, column 0: content:encoded should not contain decoding attribute (10 occurrences) [help]

  										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
  

• line 41, column 0: content:encoded should not contain sizes attribute (2 occurrences) [help]

  										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
  

• line 68, column 0: style attribute contains potentially dangerous content: max-height (194 occurrences) [help]

  										<content:encoded><![CDATA[<p>Delray Beach, FL, Oct. 13, 2025 (GLOB ...
  

• line 113, column 0: content:encoded should not contain referrerpolicy attribute (9 occurrences) [help]

  <p><img alt="" src='https://ml.globenewswire.com/media/MGI1ZjRjMGUtNmIyMC00N ...
  

• line 131, column 0: content:encoded should not contain loading attribute (3 occurrences) [help]

  <p align="justify"><img loading="lazy" decoding="async" height="260" src="ht ...
  

• line 624, column 0: content:encoded should not contain data-mce-href attribute (54 occurrences) [help]

  <p>Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global&#160;<a href="h ...
  

• line 626, column 0: content:encoded should not contain data-mce-src attribute (5 occurrences) [help]

  <p align="center"><img decoding="async" src="https://ml.globenewswire.com/Re ...
  

• line 630, column 0: content:encoded should not contain data-mce-style attribute (105 occurrences) [help]

  <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">North A ...
  

• line 889, column 3: content:encoded should not contain relative URL references: /api/ImageRender/DownloadFile?resourceId=aadf72b7-329a-47ab-9fce-b6048cb5b3c3&size=3 (2 occurrences) [help]

  ]]></content:encoded>
     ^

Source: https://singaporeoutlook.com/feed/

1. <?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
2. xmlns:content="http://purl.org/rss/1.0/modules/content/"
3. xmlns:wfw="http://wellformedweb.org/CommentAPI/"
4. xmlns:dc="http://purl.org/dc/elements/1.1/"
5. xmlns:atom="http://www.w3.org/2005/Atom"
6. xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
7. xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
8. xmlns:media="http://search.yahoo.com/mrss/" >
9.  
10. <channel>
11. <title>Singapore Outlook</title>
12. <atom:link href="https://singaporeoutlook.com/feed/" rel="self" type="application/rss+xml" />
13. <link>https://singaporeoutlook.com</link>
14. <description></description>
15. <lastBuildDate>Tue, 14 Oct 2025 02:44:45 +0000</lastBuildDate>
16. <language>en-US</language>
17. <sy:updatePeriod>
18. hourly </sy:updatePeriod>
19. <sy:updateFrequency>
20. 1 </sy:updateFrequency>
21. <generator>https://wordpress.org/?v=6.8.3</generator>
22.  
23. <image>
24. <url>https://singaporeoutlook.com/wp-content/uploads/2023/08/apple-touch-icon-150x150.png</url>
25. <title>Singapore Outlook</title>
26. <link>https://singaporeoutlook.com</link>
27. <width>32</width>
28. <height>32</height>
29. </image>
30. <item>
31. <title>AI Joins the Frontline of Disaster Risk Reduction in Sikkim</title>
32. <link>https://singaporeoutlook.com/ai-joins-the-frontline-of-disaster-risk-reduction-in-sikkim-30172/</link>
33. <comments>https://singaporeoutlook.com/ai-joins-the-frontline-of-disaster-risk-reduction-in-sikkim-30172/#respond</comments>
35. <dc:creator><![CDATA[News Desk]]></dc:creator>
36. <pubDate>Tue, 14 Oct 2025 02:43:57 +0000</pubDate>
37. <category><![CDATA[India]]></category>
38. <guid isPermaLink="false">https://singaporeoutlook.com/?p=30172</guid>
39.  
40. <description><![CDATA[<div style="margin-bottom:20px;"><img width="1200" height="675" src="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" fetchpriority="high" srcset="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9.jpg 1200w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-300x169.jpg 300w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-1024x576.jpg 1024w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-768x432.jpg 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></div>Every year, extreme weather events are becoming more frequent and unpredictable, testing the resilience of mountain communities. Yet, amid this uncertainty, one thing is becoming clear: investing in preparedness saves more lives and resources than responding after a disaster strikes. This is the message behind this year’s International Day for Disaster Risk Reduction, themed “Fund Resilience, [&#8230;]]]></description>
41. <content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="1200" height="675" src="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" srcset="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9.jpg 1200w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-300x169.jpg 300w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-1024x576.jpg 1024w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-9-768x432.jpg 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></div><p>Every year, extreme weather events are becoming more frequent and unpredictable, testing the resilience of mountain communities. Yet, amid this uncertainty, one thing is becoming clear: investing in preparedness saves more lives and resources than responding after a disaster strikes. This is the message behind this year’s International Day for Disaster Risk Reduction, themed “Fund Resilience, Not Disasters.”</p>
42. <p>In Sikkim, this philosophy is already taking root through innovations that merge technology, education, and community action. This year, on September 18, Chief Minister Prem Singh Tamang inaugurated an Automatic Weather Station at the SSDMA office in Gangtok. On the surface, it is a piece of advanced equipment that captures real-time weather data. But its meaning goes far beyond numbers.</p>
43. <p>Just a few kilometres away, students at Modern Senior Secondary School in Tathangchen are part of what is called the “Sunny Weather Labs.” These labs, set up by SEEDS in collaboration with local leaders, are small school-run weather stations designed to generate micro-level weather data. The first labs were launched in Sikkim in March 2020, and since then, every morning, children take readings, record rainfall, track wind shifts, and even sketch graphs on their classroom blackboards.</p>
44. <p><img decoding="async" class="alignnone size-medium wp-image-30175" src="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-10-300x169.jpg" alt="" width="300" height="169" srcset="https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-10-300x169.jpg 300w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-10-1024x576.jpg 1024w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-10-768x432.jpg 768w, https://singaporeoutlook.com/wp-content/uploads/2025/10/featured-10.jpg 1200w" sizes="(max-width: 300px) 100vw, 300px" /></p>
45. <p>They bring these observations home, discussing them with families, creating a ripple effect of awareness across their neighbourhoods. Technology like the AWS strengthens this effort, turning grassroots observations into hyper-local advisories for both families and authorities.</p>
46. <p>Sunny Weather Labs also fit into a much larger ambition. SEEDS has long believed that resilience is built not just through large-scale infrastructure, but through everyday engagement with risk. By creating citizen scientists at a young age, the program lays the foundation for communities that are more alert, informed, and ready to act. At the same time, the micro-data generated has the potential to feed into bigger technological solutions, including the use of artificial intelligence to identify households most at risk from storms, heatwaves, or floods.</p>
47. <p>While the initiative begins at the grassroots with young citizen scientists, its impact reaches far beyond. The Sunny Weather Labs initiative aligns with Microsoft’s AI for Humanitarian Action program, which seeks to apply technology to some of the world’s most pressing challenges, including climate change and disaster response. Taken together, these efforts open up a new frontier: AI for communities. When artificial intelligence is placed directly in the hands of those most affected &#8211; villagers, teachers, local leaders, frontline workers &#8211; it turns technology into a powerful tool for everyday resilience.</p>
48. <p>If decision-makers, managers, and frontline workers are skilled in AI, the impact can be multiplied many times over. Real-time analysis of weather patterns, predictive mapping of vulnerabilities, and hyper-local advisories could become a routine part of community life. What Sikkim has already demonstrated through its labs and early warning systems can be taken much further with AI, scaling preparedness and empowering people at every level.</p>
49. <p>This is more than an upgrade in technology &#8211; it is a game changer for building climate and disaster resilience at the community level. And in the wider context of humanitarian action, it offers a model that can be replicated across other vulnerable regions.</p>
50. <p>As the world marks the International Day for Disaster Risk Reduction, it is time to rethink how we allocate resources. True resilience does not start in response budgets. It starts in classrooms, community centers, and labs like these. If we are to “fund resilience, not disasters,” we must invest in local innovations that equip vulnerable communities with the knowledge, tools, and technologies to face the next storm before it arrives.</p>
51. ]]></content:encoded>
53. <wfw:commentRss>https://singaporeoutlook.com/ai-joins-the-frontline-of-disaster-risk-reduction-in-sikkim-30172/feed/</wfw:commentRss>
54. <slash:comments>0</slash:comments>
57. </item>
58. <item>
59. <title>Polyols Market worth $21.59 billion by 2030, at a CAGR of 5.1%, says MarketsandMarkets™</title>
60. <link>https://singaporeoutlook.com/polyols-market-worth-21-59-billion-by-2030-at-a-cagr-of-5-1-says-marketsandmarkets-30170/</link>
62. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
63. <pubDate>Mon, 13 Oct 2025 23:00:00 +0000</pubDate>
64. <category><![CDATA[Brand Post]]></category>
65. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165846/0/en/Polyols-Market-worth-21-59-billion-by-2030-at-a-CAGR-of-5-1-says-MarketsandMarkets.html3165846</guid>
66.  
67. <description><![CDATA[Delray Beach, FL, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The Polyols Market was valued at USD 16.01 billion in 2024 and is projected to reach USD 21.59 billion by 2030, at a CAGR of 5.1%, as per the recent study by MarketsandMarkets™. Polyols are functional compounds characterized by multiple hydroxyl (-OH) groups. In commercial formulations, they are essential [&#8230;]]]></description>
68. <content:encoded><![CDATA[<p>Delray Beach, FL, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; <b>The </b><a href="https://www.globenewswire.com/Tracker?data=w2xb3q9lkN-XXoCbJTy-KhcuiLaJfzoSLR5vaHg3FU6b6r9le2E0gZMIOVttlur8YOQeghmtNqxn3cxF3RVKZOcQUVgA9wGQ1NG_ImQBLx1fOQ7L0reQKlB87S-YEgwWlAwtvqXqYVmEITC7FBETeUVAeba5ZE3_CZB3irMncXZ0EFXJt_JPF_TiWUerMev_5G9Fy3mRy5TpEksiOIIqeFRkNw6ERiNFH0KnkmwdBwNzkhJ7kuHhnMdrgxYi-Zj0" rel="nofollow noopener" target="_blank" title=""><b>Polyols Market</b></a><b> was valued at USD 16.01 billion in 2024 and is projected to reach USD 21.59 billion by 2030, at a CAGR of 5.1%, as per the recent study by MarketsandMarkets<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />. </b>Polyols are functional compounds characterized by multiple hydroxyl (-OH) groups. In commercial formulations, they are essential feedstocks for producing polyurethanes. When polyols react with isocyanates, they form polyurethane foam, elastomers, coatings, adhesives, and sealants. Polyols can be classified as either polyether polyols or polyester polyols, each providing the end product with unique functionalities. They are derived from petrochemical feedstocks or renewable sources such as natural oils and sugars. Polyols can be modified to enhance the versatility and performance of plastic products. They are key feedstocks in construction, automotive, furniture, packaging, and consumer goods. The use of more bio-based polyols is expected to grow as regulatory and sustainability pressures increase worldwide.</p>
69. <p><b>Download PDF Brochure: </b><a href="https://www.globenewswire.com/Tracker?data=ac4VnYbMrIBWs7AVB_LdOwVH6dpG9tMQy97jOPAM6eDAzwkSiG0mTC3N7rAhckv7OamSUKjAwICCZmYIsLZ6xM0G8r7RJlWIdz483mWwfEvMCKJnJoSGOf9-E9gGfV_sZFQzISADr0EBoT-mlYQbaPwge1pmNBJbPD3Wmbru5wHcZIWw4umUp6KD73qqv6en4f8Yy8TzrGBmsIy6G5T2KHJk2s_KN6XF_ylD7D68O-oMK7dPSwB-JW_bm3o-IeXrv5hTxD9CmLX7GSXxuLz3S0MU1936tiYO2z2v6RaCT04=" rel="nofollow noopener" target="_blank" title=""><b>https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=725</b></a></p>
70. <p><b>Browse in-depth TOC on “Polyols Market”</b></p>
71. <p><b>415 &#8211; Market Data Tables</b><br /> <b>58 – Figures</b><br /> <b>297 &#8211; Pages</b></p>
72. <p><b>List of Key Players in Polyols Market:</b></p>
73. <ol type="1">
74. <li style="margin-top:0cm; margin-bottom:8pt;" value="1">DOW (US)</li>
75. <li style="margin-top:0cm; margin-bottom:8pt;">Covestro AG (Germany)</li>
76. <li style="margin-top:0cm; margin-bottom:8pt;">BASF SE (Germany)</li>
77. <li style="margin-top:0cm; margin-bottom:8pt;">Huntsman International LLC (US)</li>
78. <li style="margin-top:0cm; margin-bottom:8pt;">Shell (UK)</li>
79. <li style="margin-top:0cm; margin-bottom:8pt;">Stepan Company (US)</li>
80. <li style="margin-top:0cm; margin-bottom:8pt;">Wanhua Chemical Group (China)</li>
81. <li style="margin-top:0cm; margin-bottom:8pt;">Repsol S.A. (Spain)</li>
82. <li style="margin-top:0cm; margin-bottom:8pt;">PCC SE (Germany)</li>
83. <li style="margin-top:0cm; margin-bottom:8pt;">LANXESS (Germany)</li>
84. </ol>
85. <p><b>Drivers, Opportunities and Challenges in Polyols Market:</b></p>
86. <ol type="1">
87. <li style="margin-top:0cm; margin-bottom:8pt;" value="1"><b>Drivers: </b>Growth of packaging industry</li>
88. <li style="margin-top:0cm; margin-bottom:8pt;"><b>Restraint: </b>Complexity in recycling polyurethane products<b><br /> Opportunity: </b>Growing adoption of bio-based polyols</li>
89. <li style="margin-top:0cm; margin-bottom:8pt;"><b>Challenge: </b>Eco-friendly alternatives</li>
90. </ol>
91. <p><b>Get Sample Pages: </b><a href="https://www.globenewswire.com/Tracker?data=ac4VnYbMrIBWs7AVB_LdOwVH6dpG9tMQy97jOPAM6eAPjVDz97cndCPFTHDucqSzFxct6iNm7bU1TXm9aTE1neKPodrYno0kowXHY3hL4I9QJRsFYVdRQRnH7bKj9ilKT_atWVzMiOrCo7fkZ-WdtZqsp2O_kYcPoeyjnup59CRGKMNsx8L9jN6791socTF45nwA93OpZPZM49FeY-T7i4ttvN4dlvnhnHQX3WdoIUDPQgwia6-79cA8_qnXlv-KvZncpVD9UJGBSyk1w4D72r7BkS0FcAjVdqcg2xQ7sTk=" rel="nofollow noopener" target="_blank" title=""><b>https://www.marketsandmarkets.com/requestsampleNew.asp?id=725</b></a></p>
92. <p><b>Key Findings of the Study:</b></p>
93. <ul type="disc">
94. <li style="margin-top:0cm; margin-bottom:8pt;"><b>By application, flexible polyurethane foam segment to register highest CAGR during forecast period</b></li>
95. <li style="margin-top:0cm; margin-bottom:8pt;"><b>By end-use industry, building &amp; construction segment accounted for largest market share in 2024</b></li>
96. <li style="margin-top:0cm; margin-bottom:8pt;"><b>Asia Pacific accounted for largest market share in 2024</b></li>
97. </ul>
98. <p>The polyols market has been divided by type into polyether polyols and polyester polyols, with each group producing different end-uses based on their chemical structure and performance. Polyether polyols are widely used in the industry mainly due to their low viscosity, high reactivity, and compatibility with isocyanates. They are primarily employed to produce flexible and rigid polyether foams for furniture, automotive interiors, and bedding. Polyester polyols, on the other hand, offer higher mechanical strength, chemical resistance, and thermal stability, making them more suitable for CASE (coatings, adhesives, sealants, and elastomers) applications. While polyether polyols dominate in terms of volume used, polyester polyols are utilized more broadly where performance and durability are critical. Ultimately, choosing between the two depends on the performance requirements of the industry and product.</p>
99. <p>The polyols market has been segmented by application into flexible polyurethane foam, rigid polyurethane foam, and coatings, adhesives, sealants &amp; elastomers (CASE). Flexible polyurethane foam is the largest application segment overall, used for making furniture, mattresses, automotive seating, and packaging because of its comfort, cushioning, and lightweight properties. Rigid polyurethane foam is mainly used for insulation in construction and refrigeration, offering excellent thermal and structural performance. The CASE application segment uses polyalcohols as precursors to create high-performance coatings, adhesives, sealants, and elastomers, with end-use industries including automotive, construction, electronics, and others. Each application needs a specific formulation to meet different performance requirements: flexible foam focuses on softness and resilience; rigid foam emphasizes mechanical strength and insulation; and the CASE segment prioritizes durability and resistance. These application segments showcase the broad versatility of polyol chemistry across various end-use sectors.</p>
100. <p><b>Get Customization on this Report: </b><a href="https://www.globenewswire.com/Tracker?data=ac4VnYbMrIBWs7AVB_LdOwVH6dpG9tMQy97jOPAM6eAPjVDz97cndCPFTHDucqSzoWmbh-2Xju6DngneUHlGL-HA9wmuD4DVdfuJvT5OcT4Bl9-hl_bqwooCvBAuHpVCU2qY2tuL3ma3n14zhjIWu8lsp6Ru7kJLFFWFYjG-ig28AHijab2z0hmA2DMzbKMqTpYyudZbX6a934RtpA7qvSiej3g-TVXwsW7zoOO8K8LHod1PR4Hr4oRtYgEW5nP6jUbuJU1aOOYkSWuoXgNX2co_sMlIDQjKQvxGK6bt8R_HqoBs6JIciMjyXSwt1UBo" rel="nofollow noopener" target="_blank" title=""><b>https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=725</b></a></p>
101. <p>The polyols market has been segmented by end-use industry, including building &amp; construction, automotive, furnishing, packaging, electronics, and other end-use industries. In the building &amp; construction sector, polyols are vital for manufacturing rigid polyurethane foams used in thermal insulation, roofing, and wall systems. The automotive segment features both flexible and rigid foams used in seating, interior trim, and lightweight parts to enhance fuel efficiency and comfort. In the Furnishing industry, flexible foams derived from polyols play an important role in mattresses, cushions, and upholstered furniture. The packaging industry utilizes polyols in protective foams to provide effective thermal insulation in cold-chain logistics. The electronics segment includes encapsulants and sealants that protect interfaces between electronic devices from moisture, heat, and other physical damage that could harm delicate components. While the purpose of each end-use segment varies significantly, it highlights the versatility and importance of polyols across many industrial sectors.</p>
102. <p>The polyols market has been analyzed across five regions: Asia Pacific, Europe, North America, the Middle East &amp; Africa, and South America. Asia Pacific holds the largest share of the global polyols market and is also the fastest-growing region. Key growth drivers include rapid urbanization, expansion of the construction and automotive industries, and higher consumer demand in countries like China, India, South Korea, and the broader Southeast Asia region. Additionally, a strong manufacturing base, lower production costs, and increased investment in infrastructure support ongoing growth. Local, regional, and international companies are strengthening their positions by expanding production capacities and diversifying product offerings, contributing to the region’s expansion in the polyols market. North America ranks second in market share, driven by steady demand in construction, furniture, and automotive industries and a rising interest in bio-based polyols. Europe, a mature market, continues to evolve toward innovation under influences from government regulations, environmental considerations, and a shift toward sustainable manufacturing, which is transforming the polyurethane industry. In emerging markets such as the Middle East &amp; Africa and South America, consumption of polyurethane-based products is expected to increase further in building insulation, consumer goods, and transportation. While each region presents different opportunities and challenges based on raw materials, energy policies, and consumer demand, Asia Pacific remains the primary growth driver for the polyols market, fueled by its industrial base, demographics, and growing demand for energy efficiency and lightweight materials across various applications.</p>
103. <p><b>Browse Adjacent Markets </b><a href="https://www.globenewswire.com/Tracker?data=NgQc_OEQVrzdjehOV01c8Vp-VjDlE_zfbS08G0nCpprDiHVJ0AuA5TbyPKWWHtbY8kG_iPwBsS_z0EWnFxQmpqHeuo-NF25OIVuiZ6tpNwsnADNF-dzW2YodC8UMHhZjcxpwhukiXbiup0lKcgUWsCbhJcyz3-_aS72qVydo---0L2uvY3fO9L6tU_m6puNAymF4Viammi2N_dM59-rSiKiokyEYjxqZAIi1XhQIttPioHxAJrMCE1P-RTLCD-mehXOo1uKe8MocA8jVM3G6LCcCGy-Xg3X9jLW1KMdJMNU=" rel="nofollow noopener" target="_blank" title=""><b>Advanced Materials Market Research Reports</b></a><b> &amp; Consulting</b></p>
104. <p><b>Related Reports:</b></p>
105. <ol type="1">
106. <li style="margin-top:0cm; margin-bottom:8pt;" value="1"><a href="https://www.globenewswire.com/Tracker?data=OJjaquG5udmj_pIa-ofNCVPz-46NqNCMv449INLm75WsAMdVBUDlB2O_B6ofYu-X9QCnm9q5cnEa8HVZ6TY85uq6rSff2trRQ1Wg8Bxtks4PHESONBGEK0SpDC-M4TgpwJ_izvx42wTBd43Mbn-qcH9wa0EOctHVVkSQOTRhBEQUNPyCIV3cAS43aXWkhHdgB9VFri14vtsEkZLd5uG7rl4NCCuUxOPygYUX7i6S5gKRucxx4JslJDEOmtDHPhO0ElswmIEpNSRpGTqlEHisqw==" rel="nofollow noopener" target="_blank" title=""><b>Coated Fabrics Market</b></a></li>
107. <li style="margin-top:0cm; margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=RRS15xb2QAOjYnEMkSy15-U0PP69iwy47WZeDJU-eq-CbFcv5NAmhogd7d5kQuUtvebhuNynLWtw63edX-tdt3DHXw3iv6Ji2vk4FOnqLoYxVzKfQuo14KIZpJLAKQIfqVlm-5rw88NMQxU__g9Nks8WEujD0frYPy7llYXimK9ZRXy62ccvJpb5ml75mdUbBPgOZXf7JgirzjwmKoADIk1SgAkzeDXUtXMX4lxgNwLeO3s8Y0qjRuIbViJ99A6_gLrk8kZ-ik-bBQh4Gaq-fw==" rel="nofollow noopener" target="_blank" title=""><b>Texture Paint Market</b></a></li>
108. <li style="margin-top:0cm; margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=51sUmc66MhlhuShLX2dDyYbgYpGrqaOe12IkQbn5VyinryWblO4sjbVIYL5NEhzvokbmhiXQtVd_3MvitQ9zDKDKrSXVXIzqnNjEej9wWTNxghi6H49zbJGWES2lAepewJRkczOlJt-BN3A6tXsSgqXYWyJg-lSc2Sdfm5hkmSGfPx4zDn8vvlaBEw3ZtFwK0273kEV4swqZzcnODkUREDTRbn7F1DKQKdsX06z6SriM4huYU_SYVhDpc3otmbs-KFXT4_n38SXqEsg6qxRFBiQWdisY-PA-dvZMFBa3mIU=" rel="nofollow noopener" target="_blank" title=""><b>Isobutyric Acid Market</b></a></li>
109. <li style="margin-top:0cm; margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=VPgcoqmCC7T65gVe6DZbrK04kU0cSfewjk1kjGKRW1W6h9i5aNSlnynS0MZmAVPvDJCnfX0YEnMGqMBmPP7JhLRWYx_Ms5mKEab-0doSJG1XuHKYTMiBIatFTydJ6F85WKU-t3gcN4eHf5_3ltTE33wU2c2uIRjylbmtaktkG_60-QCEZyR8RkOTot_Ymmmlsn5kx4BbD2JU-lm0v7uzBcabZeXJfKOyLfw5a8ZxP-974FuCmMrv4X5Z4Ug20NomxuIZ56A1wM5Bg5WbkM8oIPmFncLOEIQuNhZ5pt2HF7Y=" rel="nofollow noopener" target="_blank" title=""><b>Marine Lubricants Market</b></a></li>
110. <li style="margin-top:0cm; margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=0pjOXcbl4uZvy50H8KR7dwTbMzBgV-hdNB2UbPJhiYOAAvG3XJ8928LJoLhG_hMjOZERyWym4e9Zxff95q7Efx2wEAlY8Pq9NUiTFdBBGaCWSoFsq6FMqUnYMFzKag0TfL1aZ1Jbjndq7m7AnxokZewgpluUBUyBQsL8c4b0GA9os21qfasSKsuoBi-8OLDRa4P0ExEUuvNUHfEcAtPG_AFKI1KKFSs12_PMc_WytSrUKTbOiZXNz0z94X3ogvFlpso-jlxpnMb_LJjGYxy4NcO2A8s5qYdTjaXIAJ0Ymd8=" rel="nofollow noopener" target="_blank" title=""><b>Hydrogen Storage Market</b></a></li>
111. </ol>
112. <pre>CONTACT: About MarketsandMarkets&#x2122; MarketsandMarkets&#x2122; has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets&#x2122; is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore&#x2122;, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets&#x2122;.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets&#x2122; INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.com</pre>
113. <p><img alt="" src='https://ml.globenewswire.com/media/MGI1ZjRjMGUtNmIyMC00NjcyLWI2YWYtNDU1ZTI2MTdiOWE2LTEyMDYwNjctMjAyNS0xMC0xMy1lbg==/tiny/MarketsandMarkets-Research-Pvt.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
114. ]]></content:encoded>
118. </item>
119. <item>
120. <title>EDENA Token Lists on Indonesia&#8217;s Largest Exchange Indodax, Followed by Mobee Exchange</title>
121. <link>https://singaporeoutlook.com/edena-token-lists-on-indonesias-largest-exchange-indodax-followed-by-mobee-exchange-30151/</link>
123. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
124. <pubDate>Mon, 13 Oct 2025 17:00:00 +0000</pubDate>
125. <category><![CDATA[Brand Post]]></category>
126. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165717/0/en/EDENA-Token-Lists-on-Indonesia-s-Largest-Exchange-Indodax-Followed-by-Mobee-Exchange.html3165717</guid>
127.  
128. <description><![CDATA[Universal Utility Token Enables Global Investors to Access Tokenized Assets Across ASEAN and MENA Markets Jakarta, Indonesia , Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; EDENA Capital Nusantara, operator of government-partnered STO platforms in Indonesia and Egypt, today announced the listing of EDENA Token on Indodax, Indonesia&#8217;s leading cryptocurrency exchange by volume and user base, on [&#8230;]]]></description>
129. <content:encoded><![CDATA[<p><em>Universal Utility Token Enables Global Investors to Access Tokenized Assets Across ASEAN and MENA Markets</em></p>
130. <p align="justify" id="isPasted">Jakarta, Indonesia , Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; EDENA Capital Nusantara, operator of government-partnered STO platforms in Indonesia and Egypt, today announced the listing of EDENA Token on Indodax, Indonesia&#8217;s leading cryptocurrency exchange by volume and user base, on October 17, followed by Mobee exchange on October 18. The token, currently trading at $3.2 on CoinStore, serves as the exclusive gateway for purchasing Security Token Offerings (STOs) across all EDENA platforms globally.</p>
131. <p align="justify"><img loading="lazy" decoding="async" height="260" src="https://blockchainwire.s3.amazonaws.com/4a09c33b6bcc75d218418e14c5fd45bd/editor_image/Untitled%20design%20%285%29.png" width="470" /></p>
132. <p align="justify"><b>Two Regional Hubs, One Global Token</b></p>
133. <p align="justify">EDENA operates two strategic STO platforms serving distinct regional markets while offering global asset access:</p>
134. <ul>
135. <li style="list-style-type:disc;"> Indonesia Platform: Serves ASEAN&#8217;s 700 million population, launching with Indonesian carbon credits and expanding to global carbon credit markets </li>
136. <li style="list-style-type:disc;"> Egypt Exchange: Covers MENA and Africa&#8217;s 1.9 billion people, starting with Egyptian real estate and scaling to international property markets </li>
137. </ul>
138. <p align="justify">The revolutionary aspect: investors worldwide can access assets listed on either platform using EDENA tokens. An investor in Singapore can purchase Egyptian real estate through the Indonesia platform, while a Dubai-based fund can acquire Indonesian carbon credits via the Egypt exchange.</p>
139. <p align="justify"><i>&#8220;EDENA&#8217;s Digital Financial Asset platform represents a strategic catalyst for Indonesia&#8217;s economic transformation,&#8221;</i> said Deputy Minister of Investment Todotua Pasaribu. <i>&#8220;We expect billions of dollars in foreign direct investment to flow through EDENA&#8217;s platform, positioning Indonesia as ASEAN&#8217;s digital finance hub.&#8221;</i></p>
140. <p align="justify"><b>Immediate Pipeline of Tokenized Assets</b></p>
141. <p align="justify"><b>Q4 2025 &#8211; Indonesia Platform Launch Preparation:</b></p>
142. <ul>
143. <li style="list-style-type:disc;"> Carbon credits from Indonesia, the world&#8217;s third-largest carbon sink </li>
144. <li style="list-style-type:disc;"> Platform testing and regulatory finalization </li>
145. </ul>
146. <p align="justify"><b>Q1 2026 &#8211; Egypt Exchange Launch:</b></p>
147. <ul>
148. <li style="list-style-type:disc;"> $250 million Cairo real estate development project First major </li>
149. <li style="list-style-type:disc;"> STO offering in MENA region </li>
150. </ul>
151. <p align="justify"><b>Expansion Pipeline:</b></p>
152. <ul>
153. <li style="list-style-type:disc;"> <b>Indonesia Platform:</b> Government-regulated carbon credits from Korea and Japan, voluntary carbon credits from Brazil, Congo Basin, and other major carbon markets globally </li>
154. <li style="list-style-type:disc;"> <b>Egypt Exchange:</b> Premium real estate from Dubai, London, New York, and other international markets </li>
155. <li style="list-style-type:disc;"> <b>Both Platforms:</b> Infrastructure projects, commodity-backed tokens, and institutional-grade investment products  </li>
156. </ul>
157. <p align="justify"><b>Why EDENA Token Demand Will Surge</b></p>
158. <p align="justify">As institutional investors recognize upcoming STO launches, strategic EDENA token accumulation becomes critical:</p>
159. <ul>
160. <li style="list-style-type:disc;"> <b>Limited Supply, Growing Demand</b>: Each major STO launch requires substantial EDENA tokens for participation </li>
161. <li style="list-style-type:disc;"> <b>First-Mover Advantage:</b> Early token holders secure priority access to oversubscribed offerings </li>
162. <li style="list-style-type:disc;"> <b>Cross-Border Efficiency:</b> Single token enables instant investment across all jurisdictions </li>
163. </ul>
164. <p align="justify"><i>&#8220;When a $250 million real estate project launches, institutional investors will need millions in EDENA tokens to participate,&#8221;</i> explained Wook Lee, CEO of EDENA Capital Nusantara. <i>&#8220;Smart money accumulates before the rush.&#8221;</i></p>
165. <p align="justify"><b>Proven Execution and Government Support </b></p>
166. <ul>
167. <li style="list-style-type:disc;"> Joint venture with Egypt&#8217;s BEK Group, led by former Prime Minister Ibrahim Mahlab </li>
168. <li style="list-style-type:disc;"> Keynote speaker at India&#8217;s Tamil Nadu Global Startup Summit (30,000 participants) </li>
169. <li style="list-style-type:disc;"> Strategic cooperation with Indonesia&#8217;s Ministry of Investment targeting $10 billion FDI </li>
170. <li style="list-style-type:disc;"> ISO 27001 and ISO 9001 certifications </li>
171. <li style="list-style-type:disc;"> Operations spanning 70+ countries through strategic partnerships </li>
172. </ul>
173. <p align="justify"><b>Global Exchange Expansion Strategy</b></p>
174. <p align="justify">Following Indonesian listings, EDENA is finalizing dates with three top-10 global exchanges for Q4 2025, plus strategic regional expansions:</p>
175. <ul>
176. <li style="list-style-type:disc;"> <b>ASEAN Markets:</b> Leading exchanges in Thailand, Vietnam, Korea </li>
177. <li style="list-style-type:disc;"> <b>MENA &amp; Africa:</b> Premier platforms in Dubai, Nigeria, Kenya </li>
178. </ul>
179. <p align="justify">This multi-regional approach ensures maximum accessibility for local investors while maintaining global reach.</p>
180. <p align="justify"><b>Token Utility Benefits</b></p>
181. <ul>
182. <li style="list-style-type:disc;"> <b>Exclusive Access:</b> Only method to purchase STOs on EDENA platforms </li>
183. <li style="list-style-type:disc;"> <b>Fee Discounts:</b> Up to 50% reduction on trading fees </li>
184. <li style="list-style-type:disc;"> <b>Priority Rights:</b> First access to premium offerings </li>
185. <li style="list-style-type:disc;"> <b>Global Reach:</b> One token for all assets across all platforms </li>
186. <li style="list-style-type:disc;"> <b>24/7 Trading:</b> Round-the-clock liquidity </li>
187. </ul>
188. <p align="justify"><b>The $16 Trillion Opportunity</b></p>
189. <p align="justify">Boston Consulting Group projects the tokenization market will reach $16 trillion by 2030. EDENA positions itself to capture significant market share by:</p>
190. <ul>
191. <li style="list-style-type:disc;"> Connecting 2.6 billion people across ASEAN-MENA regions </li>
192. <li style="list-style-type:disc;"> Minimum investment from $10 (versus traditional $1M+ minimums) </li>
193. <li style="list-style-type:disc;"> Instant settlement (versus 6-12 months for traditional real estate) </li>
194. <li style="list-style-type:disc;"> Full regulatory compliance with government partnerships </li>
195. </ul>
196. <p align="justify"><i>&#8220;EDENA isn&#8217;t just another token – it&#8217;s the key to democratizing global investment,&#8221;</i> added Lee. <i>&#8220;Whether you&#8217;re an institutional investor in London or a retail investor in Jakarta, EDENA token provides equal access to premium tokenized assets worldwide.&#8221;</i></p>
197. <p align="justify"><b>Join EDENA</b></p>
198. <ul>
199. <li style="list-style-type:disc;"> Website: <a href="https://www.globenewswire.com/Tracker?data=2hYutbcSTVRT59CTGEGjLFbS_f1YDMHyLE6LE1N0S1UItE5MN-U9_CqGxMZeeJFFI0awWCZl4hG2x__CxnDHzwaQ1U99zRahidmHLzvM8Sc=" rel="nofollow noopener" target="_blank" title="">https://edenatoken.com/</a> </li>
200. <li style="list-style-type:disc;"> Twitter/X: <a href="https://www.globenewswire.com/Tracker?data=2hYutbcSTVRT59CTGEGjLLYp3QJG_tjFTVRjwXWYvoAMUzqveV6QwgcK7UnmdaZ5eeEkre_SazOaS5ETzgOFPDGQDKtBS44zQUWVijB57nATLPCRuD0b3yf6lkcI7uS7" rel="nofollow noopener" target="_blank" title="">https://twitter.com/edenaofficial</a> </li>
201. <li style="list-style-type:disc;"> Telegram: <a href="https://www.globenewswire.com/Tracker?data=2hYutbcSTVRT59CTGEGjLLFvClhRe7XroYGqjQBPZmFFmX8pkBcn2rZ6y8RUDlUrzFIiC3jScrxbVi8Oc7eTt7dxfkWq6eWBRa05fGFeuF0=" rel="nofollow noopener" target="_blank" title="">https://t.me/EDENAofficial</a> </li>
202. </ul>
203. <p align="justify"><b>About EDENA Capital Nusantra</b></p>
204. <p align="justify">PT Edena Capital Nusantara operates regulated STO platforms in Indonesia for ASEAN markets and Egypt for MENA-Africa regions. The platforms tokenize global real-world assets including real estate, carbon credits, and infrastructure projects, enabling fractional ownership from $10 with 24/7 trading capabilities.</p>
205. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=8bILJkCuMD_RRAGx3eS5LYCd-TdlnYeIfKkUvRfCXhZRCAGyhIblYA8IiP7e0K4avqoG8L2w6SHImuMIDcOTrQ==" rel="nofollow noopener" target="_blank" title="Website">Website</a> | <a href="https://www.globenewswire.com/Tracker?data=4JT7ynRsVNUmwryhwQ7Kml3oHB9DMOpFVyASwugaYAhRa2bdJ9Fgl8xZhXaHmCCfRx74me3qYZTHVgi43fcAcqf8ykSMxkZUpIcEqdOEP4s=" rel="nofollow noopener" target="_blank" title="Twitter">Twitter</a> | <a href="https://www.globenewswire.com/Tracker?data=s6a-7nL7r4GTC2TRRy2xE-5OVZv1YcZIIQLsMLHCzOaqeQ0TPvJklnpVPCqK3kOqcG78JOAR8uOQpfut4Saw5A==" rel="nofollow noopener" target="_blank" title="Telegram">Telegram</a> | <a href="https://www.globenewswire.com/Tracker?data=i5xj-lQM94fcQGXSfsqo3Gx4whqDFGg6A0jI6L1n4WnuUuLNtlUi7Crz1uS0XhglPWQUZr-HJVQ_AxkoihNqocIJfKA5bLefPCFphv17GR_coXZY4LLsjwCiqGBXnrEp" rel="nofollow noopener" target="_blank" title="CoinMarketCap">CoinMarketCap</a></p>
206. <p align="justify"><i>EDENA Capital Nusantara</i></p>
207. <p align="justify"><i>Wook Lee</i><br /><a href="https://www.globenewswire.com/Tracker?data=tgA1NZQw7gRCNyjnI7e2Qul0JUQb2yWbOsa5iMHYirnLyz0Y7dL58kn5xqri_RgbOji2TYcQtNCgUFXdQMs5TrKTTkknzOBvqB_1qjKhMOI=" rel="nofollow noopener" target="_blank" title=""><i>media@edenacapital.com</i></a><br /><a href="https://www.globenewswire.com/Tracker?data=84mvTEh4hHx5ShSK_t8hBb3p9uau2vNHuLo22hrcO-QO799xWPLy0VUyL40z6hk6EKKDghKynsMvRVMJbpmB7ZbhIyu26GNgWIas8kCqpMA=" rel="nofollow noopener" target="_blank" title=""><i>https://edenatoken.com/</i></a></p>
208. <p align="justify"><strong><em>Disclaimer:</em></strong><em> The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. Investing involves risk, including the potential loss of capital. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release.</em> </p>
209. <p></p>
210. <pre>CONTACT: Wook Lee EDENA Capital Nusantara media at edenacapital.com</pre>
211. <p><img alt="" src='https://ml.globenewswire.com/media/Y2E0NDA0MGMtNDMyZi00OGU3LTlkZTEtYmY1ZGM1OThkNjhjLTUwMDE1MzI3OC0yMDI1LTEwLTEzLWVu/tiny/EDENA-Token.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
212. ]]></content:encoded>
216. </item>
217. <item>
218. <title>Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies &#124; DelveInsight</title>
219. <link>https://singaporeoutlook.com/pancreatic-endocrine-tumor-market-set-to-witness-significant-growth-during-the-forecast-period-2025-2034-owing-to-the-expected-launch-of-therapies-delveinsight-30150/</link>
221. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
222. <pubDate>Mon, 13 Oct 2025 17:00:00 +0000</pubDate>
223. <category><![CDATA[Brand Post]]></category>
224. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165716/0/en/Pancreatic-Endocrine-Tumor-Market-Set-to-Witness-Significant-Growth-During-the-Forecast-Period-2025-2034-Owing-to-the-Expected-Launch-of-Therapies-DelveInsight.html3165716</guid>
225.  
226. <description><![CDATA[The pancreatic endocrine tumors market landscape is poised for substantial advancement, driven by several novel therapies in development, including Zanzalintinib (Exelixis), RYZ101 (RayzeBio/Bristol Myers Squibb), and Nab-sirolimus (Aadi Bioscience), among others. These emerging treatments could profoundly reshape both the management of pancreatic endocrine tumors and the associated market dynamics in the near future. New York, [&#8230;]]]></description>
227. <content:encoded><![CDATA[<p><em>The pancreatic endocrine tumors market landscape is poised for substantial advancement, driven by several novel therapies in development, including Zanzalintinib (Exelixis), RYZ101 (RayzeBio/Bristol Myers Squibb), and Nab-sirolimus (Aadi Bioscience), among others. These emerging treatments could profoundly reshape both the management of pancreatic endocrine tumors and the associated market dynamics in the near future.</em></p>
228. <p align="justify">New York, USA, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; <b>Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight</b></p>
229. <p align="justify"><b><i>The pancreatic endocrine tumors market landscape is poised for substantial advancement, driven by several novel therapies in development, including Zanzalintinib (Exelixis), RYZ101 (RayzeBio/Bristol Myers Squibb), and Nab-sirolimus (Aadi Bioscience), among others. These emerging treatments could profoundly reshape both the management of pancreatic endocrine tumors and the associated market dynamics in the near future.</i></b></p>
230. <p align="justify">DelveInsight’s <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHc5WiQE83rAkSIYJiehFXdoF8WCrjoqzjf-44FUe1ym9aLP4wsLb13L-wtfy9iTqnNRew6I_rowXSYflt71Lsr-TTB1z5Tss7o-wocBsLxwvSGInVcWpvYyNQPUXUX633KsQHCAj8zjXzrxzhDub5nSBMZVz7Lq6vKC54GLJJpARxAtZsu0n_TxUYE31K8ShJXjzds-ufvJ9ukTkreve6e3qMhB734lkG403jvtoDc_EdV0KE3aDQb7a-xDjy0UKBs=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Market Insights</b></a> report includes a comprehensive understanding of current treatment practices, emerging pancreatic endocrine tumor drugs, market share of individual therapies, and current and forecasted pancreatic endocrine tumor market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).</p>
231. <p align="justify"><b>Pancreatic Endocrine Tumor Market Summary</b></p>
232. <ul type="disc">
233. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">The total pancreatic endocrine tumor treatment market size is expected to grow positively by 2034 in the leading markets.</li>
234. </ul>
235. <ul type="disc">
236. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">The United States accounts for the largest market size of pancreatic endocrine tumors, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.</li>
237. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Pancreatic neuroendocrine tumors (pNETs) are rare. <b>Less than 2%</b> of all cancers found in the pancreas each year are pNETs.</li>
238. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Key pancreatic endocrine tumor companies, including <b>Exelixis, RayzeBio, Bristol Myers Squibb, Aadi Bioscience, </b>and others, are actively working on innovative pancreatic endocrine tumor drugs.&#160;</li>
239. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Some of the key pancreatic endocrine tumor therapies in clinical trials include <b>Zanzalintinib, RYZ101, Nab-sirolimus</b>, and others. These novel pancreatic endocrine tumor therapies are anticipated to enter the pancreatic endocrine tumor market in the forecast period and are expected to change the market.</li>
240. </ul>
241. <p align="justify">Discover which pancreatic endocrine tumor medications are expected to grab the market share @ <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHeo6xnelrqdNgLz7kFFNVeksgc6_r5GAQ6maqlRsToxN2Djz7xLBeqdLatw3DlQQqvsCQ397RaZ32c8ZBro4jAEG1Ip1PvueiaMBhZqjO3acpfBKdOTnzcn2no8J8YbhF6yAS37uBtLl9bY-YUeCdJ3v10yE9_mrQfmCSuk7MrthcmrNXlK2z1Acpd2yIV2JxIhQYbjQfbnN1skZJzuMQfWMP4Ap37QobaZcOroCzUXRg6bbkdgDlb4Q1Rykv-r--8=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Market Report</b></a></p>
242. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=C3QeyPcHaOr8y6cE8kVHHaJbXrpPQrTYLFxOayRbeKnDbIu4KXtMsogmgCkvBS-TXB6JDviSfkYDU_q4u8Ee3DAeRxqlaJYvSYB_MKyT21IACalN0R6Mh_RuT9z-1I_4OYXlo-ImcJRMIo_RlgqzFwb9GFL2NkNtaGXLA6eC543T0-GCzdOkinZvDm7sKdiSRY5M_79A3HdbYOMxigMDRHpQxBf2EdubkSJ5B-v5rWFpnAisx1nLIxG7GTvyr7DEHVhQNG6UkzAMUJQwTXYF52Kud5P0IJV84zGif4vCRXFuJaQQfKylRKmhsWY8chbJdhVZKChPREvT6pgeys0_oQ==" rel="nofollow noopener" target="_blank" title=""><b>Key Factors Driving the Growth of the Pancreatic Endocrine Tumor Market&#160;</b></a></p>
243. <p align="justify"><b>Increasing Incidence of Pancreatic Endocrine Tumors</b></p>
244. <p align="justify">Pancreatic endocrine tumor or pancreatic neuroendocrine tumors (PNETs) are rare tumors, with an annual incidence of about <b>1 per 100,000</b> per year, and represent only <b>1–2% </b>of pancreatic neoplasms. Approximately <b>10%</b> of all pancreatic neuroendocrine tumors arise in association with a hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL) disease, neurofibromatosis type 1 (NF1), or tuberous sclerosis complex.</p>
245. <p align="justify"><b>Advancements in Diagnostic Technologies</b></p>
246. <p align="justify">The development of advanced imaging techniques, such as Gallium-68 PET/CT scans, has improved the detection and diagnosis of neuroendocrine tumors (NETs), including pancreatic endocrine tumors. These innovations enable earlier and more accurate identification of tumors, leading to better patient outcomes and increased demand for specialized treatments.</p>
247. <p align="justify"><b>Anticipated Launch of Emerging PET Drugs</b></p>
248. <p align="justify">Promising therapies in PET clinical trials include <b>Zanzalintinib </b>(Exelixis), <b>RYZ101 </b>(RayzeBio/Bristol Myers Squibb), <b>Nab-sirolimus</b> (Aadi Bioscience), and others. The anticipated launch of these therapies is expected to transform the dynamics of the pancreatic endocrine tumor market in the coming years.</p>
249. <p align="justify"><b>Pancreatic Endocrine Tumor Market Analysis</b></p>
250. <p align="justify">The management of pancreatic endocrine tumors (PETs) is highly individualized, driven by tumor type, anatomical location, disease stage, and patient health status. Surgical intervention remains the cornerstone for localized tumors, with procedures such as pancreatectomy or the Whipple procedure representing the standard of care. In advanced or metastatic cases, systemic approaches—including peptide receptor radionuclide therapy (PRRT) and somatostatin analogues like octreotide—are commonly employed to control symptoms and inhibit tumor progression. For patients with liver metastases, locoregional treatments such as radiofrequency ablation or transarterial chemoembolization provide additional therapeutic options.</p>
251. <p align="justify">Currently, the FDA has approved several targeted therapies for PETs, including <b>CABOMETYX </b>(cabozantinib, Exelixis), <b>WELIREG </b>(belzutifan, Merck), and <b>SUTENT </b>(sunitinib, Pfizer). Looking ahead, the treatment landscape is poised for substantial evolution. Several promising pipeline candidates, such as <b>Zanzalintinib </b>(Exelixis), <b>RYZ101 </b>(RayzeBio/Bristol Myers Squibb), and <b>Nab-sirolimus</b> (Aadi Bioscience), are currently under clinical development. These emerging therapies have the potential to reshape clinical management paradigms and influence market dynamics, signaling a period of notable innovation in the pancreatic endocrine tumor space.</p>
252. <p align="justify">Learn more about the pancreatic endocrine tumor treatment options @ <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHfnlZXr5JpaxmqEj03z8IIbo8j8DK4e67eBuWVr0AfM3FHSXzei_BPmoCT6-jJ9IBqaZDq5FzMON9U4rXC92oqwZwMRdgNpuB5R1z0Ig4XPza8u61EQs5WWits3IQsJ7TmrQV1PNh-SokPXZpSAvohoGT70ARitgjYsSmG3rogOuuYVVP9Wu51MCAIqlsf5NwLwPMid6ZIQaSw01T8QmHNcb4n2B3rkvD0N5__idvO9Q_S_AWllhFX_3ROBETqLSwY=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Treatment Market</b></a></p>
253. <p align="justify"><b>Pancreatic Endocrine Tumor Competitive Landscape</b></p>
254. <p align="justify">The emerging pipeline for pancreatic endocrine tumors includes <b>Zanzalintinib </b>(Exelixis), <b>RYZ101 </b>(RayzeBio/Bristol Myers Squibb), <b>Nab-sirolimus </b>(Aadi Bioscience), and others.</p>
255. <p align="justify"><b>Exelixis’ Zanzalintinib</b> is an experimental tyrosine kinase inhibitor under investigation for treating patients with locally advanced or metastatic neuroendocrine tumors, including pancreatic neuroendocrine tumors. The compound is currently being assessed in Phase II/III clinical trials. In June 2025, the company announced the launch of the STELLAR-311 Phase III pivotal trial in advanced pancreatic endocrine tumors, with progression-free survival (PFS) as per RECIST 1.1, as evaluated by blinded independent central review, as the primary endpoint.</p>
256. <p align="justify"><b>RayzeBio/Bristol Myers Squibb’s RYZ101 </b>is a first-in-class, highly potent alpha-emitting radiopharmaceutical therapy designed for patients with somatostatin receptor 2-positive (SSTR2+) solid tumors, including pancreatic neuroendocrine tumors. It delivers targeted alpha radiation to SSTR2-expressing tumors, exploiting the high energy and short path length of alpha particles to destroy tumor cells while minimizing damage to surrounding tissues selectively. The therapy is currently being evaluated in a Phase III clinical trial.</p>
257. <p align="justify">The anticipated launch of these emerging pancreatic endocrine tumor therapies are poised to transform the pancreatic endocrine tumor market landscape in the coming years. As these cutting-edge pancreatic endocrine tumor therapies continue to mature and gain regulatory approval, they are expected to reshape the pancreatic endocrine tumor market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.</p>
258. <p align="justify">To know more about new treatment for pancreatic endocrine tumor, visit @ <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHfbIU8S7zDzEjnxomK1Iz64Dr-WIw21Tg4n8gZgOshVphLEuc85FWFaj2EFdraigyGhod81wQWeqXsS6U60aTJwrDOVKLGlqucyRZJn_OTV7RVMRfGq9eODKmh4T4KzNEmsPMlWcZS2fjAVYcPWy95MYMMdpOfmiJlaYywRIPHCuKZjOG0XkPnLCwNiexgiITftQNdptegbFfpGcUo9jkmvNq43-HHhRid-AApN4GBQSg==" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Medication</b></a></p>
259. <p align="justify"><b>What is Pancreatic Endocrine Tumor?</b></p>
260. <p align="justify">Pancreatic endocrine tumor, also referred to as a pancreatic neuroendocrine tumor (PNET) or islet cell tumor, is an uncommon form of cancer arising from the hormone-producing islet cells of the pancreas. These tumors can be functional, producing excess hormones that lead to clinical syndromes such as insulinoma, gastrinoma, or glucagonoma, or non-functional, releasing no active hormones and often being diagnosed later due to vague or non-specific symptoms. They may be benign or malignant and can sometimes be associated with hereditary conditions, such as Multiple Endocrine Neoplasia type 1 (MEN1).</p>
261. <p align="justify"><b>Pancreatic Endocrine Tumor Epidemiology Segmentation</b></p>
262. <p align="justify">The pancreatic endocrine tumor epidemiology section provides insights into the historical and current pancreatic endocrine tumor patient pool and forecasted trends for the leading markets. Most people with pNETs are older, with the average age at diagnosis being <b>60</b>. In the United States, the incidence of <b>localized pancreatic endocrine tumors</b> is more prevalent than advanced or metastatic stage.</p>
263. <p align="justify">The <a href="https://www.globenewswire.com/Tracker?data=uYMnjDJgdtJtj-wu_JC_1S2lZmcg6yjqLPjT22EY3r4PLcs4dSEA-Or_OPfA_ZF9vqkpeZ--fW5hHytGR_9eP8RWWU9D6z16qUzyDOTzjqVCViypL8P-ffLOKeRyJdhEJBgoY51_S-KKTjBRa1FkGIAQ3hRNztxdeB-5wIvpW9RQFU987kJ1vLsIvo1T38maXpfqhSpDPIwTpCcCZLlaOdgBrSCu-E2HLEm0GME8c89gmuuam7i9kz2lhpJCHCHaHHQY5pvjrgl-G9498XxKApjgvUTzkzenOpH2eH13J4k=" rel="nofollow noopener" target="_blank" title=""><b>pancreatic endocrine tumor market report</b></a> proffers epidemiological analysis for the study period 2020–2034 in the leading markets segmented into:</p>
264. <ul type="disc">
265. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;">Total Incident Cases of Pancreatic Endocrine Tumor</li>
266. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Gender-specific Cases of Pancreatic Endocrine Tumor</li>
267. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Type-specific Cases of Pancreatic Endocrine Tumor</li>
268. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Age-specific Cases of Pancreatic Endocrine Tumor</li>
269. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Grade-specific Cases of Pancreatic Endocrine Tumor</li>
270. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Function-specific Cases of Pancreatic Endocrine Tumor</li>
271. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;">Total Treated Cases of Pancreatic Endocrine Tumor&#160;&#160;</li>
272. </ul>
273. <p align="justify">Download the report to understand pancreatic endocrine tumor management @ <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHfnlZXr5JpaxmqEj03z8IIbjpM5quHKIKsOwZLwdaDM1B1667Bqo2fM0fTgj2CaD4Zyj2siKLplscKzuNcUBMEkb1Em3t48oF9UtpKAUwEQa9a-ZZHaJ0mYxY1zarldxb9jRhXbk-SUzZdliTpAATaTECxYMwvH8hqRw7x4AD12v9ddGUIgREtBEOxvAN0NbtcOkVH7a6ZJE1FLHVP6HXapWIri8OBhickqOx7Lh91KfjBGHKWJAC6pgyrDTQBkBL4=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Treatment Options</b></a></p>
274. <table style="border-collapse: collapse; border-collapse:collapse ;">
275. <tr>
276. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; "><b>Pancreatic Endocrine Tumor Market Report Metrics</b></td>
277. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; "><b>Details</b></td>
278. </tr>
279. <tr>
280. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Study Period</td>
281. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">2020–2034</td>
282. </tr>
283. <tr>
284. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Pancreatic Endocrine Tumor Market Report Coverage</td>
285. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]</td>
286. </tr>
287. <tr>
288. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Pancreatic Endocrine Tumor Epidemiology Segmentation</td>
289. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Total Incident Cases of Pancreatic Endocrine Tumor</p>
290. <p>Gender-specific Cases of Pancreatic Endocrine Tumor, Type-specific Cases of Pancreatic Endocrine Tumor, Age-specific Cases of Pancreatic Endocrine Tumor, Grade-specific Cases of Pancreatic Endocrine Tumor, Function-specific Cases of Pancreatic Endocrine Tumor, and Total Treated Cases of Pancreatic Endocrine Tumor</td>
291. </tr>
292. <tr>
293. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Key Pancreatic Endocrine Tumor Companies</td>
294. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Exelixis, RayzeBio, Bristol Myers Squibb, Aadi Bioscience, Merck, Pfizer, and others</td>
295. </tr>
296. <tr>
297. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Key Pancreatic Endocrine Tumor Therapies</td>
298. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Zanzalintinib, RYZ101, Nab-sirolimus, CABOMETYX, WELIREG, SUTENT, and others</td>
299. </tr>
300. </table>
301. <p align="justify"><b>Scope of the </b><b>Pancreatic Endocrine Tumor</b><b> Market Report</b></p>
302. <ul type="disc">
303. <li style="margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;"><b>Pancreatic Endocrine Tumor Therapeutic Assessment: </b>Pancreatic Endocrine Tumor current marketed and emerging therapies</li>
304. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Pancreatic Endocrine Tumor</b> <b>Market Dynamics:</b> Conjoint Analysis of Emerging Pancreatic Endocrine Tumor Drugs</li>
305. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Competitive Intelligence Analysis:</b> SWOT analysis and Market entry strategies</li>
306. <li style="margin-top:0in; margin-bottom:0.0001pt; text-align:justify;"><b>Pancreatic Endocrine Tumor Market Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Endocrine Tumor Market Access and Reimbursement</b></li>
307. </ul>
308. <p align="justify">Discover more about pancreatic endocrine tumor drugs in development @ <a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHeJnmYbtKsndB7ubheO0j9YAUWziOqADbDbHnJOF7PBKtB5CKBihKM2PtonfTg0vYSMGayHIXWfwgkhaLdX_aDTH8bXop5oMmiejcvSPMj7B8s5gZUFriy8dtLKZA8iDGpQyURy59lIS6NZjnFZ6gX7DuEOrxeZ3rWa9PXnN75D-VFAEF85wrlYIRfrDJbWsEGNtzJU8j2E78v8f4FLcurA1WwecuxB3vtwzClQXRRmDxHOTQCkaJVRWTgL_cC6674=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Clinical Trials</b></a></p>
309. <p align="justify"><b>Table of Contents</b></p>
310. <table style="border-collapse: collapse; border-collapse:collapse ;">
311. <tr>
312. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">1</td>
313. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Key Insights</td>
314. </tr>
315. <tr>
316. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">2</td>
317. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Report Introduction</td>
318. </tr>
319. <tr>
320. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">3</td>
321. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Epidemiology and Market Forecast Methodology&#160;</td>
322. </tr>
323. <tr>
324. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">4</td>
325. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor: Market Overview at a Glance</td>
326. </tr>
327. <tr>
328. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">4.1</td>
329. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Market Share (%) Distribution of Pancreatic Endocrine Tumor by Therapies in 2024</td>
330. </tr>
331. <tr>
332. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">4.2</td>
333. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Market Share (%) Distribution of Pancreatic Endocrine Tumor by Therapies in 2034</td>
334. </tr>
335. <tr>
336. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">5</td>
337. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Executive Summary&#160;</td>
338. </tr>
339. <tr>
340. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">6</td>
341. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Key Events&#160;</td>
342. </tr>
343. <tr>
344. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">7</td>
345. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor: Disease Background and Overview</td>
346. </tr>
347. <tr>
348. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">7.1</td>
349. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Introduction</td>
350. </tr>
351. <tr>
352. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">7.2</td>
353. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Signs and Symptoms&#160;</td>
354. </tr>
355. <tr>
356. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">7.3</td>
357. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Causes</td>
358. </tr>
359. <tr>
360. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">7.4</td>
361. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Diagnosis</td>
362. </tr>
363. <tr>
364. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">8</td>
365. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Treatment</td>
366. </tr>
367. <tr>
368. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9</td>
369. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Epidemiology and Patient Population of Pancreatic Endocrine Tumor</td>
370. </tr>
371. <tr>
372. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.1</td>
373. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Key Findings</td>
374. </tr>
375. <tr>
376. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.2</td>
377. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Assumptions and Rationale: The 7MM</td>
378. </tr>
379. <tr>
380. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.3</td>
381. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Incident Cases of Pancreatic Endocrine Tumor in the 7MM</td>
382. </tr>
383. <tr>
384. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4</td>
385. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">The United States</td>
386. </tr>
387. <tr>
388. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.1</td>
389. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Total Incident cases of Pancreatic Endocrine Tumor in the United States</td>
390. </tr>
391. <tr>
392. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.2</td>
393. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Gender-specific cases of Pancreatic Endocrine Tumor in the United States</td>
394. </tr>
395. <tr>
396. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.3</td>
397. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Type-specific cases of Pancreatic Endocrine Tumor in the United States</td>
398. </tr>
399. <tr>
400. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.4</td>
401. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Age-specific cases of Pancreatic Endocrine Tumor in the United States</td>
402. </tr>
403. <tr>
404. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.5</td>
405. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Grade-specific cases of Pancreatic Endocrine Tumor in the United States</td>
406. </tr>
407. <tr>
408. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.6</td>
409. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Function-specific cases of Pancreatic Endocrine Tumor in the United States</td>
410. </tr>
411. <tr>
412. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.4.7</td>
413. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Total treated cases of Pancreatic Endocrine Tumor in the United States</td>
414. </tr>
415. <tr>
416. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.5</td>
417. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">EU4 and the UK</td>
418. </tr>
419. <tr>
420. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">9.6</td>
421. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Japan</td>
422. </tr>
423. <tr>
424. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">10</td>
425. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Patient Journey&#160;</td>
426. </tr>
427. <tr>
428. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11</td>
429. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Marketed Pancreatic Endocrine Tumor Therapies&#160;</td>
430. </tr>
431. <tr>
432. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.1</td>
433. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Key Competitors</td>
434. </tr>
435. <tr>
436. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2</td>
437. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">CABOMETYX (cabozantinib): Exelixis</td>
438. </tr>
439. <tr>
440. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2.1</td>
441. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Product Description</td>
442. </tr>
443. <tr>
444. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2.2</td>
445. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Regulatory Milestones</td>
446. </tr>
447. <tr>
448. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2.3</td>
449. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Other Developmental Activities</td>
450. </tr>
451. <tr>
452. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">11.2.4</td>
453. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Clinical Development</td>
454. </tr>
455. <tr>
456. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">11.2.4.1</td>
457. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Clinical Trials Information</td>
458. </tr>
459. <tr>
460. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2.5</td>
461. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Safety and efficacy</td>
462. </tr>
463. <tr>
464. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.2.6</td>
465. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Analyst Views</td>
466. </tr>
467. <tr>
468. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">11.3</td>
469. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">WELIREG (belzutifan): Merck</td>
470. </tr>
471. <tr>
472. <td colspan="2" style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; "><i>List to be continued in the report…</i></td>
473. </tr>
474. <tr>
475. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12</td>
476. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Emerging Pancreatic Endocrine Tumor Drugs&#160;</td>
477. </tr>
478. <tr>
479. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.1</td>
480. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Key Competitors</td>
481. </tr>
482. <tr>
483. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2</td>
484. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Zanzalintinib: Exelixis</td>
485. </tr>
486. <tr>
487. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.1</td>
488. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Product Description</td>
489. </tr>
490. <tr>
491. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.2</td>
492. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Other Developmental Activities</td>
493. </tr>
494. <tr>
495. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.3</td>
496. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Clinical Development</td>
497. </tr>
498. <tr>
499. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.3.1</td>
500. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Clinical Trials Information</td>
501. </tr>
502. <tr>
503. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.4</td>
504. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Safety and Efficacy</td>
505. </tr>
506. <tr>
507. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">12.2.5</td>
508. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Analyst Views</td>
509. </tr>
510. <tr>
511. <td colspan="2" style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; "><i>List to be continued in the report…</i></td>
512. </tr>
513. <tr>
514. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13</td>
515. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market: Seven Major Market Analysis</td>
516. </tr>
517. <tr>
518. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.1</td>
519. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Key Findings&#160;&#160;</td>
520. </tr>
521. <tr>
522. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.2</td>
523. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Key Pancreatic Endocrine Tumor Market Forecast Assumptions</td>
524. </tr>
525. <tr>
526. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.3</td>
527. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Outlook</td>
528. </tr>
529. <tr>
530. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.4</td>
531. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Conjoint Analysis</td>
532. </tr>
533. <tr>
534. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.5</td>
535. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Market Size of Pancreatic Endocrine Tumor in the 7MM</td>
536. </tr>
537. <tr>
538. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.6</td>
539. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Market Size of Pancreatic Endocrine Tumor by Therapies in the 7MM</td>
540. </tr>
541. <tr>
542. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.7</td>
543. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">The United States Pancreatic Endocrine Tumor Market Size</td>
544. </tr>
545. <tr>
546. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.7.1</td>
547. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Total Market Size of Pancreatic Endocrine Tumor</td>
548. </tr>
549. <tr>
550. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.7.2</td>
551. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">The Market Size of Pancreatic Endocrine Tumor by Therapies</td>
552. </tr>
553. <tr>
554. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.8</td>
555. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">EU4 and the UK Pancreatic Endocrine Tumor Market Size</td>
556. </tr>
557. <tr>
558. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">13.9</td>
559. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Japan Pancreatic Endocrine Tumor Market Size</td>
560. </tr>
561. <tr>
562. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">14</td>
563. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Unmet Needs&#160;</td>
564. </tr>
565. <tr>
566. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">15</td>
567. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market SWOT Analysis&#160;</td>
568. </tr>
569. <tr>
570. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">16</td>
571. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">KOL Views on Pancreatic Endocrine Tumor&#160;</td>
572. </tr>
573. <tr>
574. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">17</td>
575. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Access and Reimbursement&#160;</td>
576. </tr>
577. <tr>
578. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">18</td>
579. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Bibliography</td>
580. </tr>
581. <tr>
582. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; ">19</td>
583. <td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ; vertical-align: middle; ">Pancreatic Endocrine Tumor Market Report Methodology</td>
584. </tr>
585. </table>
586. <p align="justify"><b>Related Reports</b></p>
587. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feiqfb2D6KpVs9_Viu5d-sHeJnmYbtKsndB7ubheO0j9YT-uhcfi6DqdGKutyHYpWPFEW0RrWmyJD0jnvjri8IBCqmYDWtWdXfrknms8eprOb6XL4Dfbybmvn1j5fOvIyUfm7O-_52ACt8hcqsK2RyGTZ56FA1V_jJoGHG9VsDRlseZm6t__5zIOPObeLpZFKlX0RusGL8B7KzF7n99R1FdQ35K5fpr62jaQ4bGzcX2RVeUfT-sJP3UY6pU1BdkcytHXZxJL5mhUkbxhlD5akI1HJkOBfLLmRANvVjhSvcB1f" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Endocrine Tumor Clinical Trial Analysis</b></a></p>
588. <p align="justify"><b>Pancreatic Endocrine Tumor Pipeline Insight </b><b>– 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic endocrine tumor companies, including <b>Exelixis, RayzeBio, Bristol Myers Squibb, Aadi Bioscience, Merck, Pfizer,&#160; </b>among others.</p>
589. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feub4lQmsxPxuu8MY_xQjaynZCa4V6Lv027xhz-3i4GtpvoW5YJ6hUhGjw45n1pZWbLS-jvHcWIRTO4woK2Sk1vLo8d4_5gHHmXEFsE8_025uAOWyAhuKnAfcwoUZyavOPCUihTHJXIc0SFkh0_VQB7n9wl1TIz6PzaA0eNm2hAvcGToaVg0EuCcbwlR7wUQnpMgOnQCEzTck5ogOKBiU98rNFcRxcl5uvF5mmGCDzcyanDDNwi5-kXDiVuDE9rRaMsV1itxqqbLvvB5ntysMnQs=" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Neuroendocrine Tumors Market</b></a></p>
590. <p align="justify"><b>Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 </b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic neuroendocrine tumors companies, including <b>Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp &amp; Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen,</b> among others.</p>
591. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=hQBx2ICCKd_HqDpHMf0Feub4lQmsxPxuu8MY_xQjaymC5dFiHp9RF9emIn6SP2h4xy5jtxOEy8StIe2u0XJx9vMw8ZU18FYVoQCM38m53MCCPICZlkg9T_slJIhcOg_cmt7ZmvSF4q1o_mRo47ZTLXTSNnvDYHfqv7EXm3e0D_-R75jWuOiDF7kS5uFs93TSsHdkxWvHsA5O64QeLnvGOOXy8c6za22K4HqbGqzR1XXm-G5wMRF_u_y3qebTolMnfsawz4sRTKma10lrFy-VGRVo2TzX8ef2rDfdHia3-FKecc-9kVjZiK4bZ_g0ieNu0r9Beo7qmNEZNMqqATYheg==" rel="nofollow noopener" target="_blank" title=""><b>Pancreatic Neuroendocrine Tumors Clinical Trial Analysis</b></a></p>
592. <p align="justify"><b>Pancreatic Neuroendocrine Tumors Pipeline Insight – 2025</b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pancreatic neuroendocrine tumors companies, including <b>Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp &amp; Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, </b>among others.</p>
593. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=w4A9RXs0rSB26lt48IY0UcoJkVUrqenHs6VPAEOsPxMWLsgnKiMJloc8gtHmIQYxK0-zHlK-M7J6tMkNx2pLbCzoh47f5LZlDX5C1tIgzfDy8AJeJJkNaDXK6_Yx-UWBuaLE48x_hRNsoGVrapidXAWUPznQtAs3SLxFvSFggbKwQICA2Pb2WmCLzgz1hX2iAAY7tQWX36cE3-RQCt8nous59deFfwJhgphlGCA2RzwJB3KHP8nrRT5BdLDc_3nLUBNtiwd1xlblxi_n1U6wVQ==" rel="nofollow noopener" target="_blank" title=""><b>Neurofibromatosis Type 1 Market</b></a></p>
594. <p align="justify"><b>Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast – 2034 </b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neurofibromatosis type 1 companies including <b>Fosun Pharmaceutical, Healx, NFlection Therapeutics, Pasithea Therapeutics, AstraZeneca, Merck, SpringWorks Therapeutics,</b> among others.</p>
595. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=w4A9RXs0rSB26lt48IY0UcoJkVUrqenHs6VPAEOsPxPBQjZyzonqzUf4v6BgruVjOVpbHcCiFI4GwKI0h5X91xxTGib0a5kZoYC3FD4lAj7G_WNRKosM1SOXH7GzL_wUNv3V5FE_xDyQBMs0x5myHRaDPxnhuzzS15yHxmqmFr6j_l1aKqCdF524yAMpv8vM5aFCFm6j9IcOJynIgcqDnAfM8yAYu-PFJg_kvurqW5XdG6z9mnv2iDHMTYZe5f8k" rel="nofollow noopener" target="_blank" title=""><b>Neurofibromatosis Type 2 Market</b></a></p>
596. <p align="justify"><b>Neurofibromatosis Type 2 Market Insights, Epidemiology, and Market Forecast – 2034 </b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neurofibromatosis type 2 companies including <b>Recursion Pharmaceuticals, Takeda, Vivace Therapeutics, AstraZeneca, Recursion Pharmaceuticals Inc., Betta Pharmaceuticals Co. Ltd., Shandong Simcere-Medgenn Bio-pharmaceutical Co. Ltd, Novartis Pharmaceuticals, Genentech Inc., GlaxoSmithKline, AstraZeneca,</b> among others.</p>
597. <p align="justify"><b>DelveInsight’s</b><a href="https://www.globenewswire.com/Tracker?data=rGGCfc63reDugy9Tz5grZefLCXJbClk5LXcK5X-fGWiHEv0sE7giaYTiWT08azXL3_KXMg8bhu0HJwLWR7aKb2dafFN8CTqk3QCwFxnDjwr7Cw3ir8925KCJM772brc-tSABnSelBsHVKAkzEN0wHsiyBvbLgcuFuNtwqDlVCZ1F5udbwv2HmxFP8VVSdJN3" rel="nofollow noopener" target="_blank" title=""><b> Pharma Competitive Intelligence Service</b></a><b>: </b>Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.</p>
598. <p align="justify"><b>Other Business Pharmaceutical Consulting Services</b></p>
599. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=HfQo4rU9RXmhSCfQsEyxgDfnWNKQY-BOkJ4mWCnZARuiiTEbKvIU_s6pDQYP_kyEYvELduxB4ubwJ2uyl3SlkibWOzat9FVQTmHYJTP-prEZgIdRjTpvdGxQPc01Fhkn0Os5rupVuTiCInCyuBwZrkvIydeGDDnGtPymHb7MO4U=" rel="nofollow noopener" target="_blank" title=""><b>Healthcare Conference Coverage</b></a></p>
600. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=E5D0sk4p2F3KMu4zqD_G8gga1bbDnTfG1hMD3aNpA7_LchnINFUsYD_uryAoQi0OpTdPOOnDqiKcKsG5IhM75fbJy9HPX7v0BvllJDOWE552KbPvHlrLEU4k6PryP9QzmwUXP3xJpREBJoM8p57wxDphixuhmXvR5HSM309fZ9Y=" rel="nofollow noopener" target="_blank" title=""><b>Pipeline Assessment</b></a></p>
601. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=HfQo4rU9RXmhSCfQsEyxgFSFu0LKCi1Sw6KBgw8XgRN4DzJtYYxevl3FpwA3gJ4N7ejBUwqDd05T5ZF0BGkcW-NLyv8YJeTF_Wt4wowy9THRP1NjoFYRQowv7rXhEsr2cQEXLRPi_3jhsa4qnvVgB1piYbzZWf_Ir_RqhnGv-GU=" rel="nofollow noopener" target="_blank" title=""><b>Healthcare Licensing Services</b></a></p>
602. <p align="justify">Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our <a href="https://www.globenewswire.com/Tracker?data=eZ0-db92bhaOQKu5UJluBQfjjZGgDNPSQwX8sR5HjY1hi_g5pHnkwwAx3do8tWQ5twx61vECqrp8XnE6QoSgycrHfJ72ka9lmkIiGQd75d_5sUtc3ps3-n0c4z86Pe8NmCNf9baHyr6v2_Rd0vcE0Q==" rel="nofollow noopener" target="_blank" title=""><b>Due Diligence Case Study</b></a></p>
603. <p align="justify"><b>About&#160;DelveInsight</b></p>
604. <p align="justify">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.&#160;Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&#160;PharmDelve<b>.</b></p>
605. <p align="justify"><b>Connect with us on</b><a href="https://www.globenewswire.com/Tracker?data=FVODpfEuXtUVTZg14Q24SDTEbYdEmcgOmdpWdihkiyJorej-n0OaiMYW_9Rn8EvUOzWMkp0R-lNULyfRSmo5xdEjxmpVZiZSc6stF6Ngh1oBIaRUzJKPuL7J6QQfFtREnih9nM_W-h_pb8J2GaGgdw==" rel="nofollow noopener" target="_blank" title=""> <b>LinkedIn</b></a><b>|</b><a href="https://www.globenewswire.com/Tracker?data=ou1hic0bEIt0JoDjO9dYud9-8b8bS-mK_UnJzFVf61EqLNEkER_A5qjMriAm5fqepk5tkTFDUeZpRK-Y2qiypkWkCDNBcNqBgIwIWKyXdtk=" rel="nofollow noopener" target="_blank" title=""><b>Facebook</b></a><b>|</b><a href="https://www.globenewswire.com/Tracker?data=24qM6zWgEnrD0vCuIHQSIpASb2EfKc0c8sqzMT4BihC233gUG1CJHEXHDCEzj3sycUivbAdfQSDrN_JAcnK-sU17yKnGF_2brlI_VBYD_KY=" rel="nofollow noopener" target="_blank" title=""><b>Twitter</b></a><b></b></p>
606. <pre>CONTACT: Contact Us Shruti Thakur  info@delveinsight.com  +14699457679  www.delveinsight.com</pre>
607. <p><img alt="" src='https://ml.globenewswire.com/media/YTk2ZGE5NGMtMzY5OC00YWRmLWIxNWUtNTdhMjk1YTFhZDIxLTEyMDQ5MzgtMjAyNS0xMC0xMy1lbg==/tiny/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
608. ]]></content:encoded>
612. </item>
613. <item>
614. <title>Next-Generation Therapy Market Growth, Trends and Competitive Strategies – Towards Healthcare</title>
615. <link>https://singaporeoutlook.com/next-generation-therapy-market-growth-trends-and-competitive-strategies-towards-healthcare-30153/</link>
617. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
618. <pubDate>Mon, 13 Oct 2025 16:00:00 +0000</pubDate>
619. <category><![CDATA[Brand Post]]></category>
620. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165689/0/en/Next-Generation-Therapy-Market-Growth-Trends-and-Competitive-Strategies-Towards-Healthcare.html3165689</guid>
621.  
622. <description><![CDATA[This report provides an in-depth analysis of the global next-generation therapies market, highlighting key trends, growth drivers and regional insights. Prepared by Towards Healthcare, a sister firm of Precedence Research. Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global&#160;next-generation therapies market is experiencing a strong upward trajectory, with revenue expected to reach substantial figures, potentially [&#8230;]]]></description>
623. <content:encoded><![CDATA[<p><em>This report provides an in-depth analysis of the global next-generation therapies market, highlighting key trends, growth drivers and regional insights. Prepared by Towards Healthcare, a sister firm of Precedence Research.</em></p>
624. <p>Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global&#160;<a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7NYq1Q5sqII0XnJRRhwyxUL70By6ymWgxAS2UbCqgesqz_7QZ06KVcMVyPxc90-7cGW1rr3zN4gHgF0dA9jC0cLnMFJGlkK1JudKma2P5hx0uScJYpweFnEV4UDQFMe-csFdAMiuMKNIMoXbi3blSxNQaafnVjFSQGOOOA8Ukcs0" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty-IudAONvqcuQRTaDLk7Kh09v0EFvMLvrvCuzIr3LpwT_6QKgcIcJoHy5Mq76G1ouZ0caNH2b9EfmmuKdH7jwGhKKLpk-zR2L24KAP6ib_wx3zuHIoE-ZIWpmLhtWI5H8mQw6S7J6P1AqBGOwNe0K-BBcNYu2TA3Ilgl7WyE2NMfQ==" title=""><strong>next-generation therapies market</strong></a> is experiencing a strong upward trajectory, with revenue expected to reach substantial figures, potentially entering the hundreds of millions between 2025 and 2034. This growth is being driven by shifting consumer needs and rapid technological advancements that are transforming the landscape of healthcare.</p>
625. <p>Rising prevalence of various diseases has fueled the demand for next-generation therapies, prompting industries and research institutes to explore innovative solutions to expand their applications. Increasing collaboration among companies is further accelerating the development and launch of new therapies, while the integration of artificial intelligence is streamlining research and enhancing efficiency. Additionally, growing awareness and adoption across different regions are contributing to the market’s expansion. Together, these factors are positioning next-generation therapies as a key driver of growth in the healthcare sector.</p>
626. <p align="center"><img decoding="async" src="https://ml.globenewswire.com/Resource/Download/aadf72b7-329a-47ab-9fce-b6048cb5b3c3/image1.png" width="601.74px" height="338.47px" name="GNW_RichHtml_IMG" data-mce-src="/api/ImageRender/DownloadFile?resourceId=aadf72b7-329a-47ab-9fce-b6048cb5b3c3&amp;size=3" /></p>
627. <p><strong>The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXzM2Vt8ikwUCY1m2e4s7_6nvLv-NEAS-hcdAUesc6ufqloegXJ_hdZa4aVliYjP1Te7ievYPzWpWCg_19Sai2dTjjcpNGwJsOwQeaPKgs7Npv6PB6T39ro6JCIJZxGJke-q1k8cLXLsBkOo3RuozbD6" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7HO1B87gXTgZz2_Yhaa1QOxdu0aEWM-b7NE4QK_NaoSBQ4JqDZVAPDVKYeoZzR_jFq0AmRjsA1qxKKPuju7fXke56xrPvaWuAla89oEO9WtmueXQR3m6ptuWYWCAh4LlJTJjXIZzbtYLc3GH63Ot7R-w==" title=""><strong>https://www.towardshealthcare.com/download-sample/5823</strong></a></p>
628. <p><strong>Key Takeaways</strong></p>
629. <ul type="disc">
630. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">North America held a major revenue share by 48% of the market in 2024.</li>
631. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.</li>
632. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By therapy type, the gene therapy segment led the next-generation therapy market in 2024.</li>
633. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By therapy type, the RNA-based therapy segment is expected to witness the fastest growth during 2025-2034.</li>
634. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By application type, the oncology segment was dominant in the market in 2024.</li>
635. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By application type, the rare genetic disorders segment is expected to be the fastest-growing in the studied years.</li>
636. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By vector type, the adeno-associated virus (AAV) vectors segment registered dominance in the next-generation therapy market in 2024.</li>
637. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By vector type, the non-viral vectors segment is expected to grow rapidly in the coming years.</li>
638. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By route of administration type, the intrathecal/intracerebral segment led the market in 2024.</li>
639. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By route of administration type, the intramuscular segment is expected to be the fastest growing in the predicted timeframe.</li>
640. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By end user, the hospitals &amp; specialty clinics segment held the largest share of the market in 2024.</li>
641. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">By end user, the homecare segment is expected to grow at a rapid CAGR in the studied years.</li>
642. </ul>
643. <p><strong>What is the Next-Generation Therapy? </strong></p>
644. <p>The global next-generation therapy market covers highly targeted approaches, specifically genomic medicine, <a href="https://www.globenewswire.com/Tracker?data=-5jlcgB12jbMxV1mlzHKsV8kyrlX_uw3KrJ0IvAwai600FCV4txfqV2bttAnKh9DqyrxGT6G6zflJAiEbSdsJcLj5CD4fHbOpJaTfl7RiqIp78msPZ1RzozbFO603q7jQOiuB6Rjp0dLyMRK9Gmjqw==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdwJeNHraB0GHBH_ax5yTQFL57oTST7SoSRX4-6FPhmqSvhnun5bzS8OBc6e52qAinFRPEAuVA1wbZeI_IcTbeQTwiml1-nC2QVNCZrXnAs7VdNrqK780helpW1tysO0r2EaHJU51EE27CvA8Ax6_p9I=" title=""><strong>cell therapies</strong></a> (like CAR-T&#160;cells), and nucleic acid-based treatments (using AAVs, ASOs, siRNA) to highlight the root genetic causes of disease.&#160;The market is propelled by a <a href="https://www.globenewswire.com/Tracker?data=wI5QgSGIeCsMjlwUMZV43kW_f-JnK0ptnMcyV-v_QYHjYkxo_57RQzMLrtok_uHbjNd6LqWvarXDVegO2K7jbFbxfySLv4fxhDbI4a6zckgyI-kRthDADqjSSA1G8S0H9_6uUIlBo_yQGGyHIK8yTzPvBxbc5WAjgx9ZAeQvFRQz3Bj7y4NGZQcMVrNHNWf-mlQ9WLQhoQCnNMgNbPUXKg==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd1UA9nKet0PE7N2qhVCRSp3N5MbJOUW8a2kJlA8DRZt_88kHT009M8XDAThE36uRlkLi-oWWIQPaCgYhwBDD_NzHayPPC1HU6LA4ycoNTKbmXXhJMBICnfDrvjvopWoDP2PvWxu-tolvdCwsdmXc2Oam-fQsnRXB2daiD9ZrjEVPNtJZXLpmFiKvtXoyjeyvkw==" title=""><strong>rise in demand for personalized medicine</strong></a> and targeted treatments and continuous advances in gene and cell therapy technologies.&#160;In this era, the market is exploring innovation in robust gene editing tools, particularly CRISPR-Cas9, new delivery systems, including virus-like particles (VLPs), and the expansion of these therapies into wider applications.</p>
645. <p><strong>What are the Prominent Drivers in the Next-Generation Therapy Market?</strong></p>
646. <p>Several combined factors are contributing to the market growth, such as a rise in R&amp;D <a href="https://www.globenewswire.com/Tracker?data=9g0y3jQblWznrD6qgrnAZqOzIJWFJBBZ4sW1SdrYutTF5riKMYeip-ha5dS_oRAtkOpDyhE-e58BQVPSrPIfHuZH9qwZxk0EM22oW9wWuIVUyhdWtrQYmbYfzG8vxCta6PlriBVsTXpwvx6HTB0FJYGUguc0Dgt0owyxgCzKC6J12OAKcXO2NGt5s66Hg_4P" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd5jzCS_crLQigOuL3g4FayptluyUfa6QDnToJpWZKu90jF6GmwL8sr5UxbQXUaq_jXUnlo6EGf35Z4vh1F134zFtXK_QHiKYOIuc1F21PbfMEF0Dj_FbdZ9PhgjFLp8ZlXRc_wW0o1tLck3f7caISGUEGAH3RMySOQzNob6UC9N7ZE8FC8CgWORqrQLaY74DQA==" title=""><strong>investments by various leading pharma</strong></a> and biotech companies, as well as fostering collaborations to develop novel therapeutic platforms. Alongside the exploration of NGS services in diverse diagnostics, risk prediction, therapy selection, and monitoring in different diseases, assisting in the development and application of next-generation therapies.<strong>&#160;</strong></p>
647. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><a href="https://www.globenewswire.com/Tracker?data=XBI32A-wleR4rWy4LYl5jB9nm_xBHXOIX5HPQ5xob-Xwz4KE0e0jVsWJbeGkYCsL689sETklYL8RxoJGblhqDPzOUB8bZVTh8in2AL0Jl_rkBEyKxiz2El8_6qUONs0T" target="_blank" rel="nofollow noopener" data-mce-href="mailto:sales@towardshealthcare.com" title=""><strong>sales@towardshealthcare.com</strong></a></p>
648. <p><strong>What are the Major Trends in the Next-Generation Therapy Market?</strong></p>
649. <p>The emerging companies and well-developed players are stepping into leveraging their investments in a variety of therapies and their prospective applications.</p>
650. <ul type="disc">
651. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In August 2025, Northern Ireland-based biotech startup Dia Beta Labs secured €1.4 million in funding to support its development of next-generation therapies for obesity and Type 2 diabetes.</li>
652. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Gensaic, Inc. (Gensaic), a biotechnology company, collaborated with Novo Nordisk, a global healthcare company, to unlock next-generation precision therapies.</li>
653. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In January 2025, Coave Therapeutics, a company developing the future of genetic medicines, raised €32 million ($33 million) in Series A financing to advance its next-generation genetic medicines.</li>
654. </ul>
655. <p><strong>What is the Evolving Limitation in the Next-Generation Therapy Market?</strong></p>
656. <p>A need for higher expenditure in the development and implementation of advanced treatments, stringent regulatory requirements, and ethical considerations, are hindering the overall expansion. Also, the technical complexity of manufacturing and scaling production may raise concerns.</p>
657. <p><strong>Regional Analysis</strong></p>
658. <p><strong>How did North America Dominate the Market in 2024?</strong></p>
659. <p>By capturing the biggest share, North America led the next-generation therapy market in 2024. A significant driver is the growing demand for curative treatments, the widespread investments in research and development, and supportive regulatory policies. Currently, the US is working on advancing <a href="https://www.globenewswire.com/Tracker?data=XRLZONGSl3dfShqX7QmWuBidTv4v3RoglwFC7mZ2EXFpLaQnk7A9Zm5isJWhaGUyLtUmXMTGYhVqnhHnh49EzwCBderdme9XvypZMSwvwJmgV4R-rqkZ2Gx2lZtyX9lcB6ze9HbfD09InpvtUIaO5SRSTHtWPFul4ytiVVlHjWm9gpaxl5ZYlpz1KcBE3AXQ" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd3bF-XAmSVq2oaSxqJU__MDBRg_CTzSJSRFJ7TwPZGhKelkfGETCXaSSN-gQAZMJkbGjiC8wqESS61AjY9VbS_S-0j4HoV6eNqNZtlX5m9xxGH5F_sNjgygwNRnunWnJSWDjbesrrRv3rE66CmqZQTNU5MscmjPWX1ADwghaKKQe" title=""><strong>CRISPR-based gene editing</strong></a> in high cholesterol and sickle cell, advanced cell therapies, especially CAR-T for cancer, and <a href="https://www.globenewswire.com/Tracker?data=qLTAFmqRlYfkf6ZParwYCo-noJOemPhIls3Cbo_PSjxUl0Z8aCwfc1RkU5MKv-7lwD0RDrJ7knPrCXYbhRuDXXJzee9NkVHxRgrBIQ4XK2uGZdb-U1Du8pansXQJJkww-RPdxgOSAa-akpFOvuoU2ChHSCNe9tmc8QPH5dQxt-o=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd9xFegTDZcHqcn6ckLTYeqQ9Ema4DrVqPy6rM1Reqgf7miHiVop3QkCkNqIc2Iod8SxCvifoJGHayy9c15ruq1mOkprQGivNR6lmeLvLgGgXqYsX9t3lvAPz41XPDSDIg-aqaC-iTeFq4P5O3HssIUsU-U411XYUgu-v5TxgiL8c" title=""><strong>regenerative medicine</strong></a> using stem cells and exosomes.&#160;</p>
660. <p>For instance,</p>
661. <ul type="disc">
662. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In September 2025, Deepcell, an innovator in AI-enabled, label-free single cell analysis and sorting, partnered with InGel Therapeutics, a Harvard-spinoff biotechnology company, to expand the next-generation ocular therapies.</li>
663. </ul>
664. <p><strong>Download the single region market report @ </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXyG1b_eyaylYnp3Dr--_OJPqgN-2XVt4xYlrH1pAr5Njv55LaES2p0iBT4OoUHvPkjxGfDA3babIbqUV942b52JOr5g7p2okCXW6uod_Fm2RjY3RXUF-LcqFfbbkggxXE0=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7Hj8FKr-Vp1lw2ZinGQiyzl2_mObHraeCrqCVSXuRH3l3qH2SUkt9815SSwy8_xowOry36euL3R4PhGYXRcPEj0x_ibXGIREbJ-ji9gkMkyRqkVTUaZMaY6AW-5Q1gwlDo" title=""><strong>https://www.towardshealthcare.com/checkout/5823</strong></a></p>
665. <p><strong>Asia Pacific Next-generation Therapy Market Trends:</strong></p>
666. <p>During 2025-2034, the Asia Pacific is anticipated to register rapid expansion in the next-generation therapy market. ASAP market is fueled by a huge burden of chronic and genetic diseases, exploring healthcare infrastructure, and robust <a href="https://www.globenewswire.com/Tracker?data=QpH6ktxLbpbmzUsqPhfFuYhHhruGqUvlx-fEDbmt8ekCMAr9ZlaCieFWEB-nxWAUSM5iY8JNHt5qnxH_boZ8hWShWvFBU0cAGa5E5Re2KLwkhkm9DDIvsiw702gAqM4lkPySs1rElK4_CxQP-xb_Ovd-OJnhKpR4qsQtIEfcHL4=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd8w6P7gq7anq3tY87bB9YGvrKMhJxABOR4iTHDcg5VSoijlq4UC_9j_f7OGMHwCkUh-sHE-9lggBrhPZf5IXAy2IgZ_w5a2LQ-zGFHUfM4-sxNTJClGNeJQh0k6IFfEqBCkid6FUQLHY58ID2hk0Yj1yhmcXdalEg-hvCMhGCD26" title=""><strong>government support for biotechnology</strong></a>. In the last few years, Japan has executed its cell sheet-based gene therapy, with companies such as CellSeed Inc. and J-TEC having strong clinical pipelines.&#160;South Korea and Singapore are involved in the latest manufacturing and supply chain capabilities through the digital revolution and new funds.</p>
667. <p><strong><em>For instance,</em></strong></p>
668. <ul type="disc">
669. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In March 2025, WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization), signed a Memorandum of Understanding (MOU) with AbTis to boost ADC therapeutic innovation by integrating AbTis&#8217; cutting-edge technology into WuXi XDC&#8217;s toolbox.
670. </li>
671. </ul>
672. <p><strong>Next-Generation Therapy Market: Major Initiatives in 2025</strong></p>
673. <table data-mce-style="width: 100%; border-collapse: collapse !important;" style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width: 100%; border-collapse: collapse ;">
674. <tr>
675. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>The National Institute of Neurological Disorders and Stroke (NINDS)</strong></td>
676. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Started Ultra-rare Gene-based Therapy (URGenT) program, which propels the development of gene therapies for neurological diseases so rare that they affect as few as one in fifty thousand people.</td>
677. </tr>
678. <tr>
679. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>China’s National Healthcare Security Administration (the “NHSA”)</strong></td>
680. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Established a new reimbursement category (Category C) for unaffordable, innovative treatments, like CAR-T cell therapy, which are not covered by the basic insurance program but are encouraged for commercial health insurance coverage.</td>
681. </tr>
682. <tr>
683. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>Indian Government</strong></td>
684. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">The National Sickle Cell Anaemia Elimination Mission focused on eradicating the disease by 2047, with emphasis on screening, awareness, and comprehensive management in tribal areas.&#160;</td>
685. </tr>
686. <tr>
687. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><strong>UK Government</strong></td>
688. <td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Invested almost £30 million to develop a specialised facility to fuel the development of new RNA therapies.</td>
689. </tr>
690. </table>
691. <p><strong>Get the latest insights on life science industry segmentation with our Annual Membership: </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXzYC_EB9cRqKYfoqjrVz6NCQp_8g1SLPPWUwPIb8r1DAsyIQenOEoumhkcd3Z35wObYyO1LKDXZRoRXnSWXKabuWTCUv1trit_2v8BhhdI6Y_oc9yMmC4B1Repn6p3S8WecET9vVzYnGofgNfT6a17iVfgpVBtZB5fdCajsaetnLQ==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7HQGwOK4yJFJB-WI2D6XVvz0siSW3v3yKg8xDgBLCGyPe6WYtIY7IpFaLr9tszemg0qrFipWC48uJCDYL5l3WoBXLmXHHtJZ-yvGlSsI6WWSEIHPGbZ8bpRVYq_zUurOOd6abPS01ceMWU3HHi7Mm-ZQ==" title=""><strong>https://www.towardshealthcare.com/get-an-annual-membership</strong></a></p>
692. <p><strong>Segmental Insights</strong></p>
693. <p><strong>By therapy type analysis</strong></p>
694. <p><strong>Which Therapy Type Dominated the Next-Generation Therapy Market in 2024?</strong></p>
695. <p>The gene therapy segment accounted for a major revenue share of the market in 2024. The segment is fueled by the wider applications of these therapies in the rising cases of cancers, neurological disorders like Parkinson&#8217;s and Alzheimer&#8217;s, and cardiovascular diseases. Also, recently published advanced regulations, such as Epigenome Editing and RNA Editing, and Synthetic Circuits, are supporting further progression. Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) are both recently approved for sickle cell disease.</p>
696. <p>Besides this, the RNA-based therapy segment is predicted to expand rapidly during 2025-2034. Ongoing expansion of the pipeline of RNA-therapeutics across modalities, such as mRNA, RNAi, and ASOs, targeting unmet requirements in cancer and rare genetic diseases, is impacting the segment growth. The global market is focusing on improvements in RNA stability and delivery, AI-assisted design, and new RNA modalities, including self-amplifying RNA (saRNA) and RNA-targeting CRISPR systems (CASRX).</p>
697. <p><strong>By application type analysis</strong></p>
698. <p><strong>How did the Oncology Segment Lead the Market in 2024?</strong></p>
699. <p>In 2024, the oncology segment held the dominating share of the next-generation therapy market. The public is widely fostering awareness regarding health concerns by increasingly investing in healthcare solutions, and the <a href="https://www.globenewswire.com/Tracker?data=Y4iYCWty70fVHuqwhR2-bqPAAqZbCKGFk5D6wp5eRJB4N9tGxg341Xuycitl8R8GfnMf8_b7Pna6brDZVGiiu4BiRM_oE87YaeVIh-YSnNCSxfIZjnuOeXzB86ISbISpViWxyeXqx-onPoVNpRLHv2KKubY3OPs7BRYGZTrZGJ6kbbAOke-KONnh7ftgF0Nj0-PcBTAhBPz7vcEQ6pYphQ==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd7v1kf6mrbMmsCUtcpAZ7Ch982kX3eN3JM0cdhubTppkQ5oC4Rdh2Atzx3vL3TGzNoLzuDdJzk1ipuZXLpxgV6kBwvCW8gLt7_y9K8DBOeGTMxdYG_oL_6XA6FuEkH0FYHPBu46pbVNErbQTwvZ9TdPse4nr9X6WSLjozSn09cuNUs5j2LNsgv2NmM5MvDFazg==" title=""><strong>accelerating demand for precision medicine</strong></a> is influencing the <a href="https://www.globenewswire.com/Tracker?data=5C78byPBAyq5cDI36WmoYzvtCyyKBUVWi8rnXgs-s1gVbIFQl18WTQ4ZecGS_sqYnZOLOWip96_7KKm_PG-ahER_DDibFuxE57r9qT6EtEPA6r-zKJNvJ3W_xVQIV1BoCFTABQdkusFOK8axvayoRnG7pF0QGWr3sAUhHx5zjOs=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdxtSVZa8jLrzKmOMDR3h69mBWcOa8KE_g4JgJehfYthvu5bGpiZ2OdWLL8sVXSKbdIJWd4vSrBwiEcPwxzIxtfdElj73-cq-rS_i-AL9FQT7Jw7sc1JKSnlfaUM4MeWxWiiqyDAeLLuFT7bGBbpKRlM=" title=""><strong>entire oncology domain</strong></a>. Recently developed Tumor-Infiltrating Lymphocyte (TIL) therapy&#160;and&#160;T-cell Receptor (TCR) therapies are highly used in solid tumors to boost immune cell targeting.</p>
700. <p>However, the rare genetic disorders segment is anticipated to register rapid expansion. A rise in rare disease cases, expanding awareness, and the adoption of <a href="https://www.globenewswire.com/Tracker?data=8CGjtBgwAD-kV44W3jreNpaNktqDwzxwTUeW_SPAOQqLJKr7GhdOqpn32V5iNSzMGkTbe58WYPND2-VsQdSFz7wexsl44Uhn9taKXoc95mL_lJBs9yWSR4hpJGPOZIeW7GwDVlyzG8ckRDhHcZj9CcJlFQKsJ1z7pe3iv7upqCcV6Fj8b07QfMZDLuqCOJYd" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd_YjnMgokUAnYLmdxis03qOp4W83B_LZ_jGYocWrHdC3yLTBq-DTgPKztOtfWLRv3yxRlSBTkfd48OlzViwdugOFVxFqvflhEq7Ku5OyB-_xkev5nUaEVBG4AebnYpzpQUp0LZRWC81T6iKM4ewmXKrAmzjAbeX4Cir79eUwnWfc" title=""><strong>various gene and cell therapies</strong></a> are impacting the overall market progress. Nowadays, researchers are focusing on gene editing, RNA-based approaches, and in vivo gene therapy used in these cases. Also, leading companies are leveraging the use of AI solutions in the development of personalized approaches and new <a href="https://www.globenewswire.com/Tracker?data=BMrD5m80KZyZ1IiF5PabsUtiUIhbrb5ukJzGutvgoEoheW-3IdWlDKbFe7yhkwb_KQqyFhFDz-g9B6v_8rjdPzYbxmVNseBPeD-GYfeOpX7ECzr5n4dkXaI_L_iJG7J2dOJ8zFX8jh2DEnyxIhjXpkxL25JJji4I-NgnjiHgLts=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-4h1IZZpk1RBkwWSzuaqnqvK4y-RfMcqp5SwozTN-pb7XugRcDS0a9SShFxCxRYPaqUMnB7dWp6yc3UHU2--2H7lnNth46KthSiU5GDdzwBOVVffzBMQ_BPabeNWhcsslMrI1NIe_pxV-ilCfCpvcDo0pYui9HA8Gf98HAplye6" title=""><strong>AAV-based gene therapies</strong></a> for neurological conditions and hemophilia.</p>
701. <p><strong>By vector type analysis</strong></p>
702. <p><strong>Which Vector Type Led the Next-Generation Therapy Market in 2024?</strong></p>
703. <p>The adeno-associated virus (AAV) vectors segment accounted for a major share of the market in 2024. The wider advantages of AAV, a rise in the number of gene therapy <a href="https://www.globenewswire.com/Tracker?data=dzF9udktMpjcVnadOepvOwA8ZvpI4tA3Zt1dqwsC03TTWj5NwmkcBrTBTVIpxqB_eaYtyMq2kBDmzYD5pb8TtCIKxyEqLHaL8MA-D6a7r4qKvGZb4Pyp67q0PB90DftEGjEg8aKaiuwKtr0YidNcrNf6DbcqiXADsLg51QhDQeO_Cf6HKLcdt4-nrgERI4NJeUsqo3YtdSRvnMJPnV1Z_A==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd0W1RwEJxX2X-CRyMZXUQfc8URCyE-bB8Zf32SVU3FrnDL100L44tMVWlw-yNXof3VmwsvQr8Qx8g-9ovlVpwAnsIkc-o3kH5FF1wt5k3ED3MXuehhcgk_3R0RZGtU8li8tUJ8grelxtB6mDPlHuWTuqGJC7zSWAtpAwILAvRA7ufuzm4d-GKKMok2SYa9pkfPqxbfI-7PBHBu2nr2irN4s=" title=""><strong>clinical trials and approvals</strong></a>, technological breakthroughs in vector design and manufacturing with enhanced efficacy and minimal expenses, are fueling the adoption of AAV. Continuous use of computational tools like machine learning, as well as directed transformed methods, is supporting the faster discovery and design of new AAV capsid variants with superior properties.</p>
704. <p>On the other hand, the non-viral vectors segment is estimated to witness the fastest growth in the coming era. Widely influencing factors are the escalating demand for safer, scalable, and less immunogenic delivery systems as compared to viral vectors, the <a href="https://www.globenewswire.com/Tracker?data=CEnbg3yVwXOgaOahsTCbXQbJPLLhWKGtV2dfnW-7vvI7hhdQ-WTwBYv-H_c1OwdH8iJ7HUNKb8aGsO1d9TXoKc5FpUnqc_dyBeGo2Jkt8WV8skLkeedndviSebcAhw6G46nxdfSRmfWSuSGRsYZbgrHdK-1zEc_6UfKiY7M-F5ZIgpQv12yBBj4cgZjkdcCp" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd64vTsFVnNd5tIKcl_IOb05waGyHJD2ctS9kaPtZRvLXGyCDpvFvTuF7qacdWkVVsm-NhNY0OIO4L8O5Bg_rRtfsv0T1U5Yt6mGRqxOWb2_hZNsFPJfsfVx4tQjcH4WSLml3PvVFiPpjtcV0j09qHI1D3o2qATnl7Vt4DVctCYeGdjLIak7qwd9suJuKZJN7oA==" title=""><strong>success of lipid nanoparticles</strong></a> (LNPs) in mRNA vaccines, and advances in non-viral delivery technologies. Currently, researchers are using advanced lipid nanoparticles (LNPs), cationic polymers, inorganic nanoparticles, and virus-like particles (VLPs).&#160;</p>
705. <p><strong>Get the latest insights on healthcare industry segmentation with our Annual Membership: </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXzYC_EB9cRqKYfoqjrVz6NCQp_8g1SLPPWUwPIb8r1DAuMUolXMsNmfFWNSQ4c8Y6gEmhcE-REhwyhQk_XVvLcoG3DGuQxBjs80I40TUntgDkE4syguw-jKz9MVkHOEwikOnR9qblSOCmgGZosM7n0PUVO9LHWpMNsncwam2uKmeA==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7HQGwOK4yJFJB-WI2D6XVvz0siSW3v3yKg8xDgBLCGyPfmQ16YO8o5_rBS8YprpJ0OSlcIm7GFhaT6pBPkRs31AQP2cSj-VLPHmWV7I_sSicqgTzfdo0FMELUnVw4YNY8N22C08yTNpGLFktbH5ifSlg==" title=""><strong>https://www.towardshealthcare.com/get-an-annual-membership</strong></a></p>
706. <p><strong>By route of administration type analysis</strong></p>
707. <p><strong>What Made the Intrathecal/Intracerebral Segment Dominant in the Market in 2024?</strong></p>
708. <p>In the next-generation therapy market, the intrathecal/intracerebral segment captured the biggest share in 2024. A significant need for efficient, targeted delivery systems in managing chronic pain and neurological conditions, like multiple sclerosis (MS), spasticity, cancer pain, Parkinson&#8217;s disease, and spinal cord injuries, is supporting the adoption of this ROA. Recent approaches comprise intrathecal <a href="https://www.globenewswire.com/Tracker?data=CQVb3qV6HoFULg652czhwdmzugaS2rphzR0oP2dkHGS3FEeEs94dfG04rEwqI_kI2Bvf-05wpO3dF8yyTQB6oWQx_Zjjlb7zLnTSpPPB8MmEYrX7hNPgZObd9TwXKa-_loTjNTKYqFct-nO4uJgv_UTol6Uhz1GDxuco2ggNHb_nwSFmwB6saRFgbmy_Gagl" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdwAOKevUVuhullUqbazPw5SK_5d-1AoWgylbFbEYa2mKuKghtWXvYgwXNLsi_fe5yTKHLA4nTvacdEO5__HakE4t9qcBB39xqC_P7PQyKfCvccfOX5I47-gd_e4jzdlYwCaetGnpTb9n6-lUqWiBbYS5sy5I5aX-GE__8HcYmuJV_f917FSdJsjm8_8WfU9l8w==" title=""><strong>formulations of gene therapies</strong>&#160;</a>for&#160;spinal muscular atrophy&#160;(SMA), new&#160;nanocarriers&#160;to accelerate drug penetration and targeting, and advancements in intrathecal&#160;CRISPR/Cas genome editing&#160;techniques.&#160;</p>
709. <p>Whereas the intramuscular segment will expand rapidly during 2025-2034. This route is <a href="https://www.globenewswire.com/Tracker?data=DPGBVBsnfSyq0mqaoh7nGrHl9sXLQzadRZl5Hdeu7_gvVhzwzXr4J9E4mGw7Lk9XarIKZ8jPhiMxp-Y4mk_9QpN2vXfaIylbeawG4q69MLrWTVlK_xUuPgNIWAG2gtwmWARv2zz0fC2U6hYm21RZ1lhuhCGuyPeCtdXOX97mdUZmXNVbuH8wVehn1PNUeeUT" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd4_p3E9OQnipwhdm3nIoYdPFZ1zwVSnl1c9ObMjAWw5kO8Vldp-rG8ydgXS4GDZYCdE-Az6Dq64_1AfbwHSV1V9GI461r-CNwtUHdCnKWaqkO-Dn4BncU64WLaQruF0e8WvDA2ghiA8W5tH2mr5yuUj9u6nh8CW8EKUrcxtDzqHhdBPf2LTcUdOm7qFNjhZnaw==" title=""><strong>playing a vital role in targeted therapy</strong></a>, as well as innovations in pre-filled syringes, pen injectors, and autoinjectors are also bolstering the comprehensive drug delivery. In this era, the market is emphasizing the optimization of the physical-chemical properties of the injected materials, especially the lipid composition of LNPs, and the choice of muscle site (deltoid vs. gluteal vs. thigh).</p>
710. <p><strong>By end user analysis</strong></p>
711. <p><strong>Which End User Dominated the Next-Generation Therapy Market in 2024?</strong></p>
712. <p>In 2024, the hospitals &amp; specialty clinics segment led with a dominant share of the market. These facilities are offering their crucial role in facilitating advanced diagnostics, personalized treatments, and post-treatment care. Also, the broader patients are looking for customized treatment plans and specialized care for complex concerns, for which hospitals and specialty clinics are providing their well-equipped provisions.&#160;</p>
713. <p>On the other hand, the homecare segment is estimated to register rapid growth during 2025-2034. The rising adoption of remote patient monitoring, AI, IoT, <a href="https://www.globenewswire.com/Tracker?data=8VgOw7s05_Ow135ECqXSrE_YV3VRqbwBOlAEOLfcv-LhCBJD8BXeyMJ7odpWanammRlR0Kc6JiQdnQ0McSbO_4XMyQovz1wprrxy7tY4IK1Fw3OgJZGkIIOuHbVasS67iv7SKYDhOZNgaKBkpLvgjg==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdySkf58M5s9fv05C1jwKwiuiUXV83EP_8FerncceA0RDqYHvjp4KL47shzp6uXHBW08ERY0dAF3gFJpd0sxb16OTgkVRI70MAH4W1JPf00z5Aa-u7hAZuO2Wai18dWF-1LkQDoyPcLNKQOtGDVouVNA=" title=""><strong>telehealth</strong></a>, and smart devices, alongside suitable government policies, allows efficient and accessible treatment delivery in the home setting. Also, the population is highly using advanced smart infusion pumps, wearable injectors, AI-enabled hearing aids, and connected inhalers, which support advanced treatment delivery in a home environment.&#160;</p>
714. <p><strong>Become a valued research partner with us &#8211; </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXzMmD7MiVVjy4CJ7iZSgZDLhV2AZmjs4OGrj_1TlAAzS2d0z3djp4do04uH5DVszZE5kNrCJLag49jHZGeBO3ymqhM2NfvnexfPOyZ37TjrgznIH2gqdCaFifvaQbZ28kTsNEixxJfgPHhC37Ep0AqQ" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7HlEghVT7nEPQ2P6pLn1v6BBZPl9a4tW9fb--nFP4oVkNpzQQ5xM4_NalF-JKJr7MDx4TimyE7WFDq9LSNBWri2aLLlohPTbsIEBfIST5oIebKAwb3RE_E-ZkwHJBxCmIH" title=""><strong>https://www.towardshealthcare.com/schedule-meeting</strong></a></p>
715. <p><strong>What are the Recent Developments in the Next-Generation Therapy Market?</strong></p>
716. <ul type="disc">
717. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In October 2025, Qkine, Ltd., a specialist bioactive protein manufacturer, launched its Cell Therapy Grade proteins, developed to assist the strict requirements of cell therapy research, process development, and GMP manufacturing.</li>
718. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In October 2025, Mytos, a biotechnology company, launched its automated contract development and manufacturing organization (CDMO) to provide scalable, cost-effective manufacturing of stem cell-derived therapies.</li>
719. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In October 2025, Gemma Biotherapeutics, a leading global genetic medicines company, launched Rare Therapeutics, Inc., a clinical-stage company focused exclusively on transforming gene therapies for ultra-orphan diseases.&#160;</li>
720. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In June 2025, Eclipse Bioinnovations, Inc., the major partner for RNA-based and RNA-targeting therapeutic development, unveiled its eVERSE<img src="https://s.w.org/images/core/emoji/16.0.1/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> portfolio of AI-ready datasets.&#160;</li>
721. </ul>
722. <p><strong>Browse More Insights of Towards Healthcare:</strong></p>
723. <p>The global <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7NDQi-U4iWE8oHVHvR1lqvlBt8ZnzepiI36Jp3mwn0T08UCj7dXMQWiGyIhz1BY9uj8KfbTdV93nMjUfKPCV6tPmQgj8RFbbs8od1fZ-QzpIKmrcsOKqSzhcc46ETsdiZLLzt9rnsokCsPOHpIejuDox2efiu85PEgGg57UMJkw7" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty9H64mfYjerq4Fa8B97reo2mVdPvNlhZhn95y1fzwB5QjBxUX9JQCVVOdH55BBGFGMphaT9iBIGgS_l-3i4ALVjlIP4t1_p8bOn_0v-A1ls5XGbjrlVhz2XG03H49zc_y1f_F9or4Zd1-WCelnYVM6QC2sNslOQT7j_l14liH-S0A==" title=""><strong>next-generation CAR-T therapy market</strong></a> is witnessing strong growth, with revenue expected to reach several hundred million dollars over the forecast period from 2025 to 2034.</p>
724. <p>Similarly, the worldwide <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7DOKUoWPG1wM5Axn2PC0TJqeQ2UGSkjJCxF_FbWb8ncbfajQuqYJC1G1N8ymCfadFW9bWqTEtF65dRANmMyABvzRiYgD2t9yeQk4qAmcg_JSpbSSS8cU9OEVpQMxrHPIK6tkDRoB9N7RdlaXT2e2gOj8lMqsZ3TYDl-oLF2qAp9xOdZsowawd-jjxNpXWDm_jmKdp7ZxaAZD0hwqgga4b-I=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty8oDB58llsbmTDQ-C0MeLfj06Q-pYjFXYLthOPtLrls4nyFGFiwgA3vln-tGuI7hpsomKftyZPIQP8P9bVWIkVmXUl9ufX_-Kqc4Mz6lpX9WDeCAiJoKkXtPrsjs1L13Z2f_gHR4mcjG8j-uGVMF-WjL0N6jzT-rotwA1xYZJgR3CfbLs-Vw4x7cscIZXk5m4U=" title=""><strong>next-generation AI in life sciences market</strong></a> is expanding rapidly, with projections indicating substantial revenue growth by 2034.</p>
725. <p>The <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7DyYKpjFYI9Es6cRr6DonVAGWWBOUDRCctFkgceIxXBjknGXfE1sMq2WcvExqcz1crjo2ldB-CRUnGS8FSOwrw4vB10zB_GaFgp39zJr23I2T2vzS65Z9NeqhQkqSmObeo5U_99Xph-ScEaohrCBKZQbtxZ7N3_l_7fxseEv1FbYoRYHMSKbJgEnDCW3N9jwPQ==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty-uE2g6wAFFKr9UDHvyp9KQ-YPlSpw71ZBHMGXr_SH-7lG8cG9Qcgx23Sh_q-GY3r0eg4coeJelC2GxkKUkq1JlPymMGSF7aoItDvxvm-8MJwRLJ-6taAQJ8MvwXGb0mbG0yIzYt44pi3PYbAK586-AeDctRK4WNcLgyYYlT0_EzsPoqbWoSTlNsqUHglVIuRw=" title=""><strong>next-generation proteomics market</strong></a> is also on an upward trajectory, expected to generate hundreds of millions in revenue between 2025 and 2034.</p>
726. <p>The <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7CY0aCCaWH2afaBXadm92Dh_7W7a1hMuS2VNMYhVgK4mlg9ezG_ok-Etfr2ihcQJAZkzZZgR5m4VNwnWy0WGAMQBhH1LRmKhxQy0wuXepKTkWXi07V23sPFbf5fKGLGaNH0i2ghdD4mjGDMh_NXBZyUSzLBx2p81KLc_kHhA95hniX6fsNxl1-iVAx1edmxDNw==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty8ERFmyexCtRsbVoKjIhCFSPhw0wyaolOQ0bR9x1xWg6FTMVy3hSwCa1SlKplQHkbP7p1x1FjAh3Rm5VpR_qO_NP6TyFQal9BmLGjXyAy0tIKbrfVcu4x7lq1_U_JtaSJpzsyk-z7QU1Rx0GrbBdlccqrKxUMj8qxkfhmBTLPrc8g==" title=""><strong>next-generation drug delivery market</strong></a> is advancing at a significant pace globally, with revenue anticipated to grow substantially over the same period.</p>
727. <p>The <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7CgNfiXiMkr2i6K_oKf7iJXIU7rhr6pI_6gpl4Im81GRBdkWeBKsM7qIxMKNxtywNYWyrCzgixL56ixSCfUll-dF5-dEx633WvTpzpjzUnZJzAndr6KNib977T32I_qcx7Q0hsHrepc_GHf_Z3cYOkwY-aP_rUk-oAtR-LDFsR9SDUMMNKoFYoqj16A2fM6M9CQqx3HIHf98rAo13PtSy9s=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty-0Mh0SCyPNyoNWJHCLpc4kH5VnXlFvzyGeRCbzpieQbn_2zzh_CV0t4Cs2YBN-r8UGcMINLBEOY1o0Qfsj9r7zCuQ0PD_UKT41M270NtlMtB3nhv8CcdnELz7yCnEOTvz5D0H9Sy-zIBff5ELgC7KC75LMHXviiSOm7CyCtWVaBHBAlyrJ5uBzEV2ONU0TrHk=" title=""><strong>next-generation bispecific antibody market</strong></a> is experiencing robust expansion, with projected revenue climbing into the hundreds of millions by 2034.</p>
728. <p>The global <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7Jf_tdzNbf_5hoUn_EijJV0H1FOvp99vaBfy6eTsahZwcqf2m-UvxuFbWwe7V3nGoT1s-ha5Ffj-9-TZrQ0YYMwVg3l0xHgdlUXq-ls5SP33MGgKAPkAYCjbka-QjAXqgCPZFEnhbauVwNx0xqXb7bkT_MRn_dt7H3czX0iT6TUHC6mh9CrlNieqn96GyZemfA==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty8OzhgTq5Tlt13dzWc0jnY7T653mdVTdlvJSC5So4cxkIQMiDhGL489T6DPCiw6PpSBQjKf6WEjanbjWRuRs7_xVDBRsK6gPzqBLZfcrH6puNRCBTjh2CQ7S75Ikl3fUq97kkI0DJOQlGa_e06sDv9jygWY0oIzifuaDIqXdOP9KaOpnSJX7LSbxGM-P_GoO1c=" title=""><strong>next-generation COVID-19 vaccine market</strong></a> is poised for considerable growth, expected to achieve substantial revenue gains over the forecast years.</p>
729. <p>The global <a href="https://www.globenewswire.com/Tracker?data=MJsODnNlraspgERWpNMg7FnJVaZIbuirDPoCr1mmK_Vr9S8MdJpS4vZaRgCDj_MLWuOWJoMl7h6iJFUhLnKrT77ei5JsnpC9-m5q0DtAatUBPtkJX6IXXPf64wT5AFUW0Ds0JRsepRSoKazPyptyofqzmejllXNageUkJmev7TOMeFswYeWXQs8bj4elRb1BEYUqg_tawSwdAIY2T837gQ==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdw_4G8pXlrTQ14qAeoR-ty9pjxuCZMst46txKzGxY_MS2v3jvmtkhZiX9OCb57Xbm_VOQx0JX2hfJYndazmL-N5lesYieKT1G2mN1jLamKw1KlB6W7hM3yJUClgfmSxvYcAs5j4-5e7opNYCl3jRnZnHgZwh5AmAmul3-F3a0ALR33nOiIpi2jLWjcaRW2TjwiGd08j1y95TdBrU_VgLP5Q=" title=""><strong>next-generation sequencing (NGS) market</strong></a> was valued at USD 10.27 billion in 2024, rising to USD 12.51 billion in 2025, and is projected to reach approximately USD 73.47 billion by 2034, growing at a CAGR of 21.74% from 2024 to 2034.</p>
730. <p>The <a href="https://www.globenewswire.com/Tracker?data=zhMUoyaBo_3j-jNQLcZNvsDTqZkJErWkv1M-N5AXUh4S0RvOPR59KsXJMcmIoo8JExRlV8KYTZMCqMnbwvxkDiq_PV-k8TgyCCbLiQ9jiubSLoBghSSgYXFFK921vaRWLEa0YbprxceYZOTJ2oD4mhtNSsQvo2n5j1fzM-d0lVeb9TtJ_8qk3YxIHYFIE63A-hH2dnTkhWVSAUkjN_3UM6uOk6OCQLhZtZkCKQL6PMg=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd0NCplTAS12dNRuRtYJVyvxAUjkGn-ngiwXRXkEi8GvFaA4quqG-1KfGLMOkNmTrdUh1uaJCBJKz5Io_Hmf3wc14a4z9GUB3Nj6CpkNiIGGaofaEWHKFuqWwQ_dBLBQII78sxtFG6Tns4H1ngogpFMv-viz8kw8AF8uJ_ussFROl2s6w-lFb4NMfTBkj-htHINBJ_CMDWYda9HDErqqTRFpvjGKpSn8CfukJyxNytDTH" title=""><strong>North America next-generation sequencing market</strong></a> reached USD 5.08 billion in 2024, is estimated at USD 6.19 billion in 2025, and is expected to hit around USD 36.87 billion by 2034, reflecting a CAGR of 21.93% during 2025–2034.</p>
731. <p><strong>Next-Generation Therapy Market Key Players List</strong></p>
732. <p align="center"><img decoding="async" src="https://ml.globenewswire.com/Resource/Download/c1a2f451-4eb8-4702-914b-9b4644cb33b6/image2.png" width="601.74px" height="356.27px" name="GNW_RichHtml_IMG" data-mce-src="/api/ImageRender/DownloadFile?resourceId=c1a2f451-4eb8-4702-914b-9b4644cb33b6&amp;size=3" /></p>
733. <ul type="disc">
734. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Novartis AG</li>
735. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Gilead Sciences (Kite Pharma)</li>
736. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Spark Therapeutics (Roche)</li>
737. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Bluebird Bio</li>
738. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Moderna, Inc.</li>
739. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">BioNTech SE</li>
740. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Sarepta Therapeutics</li>
741. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">CRISPR Therapeutics</li>
742. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Editas Medicine</li>
743. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Intellia Therapeutics</li>
744. </ul>
745. <p><strong>Download the Competitive Landscape market report @ </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXyG1b_eyaylYnp3Dr--_OJPWwTi21YHooG1CtAOxDEnTBx06YfPibx6YRA_WUN6jHE7J975Hfc4YsX3ymznui20IJszHmGeK_RdFX-lfju-tl9Far6tv4AI8NYzhHAWtMk=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7Hj8FKr-Vp1lw2ZinGQiyzlxLW2FQpbtIwWwbf1v5XJnyeRpq3Mif4nNUBfywCaOusuHhOjvXAGRal8SkFStMWNjqGWeR5TlCLmluFy6xJfMjxat9rrS8PCdC7i-8HJAHO" title=""><strong>https://www.towardshealthcare.com/checkout/5823</strong></a></p>
746. <p><strong>Segments Covered in the Report</strong></p>
747. <p><strong>By Therapy Type</strong></p>
748. <ul type="disc">
749. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Gene Therapy
750. <ul type="circle">
751. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">In vivo Gene Therapy</li>
752. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Ex vivo Gene Therapy</li>
753. </ul>
754. </li>
755. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Cell Therapy
756. <ul type="circle">
757. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Autologous Cell Therapy</li>
758. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Allogeneic Cell Therapy</li>
759. </ul>
760. </li>
761. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">RNA-based Therapy
762. <ul type="circle">
763. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">siRNA</li>
764. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">mRNA</li>
765. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Antisense Oligonucleotides (ASOs)</li>
766. </ul>
767. </li>
768. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Genome Editing
769. <ul type="circle">
770. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">CRISPR-Cas9</li>
771. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Zinc Finger Nucleases (ZFNs)</li>
772. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">TALENs</li>
773. </ul>
774. </li>
775. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Epigenetic Therapy</li>
776. </ul>
777. <p><strong>By Application </strong></p>
778. <ul type="disc">
779. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Oncology&#160;
780. <ul type="circle">
781. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">CAR-T Cell Therapy</li>
782. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Oncolytic Virus Therapy&#160;</li>
783. </ul>
784. </li>
785. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Rare Genetic Disorders
786. <ul type="circle">
787. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Spinal Muscular Atrophy </li>
788. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Duchenne Muscular Dystrophy</li>
789. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Inherited Retinal Diseases</li>
790. </ul>
791. </li>
792. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Hematological Disorders
793. <ul type="circle">
794. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Hemophilia</li>
795. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Thalassemia</li>
796. </ul>
797. </li>
798. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Neurological Disorders</li>
799. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Infectious Diseases (e.g., mRNA vaccines)</li>
800. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Cardiovascular &amp; Metabolic Disorders </li>
801. </ul>
802. <p><strong>By Vector Type (for Gene Therapy) </strong></p>
803. <ul type="disc">
804. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Adeno-Associated Virus (AAV) Vectors</li>
805. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Lentiviral Vectors</li>
806. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Non-Viral Vectors
807. <ul type="circle">
808. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Lipid Nanoparticles (LNPs)</li>
809. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Electroporation </li>
810. </ul>
811. </li>
812. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Adenoviral Vectors</li>
813. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Retroviral Vectors </li>
814. </ul>
815. <p><strong>By Route of Administration</strong></p>
816. <ul type="disc">
817. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Intravenous (IV)</li>
818. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Intrathecal / Intracerebral&#160;</li>
819. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Subcutaneous</li>
820. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Intraocular</li>
821. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Intramuscular</li>
822. </ul>
823. <p><strong>By End User</strong></p>
824. <ul type="disc">
825. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Hospitals &amp; Specialty Clinics</li>
826. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Research &amp; Academic Institutions </li>
827. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Contract Development &amp; Manufacturing Organizations (CDMOs)</li>
828. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Homecare</li>
829. </ul>
830. <p><strong>By Region&#160;</strong></p>
831. <ul type="disc">
832. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">North America
833. <ul type="circle">
834. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">U.S.</li>
835. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Canada</li>
836. </ul>
837. </li>
838. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Asia Pacific
839. <ul type="circle">
840. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">China</li>
841. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Japan</li>
842. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">India</li>
843. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">South Korea</li>
844. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Thailand</li>
845. </ul>
846. </li>
847. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Europe
848. <ul type="circle">
849. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Germany</li>
850. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">UK</li>
851. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">France</li>
852. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Italy</li>
853. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Spain</li>
854. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Sweden</li>
855. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Denmark</li>
856. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Norway</li>
857. </ul>
858. </li>
859. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Latin America
860. <ul type="circle">
861. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Brazil</li>
862. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Mexico</li>
863. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Argentina</li>
864. </ul>
865. </li>
866. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Middle East and Africa (MEA)
867. <ul type="circle">
868. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">South Africa</li>
869. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">UAE</li>
870. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Saudi Arabia</li>
871. <li style="margin-bottom: 8pt;" data-mce-style="margin-bottom: 8pt;">Kuwait</li>
872. </ul>
873. </li>
874. </ul>
875. <p><strong>Immediate Delivery Available | Buy This Premium Research @ </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXyG1b_eyaylYnp3Dr--_OJPkINA1j6FuOEMLAtXE7R1SBejqfW6Nn18fR_LN_pyGkkQ53nz2eIF9sdT7dOQw1q0FvnfNo4kwh2HI-t3vvzANvsEU4m9cV4i9KrDiZJZBd4=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7Hj8FKr-Vp1lw2ZinGQiyzl2Man8uD5Fv9voiTEh5FSjUghLr41uVZmxQES47OaOmOp3PluBNm2jTlvVeV0XNlmSNXYRmdHy3R-00aRLcvUkSFrpjZoLyqTP8yMmM4ZaVC" title=""><strong>https://www.towardshealthcare.com/checkout/5823</strong></a></p>
876. <p>Access our exclusive, data-rich dashboard dedicated to the healthcare market &#8211; built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.</p>
877. <p><strong>Access the Dashboard: </strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXwuiaQ_OF6ildIW8H3urB-H4QnMiKNeP-0GtOlRkDfIBGmqYLt8ym4MkQSfZiVn1_U5T2VzJE_de4aJ9G74DeDslayc6N4rcQEToiYcTl_dGcGCaD9IDuFGIQCkxtBnoj6h5kKXVKLFW_n4GOY67Mur" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7H6tpGsR3GSklgrLZmmaIKteib1nc2j2hYOJxPUbRNjQBHX0ndgwcm3CFrwnwB7NM12cEq2yH4NIpHuVbKyYUzO3rOe-1XZwWysAWFYREwf8vgVM5Jf4UhKD-eeTGHP6j2" title=""><strong>https://www.towardshealthcare.com/access-dashboard</strong></a></p>
878. <p><strong>About Us</strong></p>
879. <p><strong>Towards Healthcare</strong> is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a <a href="https://www.globenewswire.com/Tracker?data=rZq5hdEnddv4jc4EJ6GxH5yRS7pzE8nKuGnbJYfkVMF-ulHaatm-zP6kChqTdbJSejp4xtk2Q7hkYij8BuFd7vIGpyUY1mAdatL3mBAmhr9yYRloAXaAAtUoJzpclUQTW5jdrFz3LJVgrcRv9R22mkscPon7bAkAU3c7U6bfYi49A9uQgnqEA1iG-bqo2pkI" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-zo_TVKJ6nW9GQRyK9il9JaDuBqkpzEbhmc-rdIh1HQ8vYhfxHTcb2WBL-7yl_joCL0fNRLtG-U7FpMQ-tumd68PKvzv5VtjeAA4VJ0uRPxBMZZdjMybrhm6X5eSNYYQcLmLrriNOC_8R930kLgKaJMNv8e_ewLGL3BfFEOPAeQP6KstURzf71B2VAzcpXrHA==" title=""><strong>strong emphasis on life science research</strong></a>. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.</p>
880. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><a href="https://www.globenewswire.com/Tracker?data=XBI32A-wleR4rWy4LYl5jB9nm_xBHXOIX5HPQ5xob-VMT1NuHD6xmLIY6u6YpMvQZ4CIjrT2hNs4xrkCMtonmlA-IvNYhzkm5YQYcVIV1m4k_L1lAGOgpkfTU7bCk_mv" target="_blank" rel="nofollow noopener" data-mce-href="mailto:sales@towardshealthcare.com" title=""><strong>sales@towardshealthcare.com</strong></a></p>
881. <p><strong>Europe Region: </strong>+44 778 256 0738</p>
882. <p><strong>North America Region: </strong>+1 8044 4193 44</p>
883. <p><strong>APAC Region</strong>: +91 9356 9282 04</p>
884. <p><strong>Web:&#160;</strong><a href="https://www.globenewswire.com/Tracker?data=NLrITuvDPsHzlvqxD89G1Ltvc4_CPFQkjlyCR14nTXx0DkiAefgt5tf0DLa-FB_xcBrpImp8hPDdWd3aKIO-arNwHB5L7PidtvbVyxSY8_aPEZGZYvGf9J-Qa2H0YTy7" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-7xL_bUvwquAFeCHFiONml2hbR-H-0mF96V6xQS_y7HGX4yPKl91sz88_qYg5g8b7GvEO6EyUM8Ugio2MeBPyU5tzVPEsWeDCgvrCMXqzRWb12TIE2IQYFoBhTT0tz_0A==" title=""><strong>https://www.towardshealthcare.com</strong></a></p>
885. <p><strong>Our Trusted Data Partners</strong></p>
886. <p><a href="https://www.globenewswire.com/Tracker?data=drpMIIH87hKzKMlHgSlmWL_8Csp8HToKHr6DldwZ0X51h5dmZo23AIby6DCXdplhl5smjp-P-TWXXqvFuSmTGE5j5PHdS147EVuwIlvtT9qVJgBz6K2MaU9Ug7shYJKn" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd88IhZ0lWC8GpZ45Xxh7kAHWFPrwOX8oGu3NfzFd3pz7Q4Z7sNrcC8bj4unyRPQ6Gv-46xFS-zpuFKgTAlx1rq3TqOX7u5lI9WjkXQ_iux4S" title=""><strong>Precedence Research</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=uywgnUQ6T5bYltQwt-TWCt2x7qbnhwM2Qep0_fjeMlY4vJ0w9d2EMoTo86fxW5hAQi9R_ecUL8hTD0PZoZROTRt8pXW_GpxvVV5qoeoaOwI=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd6lX6SZ80spLQNjq5QvyF8CkDnt_a3xouhF_TYSE5UVahOI6lisWIuUfs74CXYer-g4E6uvrPdFio-3KSzZNkzw=" title=""><strong>Statifacts</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kd3AmRMRuBm2Z53769hVNQwaMECybs1PvTES9NtGncxfXnmaKbuctxsjumcAa4ZhIgPKqHjwqKbCJW7Rnn83LYA=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdwniXjgeX6U0t7yHqKu1NWDXWVekmyf3ZB5hyYnpJDtnZ2VXysqFIZKcX0tXNcG0MCIjfFUlCiX1f7jyx5wlU3cA3TGj1S9hIUSiBSJlJ9Ia" title=""><strong>Towards Packaging</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kWmKpAmay4saX7gFfbH4TMfgwdvAUzoEwV6Tl8f_5a2gSPhcfEBnWZYfI50PO5iLdrO8v7Z48DqgBht0V9EQWmE27xXmq2N4swcYpY5iSUjm" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6QmdwPmmlKo9nndd7GFofosDtoNcJsqODxc3Y7xSTY_3Jv5gpknUkD6i0g880RMDQJpYFK2S6ad6YOB6ZoZdQDXaIVZNMRChF2I26XZam_WMxvi" title=""><strong>Towards Automotive</strong></a><strong> |</strong> <a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kZkq0TmK1QpyLWxBU8nM4QVUEwj8Ea5EsuHqWdnrNyRFLnbzxo6IgByI8VsblcB0u_vWiaIzVARyPMDMZ-ErkOZXOBlb_142v1DXyQ3tphHT" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd_wodIFmN1o1glK9ioVFzYwpH3kGmYYj9dP-Lpp4HhsN0YXibh3zCgPn9COdmtroZiAMpaJyHQl3Dd1dHbHj4Oh_mlTNz4xoS8JTcgDSvdcA" title=""><strong>Towards Food and Beverages</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2keGJNxouOIRTmtRecvXYmgTwziL63L3tXKmVY62PEJ0ZlAFJ_RL4mEf1JlGpinktaeNzbhbDQ2CsFdmOi-FB3G6105io7tbvmTlqHsjYZI027he661ar2a7m7K7IIxvmYg==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd3xuz3b6Duqmp_wEKfpXazfMMHSiQt-g2woZquvd521SfTRzbw0GprYW6y10rTVEwgPfZyvgLmb6tAYplMkW3PvgsUMD7o6aA75Ls3bdV-Sw2qHFYO-_FELb4Ybsxcxicw==" title=""><strong>Towards Chemical and Materials</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kQC5gSWdGlx-9g80BuEk3HIXoRg6HSJNxDzqXpQH6TXO1qefpEPvjZwooDajZgD4jAr84tY0TEjjiwT1BjKXFjQza1yZkJzctJroHReHJQjN" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd6LbIx6HrrboxxkBzFRjBmHCozvLg9kHQY01zWh4HyOousJGHFwheqAWXpVhjDdm93dfjftorMqxrkkShKVOnlJdEddNGQ15ftEoxv-tMHpj" title=""><strong>Towards Consumer Goods</strong></a><strong> |</strong> <a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kbNHodb3N7dVgmR_e_qkoqb5oMIkoWpRNVzgYiZFAWkhYov_qIkdP9upO9NAC4v1B_MY7fpVL17appcUkHdwCMM=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd78v3v3o3e4C7Su7OZrDUuMMOvz0mMaQQ67BHHFkqcbEN0-Mt0-fZJruUZeSbQjNsVQSFt4WPGT05mpYMdfTF5nI6nRlnETILBOUEdrVbQqS" title=""><strong>Towards Dental</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=0ECH_sQlS385JXgCr-z2kYD-fzRafc8FXvxBq8sHIhEyU0duuP3Pgl0z7hnfNpTCoRWjLX1e6g04FhIzD1akZqChC8gQQriHwTYXZVmPAfG_-D89p-I6d3nYkejqDGa_" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd9EgfaL-x_CHG-Ok54QpTORWftZOqMqU8Lt01tChV4ag4BxTvikIN7JI6lhkzqTYHIePEPEvphfPNLKv2fh-Xdq375gmZbRO19t0RETp9fPI" title=""><strong>Towards EV Solutions</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=j08pVDrhpP_BjChVvejvtcUnjTwsjgxfbY_n9GYz_3jd2GdQzChRGJE9R-FS1_f-TnHQ8iIN5GHHsNBrMXfsIKUz-9roJrDTcaH948BndSg=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd0EF1t2QRXOSKIBDet2sQiucLtEGndtY-iXD3x3u0clAtl4xLoE04iFyDNP4oZZuwJFajLUp6aXHkGPa6DVaJyiHZ4ukdrVQonTTwAdoT8zZ" title=""><strong>Nova One Advisor</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=DvvYXbz-HtC87xHa4cRXYqemQ-3UKeuaRcQ0mVZdaq0GthcTNeEDSbGCquDa4Z5Pd9L3HmNKD9eCiJSivVLdSjjM6Rugao_f9u_bOwSsUBw=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd48h7J3WlrmKfA-2lE980t5DDT7po0kJHe5nRxzlvDPIXQO3hAHt1lUWJKbH3hPG6G-G83ouTy2yGIijbuMTPB-QBfigHtPoeumP_pWBS0a2" title=""><strong>Healthcare Webwire</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=W0Xf5mFeipsiHfh3KkdKULuRoIo4ghJpqOGkKIvlOGsecUaIo2BHcvuiVZmBj2drXvryOKKe8f5KSOhuAj_oilsI7i8WChw6RR0sSaMNauc=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd2fEPurxEiJXA5ODnbZ9U0a6VXzGsAEGaqvdCGifnDVp1xsktUuD2f23QXWqyBVZ4fOSAgqgcU9HjckeLkK9NPulVbuaWk0hWxmdB_yNa49i" title=""><strong>Packaging Webwire</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=_kOVrmJdLoH9x8-MViEBYnoNj-AdtSBN_kq2-HEo1VzpgM5_k3JRs7wK9LRfjHnf498Y4-vYtiVHc11A-bMxcW4bEtkYkJ4Dl51ur03lwGI=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd-Pp40PRF1-G7FwQca0plhNzYttgC5pOz2wzPECiO_wZXAZObFZCIVH8ywPhvLwmW8md9GQCMQ0UtrKw41LDqENVd-Jp1YoXiOAX4N5JviK_" title=""><strong>Automotive Webwire</strong></a></p>
887. <p><strong>Find us on social platforms:&#160;</strong><a href="https://www.globenewswire.com/Tracker?data=z0npSrHuwNlk59KPNkQ9CnJS8vtdChkM2VEDk1wLsOyOJyo04lcno6Ngwr98PMG-cZeHbGwUqxFJnHeDA3w2tJAJ1clucyNYoUljzXwhQ_TT0kkPPvmVUpdVhZahGqZI" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd6HYbPCV_nVqw3nUpHMn0i-c-G1Wf9-_t23iYAzRLSzSfGPQxHxgIqGvZM_AoQkf8ZfU4jNtBNxuhtY_zFYfvixOMgqGZED-k17Kn77Tr9k2IRB4Mlcen4KwTLjmEntZJg==" title=""><strong>LinkedIn</strong></a><strong> |&#160;</strong><a href="https://www.globenewswire.com/Tracker?data=HuKAEV6GbiOZlKu7HGBFKbEvKTuVeSKxbHpYzqs8vhk1Fd1R8ZDxsxradaTScNZD7O8WOB12HPPwkhoW_Igggw==" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd9TkS2yPgmee6BLO3mIcmbl40ZNbzIqpJ6rOG8kEGXGMgSi0bfCtOx4x8SECkA64LflYtUWhinAv26aZZYMCESg=" title=""><strong>Twitter</strong></a><strong> |&#160;</strong><a href="https://www.globenewswire.com/Tracker?data=d2ojNnBqGM2Lc8XfZvyeLubbZtdsUlVHh_lPFWHNClwvLyapSIb35QFgSFJcdyYvAdkDqZAL4_TRS3zeuVm4ZK5cij-ugJjHRcu84zm_PpvQ_Vb3hYaTbpuj1Kg12NaM" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmdy-46v2TAloYVdN8sLrt3CI51YEIs-HH1q70NZig6GgBBuDNv6cgRWDht9SgOJA_gUxEVdlp9Ip9gawocG46_aV1d50dNx6_WgjD0sqHP0KV" title=""><strong>Instagram</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=LRPYuQYJvudoS35We1VJAT2Jv-Ixz7P8h5ftyQJWCTG9eTXE7w5ZjjxZA9_9z8NGMeG8WAHwAfUvYQJqzUB7Dtc6oAJ4-iZAJLvp9DetKQc=" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd4Dlp2n_TUA8pwfPYofRgA7c5rehZo7UhHpJBeGfb4reoPBvx1f1GQkAaB44Ls5wummLmSENoat3cmcLWU2g9B5qvl2d64ZCkOF-3R99Av_a" title=""><strong>Medium</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=4cT_I-vOhF8y0PdlBAEZ0xPAO9PAfhUAshFXp-0gB25xA0pJOg_NCDRn3k1icu5ekFjrhAVn54tgKnsF-7j692GCYVZS6iPNBfg7gzxKY0DEh1sGTjrJAOplVvN0kg2F" target="_blank" rel="nofollow noopener" data-mce-href="https://www.globenewswire.com/Tracker?data=AwTLPNbtQHo2Jc_aT6Qmd17XU9ziaiJ89ZxXVYH3Q-5lbTX82_bcxtBlVW0yPD49iMAP7Va1LnF6nBvLjwpBQLVUeXqAWngDWrLzp6kROzsu0L2M_2Pa6XfAg59COKHw" title=""><strong>Pinterest</strong></a></p>
888. <p><img alt="" src='https://ml.globenewswire.com/media/NWViMWFhMjItYTExNS00ZDQ1LWIwNWQtNzkwMTM3MDBlZjg3LTEyMTM4NDktMjAyNS0xMC0xMy1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
889. ]]></content:encoded>
893. </item>
894. <item>
895. <title>Drug Discovery Saas Platforms Market Growth and Competitive Landscape Insight &#124; Towards Healthcare</title>
896. <link>https://singaporeoutlook.com/drug-discovery-saas-platforms-market-growth-and-competitive-landscape-insight-towards-healthcare-30152/</link>
898. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
899. <pubDate>Mon, 13 Oct 2025 16:00:00 +0000</pubDate>
900. <category><![CDATA[Brand Post]]></category>
901. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165688/0/en/Drug-Discovery-Saas-Platforms-Market-Growth-and-Competitive-Landscape-Insight-Towards-Healthcare.html3165688</guid>
902.  
903. <description><![CDATA[This report prepared by Towards Healthcare a sister firm of Precedence Research offers an in-depth analysis of the global drug discovery SaaS platforms market. It provides key insights into market trends, growth drivers, regional dynamics and future opportunities shaping the industry. Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global drug discovery SaaS platforms market is [&#8230;]]]></description>
904. <content:encoded><![CDATA[<p><em>This report prepared by Towards Healthcare a sister firm of Precedence Research offers an in-depth analysis of the global drug discovery SaaS platforms market. It provides key insights into market trends, growth drivers, regional dynamics and future opportunities shaping the industry.</em></p>
905. <p>Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global <a href="https://www.globenewswire.com/Tracker?data=cY3ux3PffPmUMcBIPw14TsEaB7HALhkYJI0fo_xEb28IAanmKIJr2GUoG2Pbu5MBGKJzhior1g-XAodghwM92R9dD7uGXeY8kmfUekxQ6ReQFUWlgRMHBCuLHfivpHVYEQVj3_Q8ebE35w7vy2HgLWJhWHKxNiRZR6T9tenZ2w8B6t-EZfGoyTwL34mYIXJ7u3pScvGG0VQQmkJH9TZAbA==" rel="nofollow noopener" target="_blank" title=""><strong>drug discovery SaaS platforms market</strong></a> is experiencing rapid growth, with projected revenues reaching hundreds of millions between 2025 and 2034. This expansion is driven by rising investments, technological innovation, and growing demand across multiple industries.</p>
906. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=028706d8-62ee-46e4-9989-b9cc70459c93&amp;size=3" height="338.47px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/028706d8-62ee-46e4-9989-b9cc70459c93/image1.png" width="601.74px" /></p>
907. <p><strong>The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYOvvN8I4hnDOIGyI0n89CPipxeZWtII4u02VHyEhq1bi90NcOypTuGrfdVlF1Q4nqljTd6Q4_QgDMPuG0TvW181Z7yOeU0WAL--wfv3DJ2rI6951tHzehkbaeJp5k8aroL49rPy1wH9DeMys6JCwI7v" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/download-sample/5818</strong></a></p>
908. <p>The market’s acceleration is fueled by increased pharmaceutical R&amp;D spending, widespread adoption of AI and machine learning, and the need for cost-effective, scalable solutions. North America currently leads the market, supported by a strong presence of key SaaS providers and a growing demand for <a href="https://www.globenewswire.com/Tracker?data=yB07R7OoIp5JckqA-4vnchyqwGP992bRhQ5GaslJwLlBlWHZnqCwn_IGvLJQonKPJsvtDudGcr-YgGKUFaHvOGlAEQ08CXTVLAymDE7ZVKvQ5yjzw2iGAxqfugYPjx2snY9YLWIyMS6DNn-Sez24SLitvJBa0pTvpLAATO2GmuX18uCcDKgwJFssNbp7jZjS" rel="nofollow noopener" target="_blank" title=""><strong>advanced drug discovery solutions</strong></a> to tackle healthcare challenges. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by the adoption of digital technologies by <a href="https://www.globenewswire.com/Tracker?data=YQgNw-r8Nxm3a9U8docKbY23rw1OTG7PZA8KYQ9rLqT5zGefOohDfBxacPwKIU0m8MDQPVnRcOr9zzGFioR1qL6jtq3OXYDMCkbzsCUM0OXIa2QwOwIhHsrnLeUcDPXYg5segTrEg7RrB0q8o8xUc8Q0oLGwNxuQoUqMx1m6OcQ=" rel="nofollow noopener" target="_blank" title=""><strong>pharmaceutical companies</strong></a> and heightened collaboration with contract research organizations (CROs).</p>
909. <p>The growth of the market is driven by increasing costs and complexity of traditional drugs, which <a href="https://www.globenewswire.com/Tracker?data=3ju-iKnVMyptIPKElNlfhImxeVfvpgtYCYg4FtMIrNDx0ZbZgmdU-GtkSNL1pdbp1vGRLfl9XwHuknX6vc5kE3BKJPbbAuQhcicrAKDBd9v2iOXMSLwZH60s-dD-Cko1zV0Npphk7SsvOzQ0GIICbiCfrHc5V6w3iUxiCrFIu8w=" rel="nofollow noopener" target="_blank" title=""><strong>demand new and advanced drugs</strong></a> with the integration of AI, fueling the growth of the market.</p>
910. <p><strong>Key Takeaways</strong></p>
911. <ul type="disc">
912. <li style="margin-bottom:8pt;">North America dominated the drug discovery SaaS platforms market in 2024 with a 50% share.</li>
913. <li style="margin-bottom:8pt;">Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035.</li>
914. <li style="margin-bottom:8pt;">By solution type, the AI/ML-based drug discovery segment for the largest market revenue in 2024, with a 30% share.</li>
915. <li style="margin-bottom:8pt;">By solution type, the data management &amp; analytics segment is estimated to fastest-growing over the forecast period.</li>
916. <li style="margin-bottom:8pt;">By therapeutic area, the oncology segment is dominant in the market in 2024 with a 35% share.</li>
917. <li style="margin-bottom:8pt;">By therapeutic area, the infectious diseases segment is expected to register the fastest growth over the forecast period.</li>
918. <li style="margin-bottom:8pt;">By end user, the pharmaceutical companies segment is dominant in the market in 2024 with a 55% share.</li>
919. <li style="margin-bottom:8pt;">By end user, the academic &amp; research institutes segment is expected to register the fastest growth over the forecast period.</li>
920. <li style="margin-bottom:8pt;">By deployment mode, the cloud-based SaaS segment was dominant in the market in 2024 with a 75% share.</li>
921. <li style="margin-bottom:8pt;">By deployment mode, the hybrid deployment segment is expected to register the fastest growth over the forecast period.</li>
922. </ul>
923. <p><strong>Market Overview &amp; Potential</strong></p>
924. <p>Drug Discovery SaaS (Software as a Service) platforms are cloud-based software solutions designed to streamline and accelerate the drug discovery process. These platforms provide tools for computational modeling, data analysis, collaboration, and project management accessible via the internet without the need for local installation. SaaS drug discovery platforms enable pharmaceutical and <a href="https://www.globenewswire.com/Tracker?data=AErUgxRQjLJTQ6DAnoau4KsqBCsyrv5uEruiiiaoKktatL4iQgpmzJ25G5P7kUyCdRZqj3yivGP3HX5i3PqBycjG4dh6dKYmy8PQJzx2jT694NClkNyAZXG-cZi8SLQOYyA1NEiMDk5Wv7YAB2_65w==" rel="nofollow noopener" target="_blank" title=""><strong>biotech companies</strong></a>, CROs, and research institutions to access advanced drug discovery capabilities on demand, offering scalability, cost efficiency, and remote collaboration benefits.</p>
925. <p><strong>Become a valued research partner with us &#8211; </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYPKtQ9S8FckuRozqsQXjyidGo25OTePiTqsHSQCJpBndJ3CnoSDiXWEoyUnfFxAfBe7MtloCxAjgzdgmW7itS97BVnGv_05cwUdUD7xMW3qJiiX61xS0f_Bws6eyqtQpCw=" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/schedule-meeting</strong></a></p>
926. <p><strong>What Is The Growth Potential Responsible For The Growth Of The Drug Discovery Saas Platforms Market?</strong></p>
927. <p>Key drivers for the drug discovery SaaS platform market include the escalating demand for new pharmaceuticals, driven by rising chronic and infectious diseases, and the need to accelerate lengthy and costly R&amp;D processes. Advanced technologies like Artificial Intelligence (AI) and machine learning are integrated into SaaS platforms to enhance data analysis and predictions, alongside a <a href="https://www.globenewswire.com/Tracker?data=dg9W3lulry9GAYufgCDtBxqaN_r6HFeQUVcJ_TSbc525JLGyVVU99ha_jckoJB6vd0WzLXcwDIz2WTfZMprEE2vr0UkA7WoIgUTwWFeD0CSDadjJv-67ZCXC_HWbzUkV12X1FY-AVTMr1kRCXbdCCeS_bRSQIOx6mCnh71AmRBDM6OHKzZknZBZZomQTzj3r" rel="nofollow noopener" target="_blank" title=""><strong>growing focus on personalized medicine</strong></a> and precision therapies. Furthermore, the scalable, subscription-based, and cost-effective nature of SaaS platforms, which minimizes upfront investment, encourages adoption across pharmaceutical and biotech companies, fostering global collaboration and efficient data management.  </p>
928. <p><strong>What Are The Growing Trends Associated With The Drug Discovery Saas Platforms Market?</strong></p>
929. <p><strong>AI and Machine Learning:</strong></p>
930. <ul type="disc">
931. <li style="margin-bottom:8pt;">AI and ML-based platforms are a dominant technology, improving efficiency, reducing costs, and accelerating the drug discovery timeline by helping identify new drug targets and predict drug behavior.</li>
932. </ul>
933. <p><strong>SaaS Dominance:</strong></p>
934. <ul type="disc">
935. <li style="margin-bottom:8pt;">SaaS platforms are expected to account for a significant market share, with some reports suggesting they will hold over 75% of the cloud-based drug discovery platform market.</li>
936. </ul>
937. <p><strong>Public Cloud Services:</strong></p>
938. <ul type="disc">
939. <li style="margin-bottom:8pt;">The public cloud segment is expected to capture the largest market share within the cloud-based drug discovery platform market.</li>
940. </ul>
941. <p><strong>High R&amp;D Costs:</strong></p>
942. <ul type="disc">
943. <li style="margin-bottom:8pt;">Increasing research and development costs in the pharmaceutical industry are driving the need for more efficient, cloud-based solutions.</li>
944. </ul>
945. <p><strong>What Is The Growing Challenge In The Drug Discovery Saas Platforms Market?</strong></p>
946. <p>Key challenges for drug discovery SaaS platforms include data security and privacy concerns, the high cost and rapid obsolescence of AI models, a disconnect between AI development speed and the slow pace of experimental validation, and technical issues like system downtimes and latency. Other challenges involve integrating diverse data types, overcoming regulatory hurdles, managing high research costs and attrition rates, and ensuring effective collaboration across different research teams and institutions. </p>
947. <p><strong>Regional Analysis</strong></p>
948. <p><strong>How Did North America Dominate The Drug Discovery Saas Platforms Market In 2024?</strong></p>
949. <p>North America is dominant in the drug discovery SaaS platforms market in 2024 with a 50% share. The growth of the market in the region is driven by the technological advancements and adoption of cloud-based platforms, and AI and ML integrated solutions fuel the demand and growth of the market. Cloud systems facilitate global collaboration, improving access to data from healthcare organizations and Contract Research Organizations (CROs). The high investments in pharmaceuticals and research and development of new drugs and drug discovery due to the presence of key layers in the market fuel the growth of the market in the region.</p>
950. <p><strong>Download the single region market report @ </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYMd3Fk5cE82DfJCqiqUu65WPOBuhM_JJZMntiR_fDfYqXwvV12JE__YsJBBjl2pEVNKyMbFGBzVx9REy1tQcpatzhil6pd851CuyjUtNRWi9hFA-wXwzp0ncqKoWTbvuBY=" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/checkout/5818</strong></a></p>
951. <p><strong>What Made The Asia Pacific Significantly Grow In The Drug Discovery Saas Platforms Market In 2024? </strong></p>
952. <p>Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035. The Asia Pacific region is emerging as a major hub for drug discovery SaaS adoption, driven by rising pharmaceutical R&amp;D spending and supportive digitalization policies. Countries such as India, China, Japan, and South Korea are investing in <a href="https://www.globenewswire.com/Tracker?data=SATIPFwTVUu-GYKNfccmX-iQKSPOS1Yz0-MG0mmeXjVoNj-JDLyA0g7DC30a5F8aocCP5OqgXxBirT1cxxoZRmMR7GyzaHZAdKyKlApiuC8YEtFGSRdwSn0g3YwyZDhsKcfRonLeLdmekfEzOp8K4kduQ4t9YCV9ooaehr6m_lA=" rel="nofollow noopener" target="_blank" title=""><strong>AI-powered healthcare innovation</strong></a> and precision medicine. Growing collaborations between regional biotech startups and global cloud providers are accelerating the shift toward computational drug design and virtual screening platforms.</p>
953. <p><strong>Segmental Insights</strong></p>
954. <p><strong>By Solution Type, </strong></p>
955. <p>The AI/ML-based drug discovery segment for the largest market revenue in 2024, with a 30% share. AI/ML-based drug discovery platforms are revolutionizing early-stage R&amp;D by improving lead identification, molecular screening, and target validation. These tools reduce time-to-market by predicting compound behavior and optimizing trial design. Pharmaceutical firms increasingly adopt these solutions for personalized medicine and repurposing existing drugs. As AI models evolve, predictive accuracy and automation are expected to enhance efficiency in preclinical and clinical phases.</p>
956. <p>The data management &amp; analytics segment is estimated to fastest-growing over the forecast period, 2025 to 2035. Data management and analytics solutions enable efficient integration and interpretation of large-scale biological datasets, including genomics, proteomics, and clinical trial data. These platforms provide structured insights, ensuring regulatory compliance, data security, and interoperability. By enabling collaborative access to real-time information, they streamline workflows between researchers, CROs, and pharma R&amp;D teams. This segment is growing rapidly with rising demand for secure cloud infrastructures supporting end-to-end research management.</p>
957. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><a href="https://www.globenewswire.com/Tracker?data=WqisulkNSmV10Zm1NpGXHwR1ImhKYn2MRnOrVH43mr4JRmOWYQl9oXci38h8v3Y0b0cwD0ypDjE1AYbGg-W0ZerFBqno00ybCV9-rJLgyhbR0rSrJhhfG7rLdF8ZEGZc" rel="nofollow noopener" target="_blank" title=""><strong>sales@towardshealthcare.com</strong></a></p>
958. <p><strong>By Therapeutic Area, </strong></p>
959. <p>The oncology segment is dominant in this market in 2024 with a 35% share. Oncology remains the largest application area for SaaS-based drug discovery platforms. AI-driven predictive models assist in identifying novel oncogenic targets, improving biomarker discovery, and designing personalized treatment strategies. Pharmaceutical companies are investing heavily in computational oncology tools to accelerate the discovery of immunotherapies and precision drugs for rare cancers. These SaaS platforms also facilitate real-time data sharing between hospitals, labs, and research centers for enhanced collaboration.</p>
960. <p>The infectious diseases segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Infectious diseases represent another rapidly expanding therapeutic area, particularly in the post-pandemic era. SaaS-based solutions support fast pathogen sequencing, drug repurposing, and resistance modeling to tackle emerging viruses and bacterial infections. The integration of AI and big data analytics helps in identifying antiviral and antimicrobial candidates faster. Governments and healthcare organizations are increasingly funding digital platforms for epidemic preparedness and rapid response drug discovery.</p>
961. <p><strong>By End User, </strong></p>
962. <p>The pharmaceutical companies segment is dominant in the market in 2024 with a 55% share. Pharmaceutical companies are the dominant users of drug discovery SaaS platforms, leveraging them to shorten R&amp;D cycles and improve success rates. These systems enable efficient management of complex workflows, from compound design to clinical validation. With cloud-based infrastructure and AI integration, pharmaceutical R&amp;D pipelines are becoming more data-driven, collaborative, and cost-effective. The adoption trend is particularly high among global firms focusing on personalized medicine and niche biologics.</p>
963. <p>The academic &amp; research institutes segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Academic and research institutes utilize SaaS drug discovery platforms to accelerate translational research and improve collaboration across institutions. These platforms provide affordable access to high-performance computing resources, enabling data visualization, molecular modeling, and simulation. They also promote open science and reproducibility by storing datasets securely in shared environments. Universities and non-profit research organizations are increasingly partnering with SaaS providers to democratize computational drug discovery.</p>
964. <p><strong>Get the latest insights on life science industry segmentation with our Annual Membership: </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYMCgdN81FBTUF5lL9_aDtOZS-AITCEg-qDBBM09hqR6-bf5D1Q0aadeQui0YtfTsIbiEzJGW_jPwK2NMPrfynF0qqKWScfGbff6ks5WQhSOEuJMeHZXexNTOZrDGyr9NojcVts5_lXryvQMKsCCEhWuUYw68aqn6e6sQXrq2LCZFQ==" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/get-an-annual-membership</strong></a></p>
965. <p><strong>By Deployment Mode, </strong></p>
966. <p>The cloud-based SaaS segment was dominant in the market in 2024 with a 75% share. Cloud-based SaaS deployment dominates the market, driven by its scalability, cost efficiency, and ease of integration with AI/ML tools. It allows seamless access to large datasets and computational resources without heavy infrastructure investment. Pharmaceutical firms favor cloud deployment for real-time collaboration, faster data processing, and enhanced global accessibility. Major cloud vendors are offering specialized platforms optimized for drug discovery applications.</p>
967. <p>The hybrid deployment segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Hybrid deployment models combine on-premise control with cloud flexibility, ensuring both data privacy and computational agility. This approach is favored by organizations handling sensitive clinical or genomic data subject to stringent compliance regulations. Hybrid SaaS supports secure internal data management while utilizing cloud resources for computationally intensive tasks. It offers the right balance between scalability, security, and operational efficiency, particularly in multinational research settings.</p>
968. <p><strong>Browse More Insights of Towards Healthcare:</strong></p>
969. <p>The global <a href="https://www.globenewswire.com/Tracker?data=3dngL6b5tLlw3JO6reAmif9AZT8HShP73aQ48aU7IOJE2ZVWiDVhKWty7BEj2Ctix_eUBiAHIa0ZdzMQ_FMoKAUp6xKz-vDwo855kZQx2hOBazx0aR1Aqc5-MuCZFW4AwX8fis6CurYQHxPll2pfkjtsx3-rxnLWTMKAYSHoLmJJl-WKkzQZJKcdbyzz76x5" rel="nofollow noopener" target="_blank" title=""><strong>antibody discovery market</strong></a> was valued at USD 8.31 billion in 2024 and is expected to increase to USD 9.1 billion in 2025. Forecasts indicate a strong growth trajectory at a CAGR of 9.54%, reaching USD 20.71 billion by 2034.</p>
970. <p>The global <a href="https://www.globenewswire.com/Tracker?data=cY3ux3PffPmUMcBIPw14Tkar8hauP3d4q3Pqgfjl_IdLC22nosDdUt_Klca0h9I9RBJozIQdFjNQRjpxrjcUrFOMc4HaWdbjll1P2RdgylKPGVO4MVpGzemNlJb0iOVjSUK4hx-JqF43toFW476p0SKjpIQGNAWbqjAYMH1HTjtssjG75-q3TkOUnH_gEEia0zzRNTeIbhtJvWbRXzhojw==" rel="nofollow noopener" target="_blank" title=""><strong>drug discovery-as-a-service (DDaaS) market</strong></a> was estimated at USD 21.3 billion in 2024, rising to USD 24.32 billion in 2025. The market is projected to expand at a CAGR of 14.17%, reaching approximately USD 79.82 billion by 2034.</p>
971. <p>The global <a href="https://www.globenewswire.com/Tracker?data=nprs7L81GyH01GZJw0r2FNgHjAdtf3s1d0ds-Y0gMFPuR1oEnB0fXW3KUHS2qGn6KQ0kydVbzSwmL2wxmAipem3aY469fWKVfVP0ZRsYuYoX3Ria6w8YigkiPjR1bjDvGHdFuFvKMiOaFGHHt9X8hiNzj3hzHKeqCrj-lpgKskEUmeXq9lVhZapEwHSrtWq7-fZY_0ykjcBDw0_3IjA1-w==" rel="nofollow noopener" target="_blank" title=""><strong>generative AI in drug discovery market</strong></a> is poised for rapid growth, with a market size of USD 250 million in 2024, increasing to USD 318.55 million in 2025. By 2034, the market is expected to reach USD 2,847.43 million, growing at a CAGR of 27.42% from 2025 to 2034.</p>
972. <p>The worldwide <a href="https://www.globenewswire.com/Tracker?data=3bbCZDK0PxIdvx5tTv3Fqy8kngzWRnD9kraMT6IT_klSW2nELBp4_Dfu7ryD4FJOxsF5bN-J9P5OOHTKGzRxNHLzgTisgWInfnHYFjd_hmn7kRRJk5hMoy3Z8PN0S-ji0U_fVqJMYZTRJw_xq4OVPuCrejnSYhigwIP7sN9bdAU3yHXwtn9UrWXifo63jJ9B83FVhAGIHk80PFyanekzniwwR0QR8g4xtwJb3cT-HDQ=" rel="nofollow noopener" target="_blank" title=""><strong>machine learning in drug discovery market</strong></a> is witnessing substantial growth, with revenues projected to climb into several hundred million dollars over the forecast period from 2025 to 2034.</p>
973. <p>The <a href="https://www.globenewswire.com/Tracker?data=cu6IwfqCwy2ij_UHvRkYEVqDdLJIUVIVK2xPhIR3LU_1J8eaY9RPUN5-m9Y1rEjbI1JiJExt7Y7Ol62mvhuhwJu2-yv6khcZ_XYnjM5niGGGA5vuBQfYf1H5jn6Gu5K3jYBcq6clD3xNKhFWdqdVxo6_KErZFn2v4daw7df4v5CgzO3TjBk4tuhkmgDVs7zBrwBtCrZexIVEC60VIHIxMw==" rel="nofollow noopener" target="_blank" title=""><strong>robotics in drug discovery market</strong></a> is set for robust expansion from 2024 to 2034, driven by advancements in automation, artificial intelligence, and high-throughput screening technologies.</p>
974. <p>The <a href="https://www.globenewswire.com/Tracker?data=xQHnQK9NDXFJi4Ro22oZBVul67ZOa6G0TRe0mseZtB40zNfN6EwKjpZ-igEljhnwgivN2fbQ3cKXopuAlvLOGZyiHeOKyqSSs3BkBleKUG5vt7a7oTS66IeEaAJ03YjQLWtH631fMh4zb50GE7zQXLyx_ShpLswGlaQNsHC7fOodsz8fT6Edo9OMybEu6TAo" rel="nofollow noopener" target="_blank" title=""><strong>oncology drug discovery market</strong></a> is expected to grow significantly during the same period, fueled by progress in precision medicine, AI-enabled drug development, and an expanding pipeline of targeted therapies.</p>
975. <p>The <a href="https://www.globenewswire.com/Tracker?data=sqfzhM_WIqF77NC9HbJKKvCagWKAuSO28rFEVn8uxU8KjQWJgeJs6FQezdlcgp6M15nMzGne5ltimY3uKTfeKq8-UmYaWsxXLGSoP6w4WVovDPuA-q-3O5hGQRFbWlanKESZxJHtZCn6Oj4kKE1KSKNYfuSf7VGbU_xXTfC0tZJ5fFh2vuCoQLs61UWD6qWrlcQMaUU0U7gAGSkk7cWM-A==" rel="nofollow noopener" target="_blank" title=""><strong>multiomics in drug discovery market</strong></a> is also experiencing strong growth, with revenue projections reaching several hundred million dollars by 2034.</p>
976. <p>The global <a href="https://www.globenewswire.com/Tracker?data=cY3ux3PffPmUMcBIPw14TooDCw5N5sWJJR41db3wmaEzLv8oonbgoK5gn8FlD4-roe3Em_WMzGxrZE0xEwf4ck4BDgVS1hs4-uIIpBnNCVJNxcp1i7WkSo_0Vb6QIxqT4ss7kkQ4y9GHyc5fGCCaMTMYDpxgH167Vn-3Z4VNSqoyORZdVc2VDCqpeUN2bH-X" rel="nofollow noopener" target="_blank" title=""><strong>drug discovery platforms market</strong></a> was valued at USD 186.24 million in 2024 and increased to USD 211.26 million in 2025. It is expected to reach USD 635.45 million by 2034, growing at a CAGR of 13.44% between 2025 and 2034.</p>
977. <p>The global <a href="https://www.globenewswire.com/Tracker?data=2Y15VwuIYR9ZG7udQLfye1ukgWHgYzCHQirPUB3-mGBBEsUh0aCHHfbynAjD_afdUOTh7LrVaIGaURHy4Ea9xviVBeOpLR0XrZ3ETH413nVYMAQIJvLZTRXMYK6ZxUAE6Q7lNmV1t3Fuz7Iq0Au_AkPqCvvqSliTDFyN9gkrDO0yTWwpPZye5w2sn1O3OkEq" rel="nofollow noopener" target="_blank" title=""><strong>AI in drug discovery market</strong></a> was evaluated at USD 19.89 billion in 2025 and is projected to reach USD 133.92 billion by 2034, expanding at a CAGR of 23.22% from 2024 to 2034.</p>
978. <p>Finally, the global <a href="https://www.globenewswire.com/Tracker?data=2Y15VwuIYR9ZG7udQLfye46X2-1Jj3pYHLEhWjRNaSybwa3vQnZ9vzMGX-digLfdshcDgixLG__RVX6FYErYv4WG_7aJHE9DJ1Btiy1FBS0F87F5_Y_VbkbiECrivtlU9FRXYMlg809nvSwjiOrf8qf3oJnl34nrp5OC-T0adYU=" rel="nofollow noopener" target="_blank" title=""><strong>AI in life sciences market</strong></a> was valued at USD 2.25 billion in 2024 and is estimated to grow to USD 2.71 billion in 2025. By 2034, the market is anticipated to reach USD 14.20 billion, achieving a strong CAGR of 20.21% from 2024 to 2034.</p>
979. <p><strong>Recent Developments</strong></p>
980. <p>In June 2025, BioAro launched PanOmiQ Research in a Breakthrough for AI-driven drug Discovery and Multi-Omics. The platform also adds multilingual clinical reporting and a beta-stage AI-powered deep drug discovery module, making it the first unified, scalable “omics-to-therapeutics” ecosystem of its kind.</p>
981. <p>In April 2025, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch Signals One, a unified software platform evolved from the Company&#8217;s existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the increasing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities and fosters collaboration in multidisciplinary workflows.</p>
982. <p>In January 2025, Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, announced a strategic collaboration to discover novel small-molecule agonists of the Amylin Receptor.</p>
983. <p><strong>Drug Discovery SaaS Platforms Market Key Players List</strong></p>
984. <p align="center"><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=1c157a1d-bc65-460c-ba72-a848da790a5f&amp;size=3" height="356.27px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/1c157a1d-bc65-460c-ba72-a848da790a5f/image2.png" width="601.74px" /></p>
985. <ul type="disc">
986. <li style="margin-bottom:8pt;">IBM Corp.</li>
987. <li style="margin-bottom:8pt;">Accenture PLC</li>
988. <li style="margin-bottom:8pt;">BioXcel Corporation</li>
989. <li style="margin-bottom:8pt;">Cloud Pharmaceuticals, Inc.</li>
990. <li style="margin-bottom:8pt;">WuXi AppTec (Shanghai) Co., Ltd.</li>
991. <li style="margin-bottom:8pt;">Dassault Systemes</li>
992. <li style="margin-bottom:8pt;">BIOVIA Ltd.</li>
993. </ul>
994. <p><strong>Download the Competitive Landscape market report @ </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYMd3Fk5cE82DfJCqiqUu65Wx5eRqzsjQRTpUG3sXnuqz2DS_6k9m5eaLZpYMUlC4RMUdyyW16XQImBDGlOoPqSTuhz8ThEyM2N88G8kIIjoGjx9iUW8a1rWuCOFSrC4oUo=" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/checkout/5818</strong></a></p>
995. <p><strong>Segments Covered in The Report</strong></p>
996. <p><strong>By Solution Type</strong></p>
997. <ul type="disc">
998. <li style="margin-bottom:8pt;">Molecular Modeling &amp; Simulation:
999. <ul type="circle">
1000. <li style="margin-bottom:8pt;">Molecular Docking</li>
1001. <li style="margin-bottom:8pt;">Molecular Dynamics</li>
1002. <li style="margin-bottom:8pt;">QSAR Modeling</li>
1003. <li style="margin-bottom:8pt;">Pharmacophore Modeling</li>
1004. </ul>
1005. </li>
1006. <li style="margin-bottom:8pt;">Bioinformatics &amp; Genomics Analysis:
1007. <ul type="circle">
1008. <li style="margin-bottom:8pt;">Sequence Analysis</li>
1009. <li style="margin-bottom:8pt;">Structural Bioinformatics </li>
1010. <li style="margin-bottom:8pt;">Genomic Data Interpretation</li>
1011. <li style="margin-bottom:8pt;">Proteomics</li>
1012. </ul>
1013. </li>
1014. <li style="margin-bottom:8pt;">AI/ML-Based Drug Discovery: 
1015. <ul type="circle">
1016. <li style="margin-bottom:8pt;">Predictive Modeling </li>
1017. <li style="margin-bottom:8pt;">De Novo Drug Design</li>
1018. <li style="margin-bottom:8pt;">Virtual Screening</li>
1019. <li style="margin-bottom:8pt;">Biomarker Discovery </li>
1020. </ul>
1021. </li>
1022. <li style="margin-bottom:8pt;">Data Management &amp; Analytics: 
1023. <ul type="circle">
1024. <li style="margin-bottom:8pt;">Laboratory Information Management Systems (LIMS) </li>
1025. <li style="margin-bottom:8pt;">Electronic Lab Notebooks (ELN)</li>
1026. <li style="margin-bottom:8pt;">Big Data Analytics</li>
1027. <li style="margin-bottom:8pt;">Visualization Tools </li>
1028. </ul>
1029. </li>
1030. <li style="margin-bottom:8pt;">Collaboration &amp; Workflow Management: 
1031. <ul type="circle">
1032. <li style="margin-bottom:8pt;">Project Management Tools </li>
1033. <li style="margin-bottom:8pt;">Collaborative Platforms </li>
1034. <li style="margin-bottom:8pt;">Cloud Storage &amp; Sharing</li>
1035. <li style="margin-bottom:8pt;">Automation &amp; Integration</li>
1036. </ul>
1037. </li>
1038. <li style="margin-bottom:8pt;">Others: 
1039. <ul type="circle">
1040. <li style="margin-bottom:8pt;">Cheminformatics Platforms</li>
1041. <li style="margin-bottom:8pt;">Virtual Screening Tools </li>
1042. </ul>
1043. </li>
1044. </ul>
1045. <p><strong>By Therapeutic Area</strong></p>
1046. <ul type="disc">
1047. <li style="margin-bottom:8pt;">Oncology </li>
1048. <li style="margin-bottom:8pt;">Infectious Diseases</li>
1049. <li style="margin-bottom:8pt;">Cardiovascular Diseases </li>
1050. <li style="margin-bottom:8pt;">Neurological Disorders</li>
1051. <li style="margin-bottom:8pt;">Metabolic Disorders</li>
1052. <li style="margin-bottom:8pt;">Autoimmune Diseases</li>
1053. </ul>
1054. <p><strong>By End User </strong></p>
1055. <ul type="disc">
1056. <li style="margin-bottom:8pt;">Pharmaceutical Companies</li>
1057. <li style="margin-bottom:8pt;">Big Pharma </li>
1058. <li style="margin-bottom:8pt;">Mid-sized Pharma </li>
1059. <li style="margin-bottom:8pt;">Biotechnology Companies </li>
1060. <li style="margin-bottom:8pt;">Contract Research Organizations (CROs) </li>
1061. <li style="margin-bottom:8pt;">Academic and Research Institutes </li>
1062. <li style="margin-bottom:8pt;">Government &amp; Non-profit Research Centers
1063. </li>
1064. </ul>
1065. <p><strong>By Deployment Mode</strong></p>
1066. <ul type="disc">
1067. <li style="margin-bottom:8pt;">Cloud-Based (Pure SaaS) </li>
1068. <li style="margin-bottom:8pt;">Public Cloud </li>
1069. <li style="margin-bottom:8pt;">Private Cloud</li>
1070. <li style="margin-bottom:8pt;">Hybrid Deployment </li>
1071. <li style="margin-bottom:8pt;">On-premise integrated with Cloud</li>
1072. </ul>
1073. <p>B<strong>y Region</strong></p>
1074. <ul type="disc">
1075. <li style="margin-bottom:8pt;">North America
1076. <ul type="circle">
1077. <li style="margin-bottom:8pt;">U.S.</li>
1078. <li style="margin-bottom:8pt;">Canada</li>
1079. </ul>
1080. </li>
1081. <li style="margin-bottom:8pt;">Asia Pacific
1082. <ul type="circle">
1083. <li style="margin-bottom:8pt;">China</li>
1084. <li style="margin-bottom:8pt;">Japan</li>
1085. <li style="margin-bottom:8pt;">India</li>
1086. <li style="margin-bottom:8pt;">South Korea</li>
1087. <li style="margin-bottom:8pt;">Thailand</li>
1088. </ul>
1089. </li>
1090. <li style="margin-bottom:8pt;">Europe
1091. <ul type="circle">
1092. <li style="margin-bottom:8pt;">Germany</li>
1093. <li style="margin-bottom:8pt;">UK</li>
1094. <li style="margin-bottom:8pt;">France</li>
1095. <li style="margin-bottom:8pt;">Italy</li>
1096. <li style="margin-bottom:8pt;">Spain</li>
1097. <li style="margin-bottom:8pt;">Sweden</li>
1098. <li style="margin-bottom:8pt;">Denmark</li>
1099. <li style="margin-bottom:8pt;">Norway</li>
1100. </ul>
1101. </li>
1102. <li style="margin-bottom:8pt;">Latin America
1103. <ul type="circle">
1104. <li style="margin-bottom:8pt;">Brazil</li>
1105. <li style="margin-bottom:8pt;">Mexico</li>
1106. <li style="margin-bottom:8pt;">Argentina</li>
1107. </ul>
1108. </li>
1109. <li style="margin-bottom:8pt;">Middle East and Africa (MEA)
1110. <ul type="circle">
1111. <li style="margin-bottom:8pt;">South Africa</li>
1112. <li style="margin-bottom:8pt;">UAE</li>
1113. <li style="margin-bottom:8pt;">Saudi Arabia</li>
1114. <li style="margin-bottom:8pt;">Kuwait</li>
1115. <li style="margin-bottom:8pt;">Germany</li>
1116. </ul>
1117. </li>
1118. </ul>
1119. <p><strong>Immediate Delivery Available | Buy This Premium Research @ </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYMd3Fk5cE82DfJCqiqUu65Wl44SMgYkS8oAsG2MFgTNax1B3hxZFFvGPvl-L4xjyoaaEaYjvbbpVee-MHBzPcFXWHY56A75VTmyhS_7CU5FFtwx09g4S_xNWzTp1hBimvA=" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/checkout/5818</strong></a></p>
1120. <p>Access our exclusive, data-rich dashboard dedicated to the healthcare market &#8211; built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.</p>
1121. <p><strong>Access the Dashboard: </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYPjovmNVVSJeFBWvVnMzkoIh8RKwine9gOSWJCnEffNcxWkviITX1REWr82_PFka1ri4RbIcd29PXiJGspwKqbG07HF0axVzG-QhWc3Wx6CWl4rs8tlatDvO1uFSW6nGt0vp-zJpzriQ7lg0akSmtrP" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com/access-dashboard</strong></a></p>
1122. <p><strong>About Us</strong></p>
1123. <p><strong>Towards Healthcare</strong> is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a <a href="https://www.globenewswire.com/Tracker?data=ORhsthrjjO9GApSPb9ITZ-Jxh9haHQxHP_m6SL1JjYvp61r4vq4S9lbOF_PH76tPA0EriGclkMeWl3dw77qZGFBboTMa9xBzVlhLQFstwL8PPm5W9PPGf9kIkGNiVIpjpErkS23leRoGsvWlb9QXc9a6b_CltCertifW-yrEI7ZnL0gw3bxzsI67EGnANneP" rel="nofollow noopener" target="_blank" title=""><strong>strong emphasis on life science research</strong></a>. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.</p>
1124. <p><strong>You can place an order or ask any questions, please feel free to contact us at </strong><a href="https://www.globenewswire.com/Tracker?data=WqisulkNSmV10Zm1NpGXHwR1ImhKYn2MRnOrVH43mr5PF1A1OMVFu-bxYoxYsVVeFqjZTHuiDS_JYdyBFjIKuTSvOQ6JLGgL91BhF-NyR-DhgyhsVzlyChRlCZsB4s2L" rel="nofollow noopener" target="_blank" title=""><strong>sales@towardshealthcare.com</strong></a></p>
1125. <p><strong>Europe Region: </strong>+44 778 256 0738</p>
1126. <p><strong>North America Region: </strong>+1 8044 4193 44</p>
1127. <p><strong>APAC Region</strong>: +91 9356 9282 04</p>
1128. <p><strong>Web: </strong><a href="https://www.globenewswire.com/Tracker?data=-il3ZR8OG5BwIbrjXXmPnMKm7MJPuh_7CQFU4jNmWYO4q5aL85MsmQ-Xzc4T7hjAFQYBUb0i7_my60ZX9fLvXkT1NkH-k09PeixSxV2Ug7r25pAgLsBqX0eKkbRTCMQt" rel="nofollow noopener" target="_blank" title=""><strong>https://www.towardshealthcare.com</strong></a></p>
1129. <p><strong>Our Trusted Data Partners</strong></p>
1130. <p><a href="https://www.globenewswire.com/Tracker?data=H3VYcSCgeQp6SgbPNYb9jT3iR9uBb4MdCGbgCDeF7WXDs3cF-azpdirL_wC7SVhpg13AbE1vQJs6svxAzxjnlcb1pk9LSBq8EIqboKBoY0bmHcBOvT_MAZLSkVI6OgII" rel="nofollow noopener" target="_blank" title=""><strong>Precedence Research</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=hC0amHW30E3y-yGtsDvxrUP_2zbnAdM7VMXNO7kzsidBhbgrwbe1QlhAmaN7leXovNQG8CfABHVv0m5JKChRYtt6iH2dQQ8c8169XL4kFjw=" rel="nofollow noopener" target="_blank" title=""><strong>Statifacts</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBWRnlStigm7uX0ujhI6W8tIdDtbcv7bNc5YfirbS1fGgYZQqoZtGLS120RkWYkZFDBm-N_4403aalqYcRIT8HfM=" rel="nofollow noopener" target="_blank" title=""><strong>Towards Packaging</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBen7eXrREpb2WOPhIfxOCHhM5RLWtqMwwUBc1jww5-qsNjOIcWhfkf7pHoYYFO1gLhTdp9TbwhbWYnb9CCraiUMnqiRHJkwA5ah0QKe8RsSX" rel="nofollow noopener" target="_blank" title=""><strong>Towards Automotive</strong></a><strong> |</strong> <a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBWcPBOGvFN8ul-DBePRaJV0l7ier8aRYrn2lJ4d_JqCuR34XzQhkhsWtTlsXH7AuJ34TjN673-sRC7mOgQBlgiEEUd8RiFK7eMTGoQtaw8a-" rel="nofollow noopener" target="_blank" title=""><strong>Towards Food and Beverages</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBX2IzM4c_ZVDBCgEkzXgF5u-NcqitFhB13xaI88MG25SXV01T3JRbvqjMh6Qb4KjB9y7GQw_IxGSymq_z92h0ChDInJV6KCsBg9WJ6mHKgxz5Q1CS5HwKsRbml5EJXtgkg==" rel="nofollow noopener" target="_blank" title=""><strong>Towards Chemical and Materials</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBfTI2v3hENmEWPPCAiEvy1K2Eu3gC6ftiaaIP9qlpS62LnMqTDme_SDfmLy5UIRhOiW2Rlz7tmMMDMt0yDCbUi1vsXESLn_61b5Sp8X0v1mm" rel="nofollow noopener" target="_blank" title=""><strong>Towards Consumer Goods</strong></a><strong> |</strong> <a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBXLoFKYvnkmClrmPlID1qf86eohthrZt3I_mhJvCWywrr5uv2_5LNKkSVC4y1irrwsB5yVOvV0pOgU5_CfWyEeo=" rel="nofollow noopener" target="_blank" title=""><strong>Towards Dental</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=pBeCKnCwegIfXQFYWbOZBYcZpPvVm12xjAOSir6wg9Aa8HnplOoEk_7XUi3W58Unw08JlT3EBX8P_9SmhfQeYVpMCQ0t23o_Vr-fwH3LXFe3Gq8cDif0T22sWjEgL-Qv" rel="nofollow noopener" target="_blank" title=""><strong>Towards EV Solutions</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=MW8hmGT_neVW2DYuov_jF5kQYCMG7_QJ5eYH-nJk-IGcNSPmxbVcxPWVZ0EfCojuspNpg3Big2AoUHUsajMVNNYeBYQfXjuTwo7AdFop4Ps=" rel="nofollow noopener" target="_blank" title=""><strong>Nova One Advisor</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=UaMcAZAs9WzHe_nt_9s3ZM2KhKJcuHe7ifKPiBGUgyn3S7HEv2WUwND4CM-BbHNQDuOCyzmObgzPeFsny6DkDeXGgL7eQ9NC35XuthldGww=" rel="nofollow noopener" target="_blank" title=""><strong>Healthcare Webwire</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=eatp2iB2AVRnwoUS588ZUtghQdQIafk50FKd8UqMyJPygT9QQXAipzMkXPrPsH-sXTxau0vzcefrt-_d6uGTu3STPwpjAIVAYfhhcGW2NBY=" rel="nofollow noopener" target="_blank" title=""><strong>Packaging Webwire</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=S5TSlVdnBcuiCRyvo1wPvmk1W8o6CbzlYIx2eGqI6yupD2NepqO1VGt17FZmqh95Cr7zEkewgHXPGK5_tGUnbAPQc-CeV-uqHlm-ilIb0hg=" rel="nofollow noopener" target="_blank" title=""><strong>Automotive Webwire</strong></a></p>
1131. <p><strong>Find us on social platforms: </strong><a href="https://www.globenewswire.com/Tracker?data=EohZnA6RJWYZHH1AlocY5BqT59RumrdxWvkAhttBxJuz5o1Vr5YFm6mdBHr5nlLUeOJ0KvUbQWGbbLYBU8lhO_Mg8doysk8lfC7UsLrNrxKbHZ5Ir99KGpI_flbQ2Mmr" rel="nofollow noopener" target="_blank" title=""><strong>LinkedIn</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=jmFWD2V81Tu_cTMI6eGmU5lQXZj5o82Gkuri6WtWwC5j1ly-eAeBlwf9PdJA4sW0gmrRq0_tFV8QDXffyC96IA==" rel="nofollow noopener" target="_blank" title=""><strong>Twitter</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=g7PSfadop3MGZnONoHvneY6Ra2kUAE5kDLJQH9u4I9V0gWcyGBtnpizq4BuKnsevIE26gR6m2-IwKr6p6SqkdF8j8_9d3EH5YlYtoN5goQ2jMjboT7tpXtPk14HU8SS4" rel="nofollow noopener" target="_blank" title=""><strong>Instagram</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=4URS7KFs3PzQJzA5ZUi78D6jwukiNipvXFxo2RMw0XWEVQGOGQGESd02NNsMaNe4I_Ttd82HwGC3X9YbK_DDm1OaVNp7tZlepEFRb7tu0Xw=" rel="nofollow noopener" target="_blank" title=""><strong>Medium</strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=rxgIlZFvpeaDD3whYlVFQRMQgtjdQWClIm2fz-SoMCNVKYgslMkFdQeC5HTB59f_CvFKmk8eQJ2HK2H9y4fyhEK2VQZ3M3NaZ57O830b-57j8JW58ql0XeNGsYR2HMyy" rel="nofollow noopener" target="_blank" title=""><strong>Pinterest</strong></a></p>
1132. <p><img alt="" src='https://ml.globenewswire.com/media/MmM0NjFlNzQtNTU2MC00ZjI5LWI5ZjktNmY2Mzg5NTMxMTc1LTEyMTM4NDktMjAyNS0xMC0xMy1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
1133. ]]></content:encoded>
1137. </item>
1138. <item>
1139. <title>“Best Fintech Forex Broker” Award Presented to CXM at Forex Expo Dubai 2025</title>
1140. <link>https://singaporeoutlook.com/best-fintech-forex-broker-award-presented-to-cxm-at-forex-expo-dubai-2025-30154/</link>
1142. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
1143. <pubDate>Mon, 13 Oct 2025 15:36:00 +0000</pubDate>
1144. <category><![CDATA[Brand Post]]></category>
1145. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165651/0/en/Best-Fintech-Forex-Broker-Award-Presented-to-CXM-at-Forex-Expo-Dubai-2025.html3165651</guid>
1146.  
1147. <description><![CDATA[DUBAI, United Arab Emirates, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; CXM has been honored with the prestigious “Best Fintech Forex Broker” award at the renowned Forex Expo Dubai 2025, reinforcing its position as a global leader in the Forex and CFD industry. As an Elite Sponsor, CXM’s MENA team captivated attendees with its cutting-edge trading [&#8230;]]]></description>
1148. <content:encoded><![CDATA[<p>DUBAI, United Arab Emirates, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; CXM has been honored with the prestigious “Best Fintech Forex Broker” award at the renowned Forex Expo Dubai 2025, reinforcing its position as a global leader in the Forex and CFD industry. As an Elite Sponsor, CXM’s MENA team captivated attendees with its cutting-edge trading platforms, fintech innovations, advanced tools, and globally recognized partnership programs at one of the world’s most influential financial events.</p>
1149. <p><img loading="lazy" decoding="async" alt="Banner_1" data-mce-style="display: block; margin-left: auto; margin-right: auto;" height="338" src="https://ml-eu.globenewswire.com/Resource/Download/34ed51b2-9b59-4a7c-8a6e-3eb87d1c0422/banner-1.jpg" style="display:block; margin-left:auto; margin-right:auto;" width="600" /></p>
1150. <p>Throughout the Expo, CXM’s presence reflected its innovation, leadership, and deep commitment to empowering traders worldwide. This dedication was recognized with the “Best Fintech Forex Broker” award, a testament to CXM’s pioneering technology, exceptional trading conditions, and international presence.</p>
1151. <p>With 10+ offices globally, 500,000 clients and over 100,000 partners, <a href="https://www.globenewswire.com/Tracker?data=IzymgFi2_T4Npd-FXd4d7_keLcRMuUgFaZv-UBf1OxpZHUFE5dFyKNo0CS81-R5yuQxX1flAm_SkulIuO_b1Kw==" rel="nofollow noopener" target="_blank" title="CXM">CXM</a> continues to set new standards for fintech excellence and partnership success within the Forex and CFD industry. Attendees experienced firsthand CXM’s unique solutions designed to empower both traders and partners. </p>
1152. <p>“This award reinforces our mission to empower traders, partners, and institutions with the best trading conditions and fintech solutions available,” said Bassel El Harakeh, CEO of CXM (MENA).</p>
1153. <p>Winning the “Best Fintech Forex Broker” award at Forex Expo Dubai 2025 marks another key milestone in CXM’s path of innovation and excellence, underscoring the company’s commitment to driving fintech innovation across the global trading landscape.</p>
1154. <p><strong><u>About CXM Group</u></strong></p>
1155. <p>Established in 2015, CXM Group is a global leader in the Forex and CFD industry and one of the largest B2B brokers in Asia. The company serves more than 500,000 clients, over 100,000 partners, and operates across 10 global offices. CXM provides a wide range of services to institutional and retail clients, handling more than 1,000,000 daily trades across 50+ countries. As a globally regulated firm, CXM offers a diverse selection of financial products spanning various asset classes, including Forex, Metals, Commodities, Indices, Shares and Cryptocurrencies, and ETFs. For more information, visit CXM&#8217;s <a href="https://www.globenewswire.com/Tracker?data=pwQaC7Bgr6TlaUgJFDjt-fhNiFZk7Cs6Hl5hfaH579F_gcJE7DmKEIY3uPAmEF21yg6jdwjNVzQa89nJ8Z3ZgQ==" rel="nofollow noopener" target="_blank" title=""><u>website.</u></a></p>
1156. <p><strong>Press Contact</strong><br />Danny Salman<br />Email: danny.s@cxm.com<br />Web: <a href="https://www.globenewswire.com/Tracker?data=EP0SWTPWY3jto2r9gHJnpRVkH4xAnnBNhsDii6VKTmyGJeZuQFmknObq63ms74UjIMGpP17J9KIfOTSdlpC7PvQZv48rGkF_a6E7KJnIuMrMZfoVUnHeHT6wobHLYvMi5ET1RJ3TlimCp5OvnvKaHqGEf0Mn5ImykPIfg6U4H6BNx3ut16JCS2jyEtFI4OMtCUcfgGXt5XzWIKx3i9uDvidPlAYqPnrR0R6Zx9cWJqg=" rel="nofollow noopener" target="_blank" title="www.cxm.com">www.cxm.com</a></p>
1157. <p>A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=hwmfq8N21tLu3PXuaMVqQC5MZodph62AxiR9mQFcTYoV3BiiL9vb0m-xyd_xr6749CZEHoNqgzUut_Ep0GNTXQewINjsWgoyb1_6t6x6SZdelUpiijQn5lUsmelujQRWEZUJTH6mJxpqLC_KtHgN3G0foGHA3ER75Bk0OaWEjvl_xSyqF76f2gkaSHkqLrgXNNChA3sfwTM28JqezmQbON8dPTYNO8_vM5dsqe7MeVCVgF9_H7UuOdQzcO_Y9qwj4fyGY8Fgz91oPOOiPlv_EA==" rel="nofollow noopener" target="_blank" title="">https://www.globenewswire.com/NewsRoom/AttachmentNg/34ed51b2-9b59-4a7c-8a6e-3eb87d1c0422</a></p>
1158. <p><img alt="" src='https://ml-eu.globenewswire.com/media/YTQ1OTQ3NDYtYjQ4Mi00MDJhLWFkZDMtZDkwNjdlMTUyNGI1LTEzMTM0MzgtMjAyNS0xMC0xMy1lbg==/tiny/CXM-Direct.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
1159. ]]></content:encoded>
1163. </item>
1164. <item>
1165. <title>Globevisa Global Citizen Conference 2025: Asia’s Premier RCBI Summit on Strategy, Credibility &#038; Access</title>
1166. <link>https://singaporeoutlook.com/globevisa-global-citizen-conference-2025-asias-premier-rcbi-summit-on-strategy-credibility-access-30155/</link>
1168. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
1169. <pubDate>Mon, 13 Oct 2025 15:10:00 +0000</pubDate>
1170. <category><![CDATA[Brand Post]]></category>
1171. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165646/0/en/Globevisa-Global-Citizen-Conference-2025-Asia-s-Premier-RCBI-Summit-on-Strategy-Credibility-Access.html3165646</guid>
1172.  
1173. <description><![CDATA[By Asians, for Asians, focusing on Asian opportunities in global citizenship &#038; residency SINGAPORE, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; In October 2025, Singapore will host an event that is set to redefine the conversation on wealth mobility and cross-border citizenship planning. The Globevisa Global Citizen Conference (GGCC2025), taking place from October 22 to 24 [&#8230;]]]></description>
1174. <content:encoded><![CDATA[<p><em>By Asians, for Asians, focusing on Asian opportunities in global citizenship &#038; residency</em></p>
1175. <p align="left">SINGAPORE, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; In October 2025, Singapore will host an event that is set to redefine the conversation on wealth mobility and cross-border citizenship planning. The Globevisa Global Citizen Conference (GGCC2025), taking place from October 22 to 24 at the Equarius Hotel, Resorts World Sentosa, is more than another industry summit. It is a strategic forum designed in Asia, for Asia, with Asia as its focus, yet carrying implications that extend across the globe.</p>
1176. <p align="left"><img loading="lazy" decoding="async" alt="GLOBEVISA" height="375" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/b85382e6-c3a8-42fb-a36a-624d91846abd/glo1.png" width="600" /></p>
1177. <p align="left"><strong>Why GGCC2025 Matters to Investors</strong></p>
1178. <p align="justify">The Globevisa Global Citizen Conference is not designed as a trade fair. It is a closed-door gathering of the people who make decisions that directly affect investors.</p>
1179. <p align="justify">Attending the conference means access to:</p>
1180. <ul type="disc">
1181. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">First-hand intelligence from government officials before reforms are formally announced.</li>
1182. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Direct insights into where capital is moving across Asia, Europe, and the Americas.</li>
1183. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Comparative perspectives from multiple stakeholders: policymakers, program designers, wealth managers, and clients.
1184. </li>
1185. </ul>
1186. <p align="justify">For investors, this breadth of perspectives creates a comprehensive understanding of the global mobility landscape, a feature that resonates with Globevisa’s mission: to help people make informed decisions.</p>
1187. <p align="left"><strong>Panels That Define the Future of Global Mobility</strong></p>
1188. <p align="justify">Over three days, GGCC2025 will host ten carefully curated panels that address the most pressing issues facing global investors. Highlights include:</p>
1189. <ul type="disc">
1190. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">AI in the RCBI Industry: How artificial intelligence is changing due diligence, fraud detection, and application processing.</li>
1191. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">The Changing Faces of HNWI: From Gen Z investors to the longevity economy, how new demographics are shaping priorities.</li>
1192. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Asia as Capital Engine: Why Asia remains both the world’s largest source and most dynamic destination for wealth migration.</li>
1193. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Agencies in Transition: How immigration consultancies are evolving from brokers to trusted advisors in an era of complexity.</li>
1194. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">The Investor’s Journey: Testimonials from billionaire clients who have navigated citizenship planning firsthand.
1195. </li>
1196. </ul>
1197. <p align="justify">Together, these conversations do not just provide updates. They map the strategic landscape for the next decade of global mobility.</p>
1198. <p align="left"><strong>Asia at the Core</strong></p>
1199. <p align="justify">What truly differentiates GGCC2025 from other global gatherings is its Asian lens. Globevisa, founded and headquartered in Asia, has built its identity on serving Asian clients and understanding Asian priorities.</p>
1200. <p align="justify">The conference reflects this in three ways:</p>
1201. <ol style="list-style-type:decimal;">
1202. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Organized in Asia: Singapore is not just a convenient host; it is a strategic hub where East meets West in finance, law, and governance.</li>
1203. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">For Asian Interests: From Chinese wealth flows to Southeast Asian emerging markets, the panels address what matters most to Asian investors.</li>
1204. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Focused on Asian Destinations: While Europe and the Americas remain central to global mobility, Asia itself is now a sought-after destination for residency and capital.
1205. </li>
1206. </ol>
1207. <p align="justify">This triple focus ensures that participants, whether they are Asian investors or global players seeking to serve them, leave with unique intelligence not available anywhere else.</p>
1208. <p align="left"><strong>Luxury Venue, Exclusive Access</strong></p>
1209. <p align="justify">The Equarius Hotel at Resorts World Sentosa was chosen for its blend of privacy, exclusivity, and luxury. For three days, its halls will host a gathering that is equal parts discreet and influential. Attendees can expect the comfort and security befitting the caliber of global citizens who will be present.</p>
1210. <p align="left"><strong>Why Investors Should Attend</strong></p>
1211. <p align="justify">For high-net-worth families, GGCC2025 offers:</p>
1212. <ul type="disc">
1213. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Early access to reforms that could impact investment strategies.</li>
1214. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">Direct dialogue with policymakers who shape the programs.</li>
1215. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">A panoramic view of the market from multiple stakeholders.</li>
1216. <li style="margin-top:3pt; margin-bottom:3pt; text-align:justify;">The chance to benchmark against peers, including billionaires who have successfully navigated second citizenship planning.
1217. </li>
1218. </ul>
1219. <p align="justify">In an era where governments can change policies overnight and capital restrictions can appear with little warning, staying ahead is no longer optional. GGCC2025 equips investors with the clarity and foresight they need.</p>
1220. <p align="left"><strong>Secure Your Place</strong></p>
1221. <p align="justify">The Globevisa Global Citizen Conference is limited to 300 attendees to preserve exclusivity and access. Investors, family offices, and advisors who wish to safeguard their wealth and secure their family’s future should see this as an essential appointment in their calendar.</p>
1222. <p align="justify">GGCC2025 is not about abstract discussions—it is about practical intelligence, delivered in Asia, for Asia, with implications for the world.</p>
1223. <p align="justify">Join us in Singapore, October 22–24, 2025, for a conference that will define the next chapter of global mobility.</p>
1224. <p align="justify">Reserve your ticket now:</p>
1225. <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=bON1QOUpqPg_exaR-k9dlZX00sdVXHDGnGHq9R1n3DV2pzYNcCkvfCpovq6Qy3N7jCG9y8gc3PpA4MZIFeYw-CDQG7-NNTMmY96vOh2Iq1jXEF2LUb6UvwDbmHp_3LejyODagc9txI44WMgUV8-wdhMiJnWkjg-erPfQomWrO54LB58gM6MtPmYnU275E-JTI2GLUDJWbUaVLXXExy8EriuAFrYs6FP3XBoqgCr8hXpSi_jz2mypSYSmQJkYTDtS" rel="nofollow noopener" target="_blank" title="">https://web-eur.cvent.com/event/57e528e9-70be-48cb-bef7-b5cbb7f25876/register</a></p>
1226. <p align="justify">Contact:</p>
1227. <p align="justify">Huang Yingqi, <a href="https://www.globenewswire.com/Tracker?data=sKlgRPEQnCvZTkf1EAIyhkDZIX5R5QllA8ixSns3F5AXrSwqo2cMpPzokGjX41qYQBDTTuSRa6Ltuu38OtgNyinDxkPFwnyVLC1-6ZUHJIMU2HkYx6NOQHFcmQuWEksA" rel="nofollow noopener" target="_blank" title="lenahuang@globevisa.com">lenahuang@globevisa.com</a></p>
1228. <p>A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=bON1QOUpqPg_exaR-k9dlf9bVaheRUDDYMVcYE1HKNs80WbsZyqXxiMvl7069BkRBuXY2Kl5zUt7zaezGWtgjZRjIHDsp7xpjLEXS-t--xykaGHCGx3X37e97ZS4VYg6mfJSDuC41yBMgqwwbxG3BFUm2trbxHvOVttqa5eChZJ4d8CBIf3vgsFle2GYgopr5pXjXSwZTCe2oocrktqmysNahKzsefJI8s4IFa4Ryoi99z4CL4Ajctj_mCbhcIb5K19JIK6bEgOu5LSOL_N51A==" rel="nofollow noopener" target="_blank" title="">https://www.globenewswire.com/NewsRoom/AttachmentNg/b85382e6-c3a8-42fb-a36a-624d91846abd</a></p>
1229. <p><img alt="" src='https://ml.globenewswire.com/media/YjNiNmE0YmYtNzljYy00ZGQ2LTlhOTItZmFhODVhYTQ3ZmZiLTUwMDE1MzI0My0yMDI1LTEwLTEzLWVu/tiny/GLOBEVISA-GROUP-HONG-KONG-LIMI.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
1230. ]]></content:encoded>
1234. </item>
1235. <item>
1236. <title>U.S. Metal Recycling Market Size to Cross USD 121.04 Bn by 2034</title>
1237. <link>https://singaporeoutlook.com/u-s-metal-recycling-market-size-to-cross-usd-121-04-bn-by-2034-30156/</link>
1239. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
1240. <pubDate>Mon, 13 Oct 2025 14:54:00 +0000</pubDate>
1241. <category><![CDATA[Brand Post]]></category>
1242. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165636/0/en/U-S-Metal-Recycling-Market-Size-to-Cross-USD-121-04-Bn-by-2034.html3165636</guid>
1243.  
1244. <description><![CDATA[According to Towards Chemical and Materials, the U.S. metal recycling market size is calculated at USD 90.76 billion in 2025 and is expected to be worth around USD 121.04 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.25% over the forecast period 2025 to 2034. Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) [&#8230;]]]></description>
1245. <content:encoded><![CDATA[<p><em>According to Towards Chemical and Materials, the U.S. metal recycling market size is calculated at USD 90.76 billion in 2025 and is expected to be worth around USD 121.04 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.25% over the forecast period 2025 to 2034.</em></p>
1246. <p>Ottawa, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The <a href="https://www.globenewswire.com/Tracker?data=D5dvdg9uQkgtYjM2mopE0y5Fxcbr3sOjFPjcN6qJdZEvdi_s7Bp_1wYBGiXhxBVfimJ2HLB9dFTnH_-sdVw5PckCXy2IWQx9KvgeD00QlnoWZmyAU0BlnKNazgCSvu-L7lfzUu0eiR9ouUwaf2Mdfl8WNaCpQstHfrNq-0PxU_Q=" rel="nofollow noopener" target="_blank" title=""><strong><u>U.S. metal recycling market</u></strong></a> size was valued at USD 87.91 billion in 2024 and is anticipated to reach around USD 121.04 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.25% over the forecast period from 2025 to 2034. A study published by Towards Chemical and Materials a sister firm of Precedence Research.</p>
1247. <p>The Rising demand for sustainable raw materials and circular economy initiatives is driving growth in the market.</p>
1248. <p><img decoding="async" data-mce-src="/api/ImageRender/DownloadFile?resourceId=a10e580d-eba6-4c27-950f-51be4c646896&amp;size=3" data-mce-style="display: block; margin-left: auto; margin-right: auto;" height="330.81px" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/a10e580d-eba6-4c27-950f-51be4c646896/image1.png" style="display:block; margin-left:auto; margin-right:auto;" width="588.1px" /></p>
1249. <p><strong>Download a Sample Report Here@ </strong><a href="https://www.globenewswire.com/Tracker?data=pTVBlbxZYQRPXLUQlZn7UeglwYqcA1KORWey4aOKBzLBOU5_UadYKWPVXGIDztuQlcKzaA338RRePsPRTi2pKhzinSOpArO-9k1HjodypMd-wDFoD6tUFi8cb8pCU1wg-2vanglQ0dCBCAAgr3pX58SQegJFKW6eq0KuwJcsIPph0bz-09VEAO2ah7pYHL2lyZDTlbRy4a3LcHgCMKBcLQ==" rel="nofollow noopener" target="_blank" title=""><strong><u>https://www.towardschemandmaterials.com/download-sample/5873</u></strong></a></p>
1250. <p><strong>U.S. Metal Recycling Overview</strong></p>
1251. <p>The U.S. <a href="https://www.globenewswire.com/Tracker?data=pj5L17B2ivwhpV4V77qgdcO5vr2v4ldeUXafg7zEvH7e0zf04PzK-Wf0ZCaCGA51xHnc3FawPgazkSa5hxpehjpdfIaLJV-YZ4hceAZy44aGtM30Pg2dZae_vk-lzrUP7tx8hmXMRi2qtNMT6v58wZACY252dxBKtazHrnQQmEQ=" rel="nofollow noopener" target="_blank" title=""><strong><u>metal recycling market</u></strong></a> is experiencing strong momentum driven by growing environmental awareness, increasing demand for sustainable raw materials, and government initiatives promoting circular economy practices. The industry plays a critical role in reducing waste, conserving energy, and lowering carbon emissions by transforming discarded metals into reusable resources for various sectors. Ferrous metals dominate the market due to their widespread use in construction, automotive, and heavy machinery applications, while non-ferrous metals such as aluminium, <a href="https://www.globenewswire.com/Tracker?data=MNVrUPPthfytlot_TY0QXKBPRq-C3TrN_f3C7mQn3tTVmFfoB4TmNnpL6syXpIy4y8q0MKRAFHzLVL-v5Am7GYEY4VFKmzhThoMfs3cl-2BcfxhWzGbwjhGxb4H7hLvn" rel="nofollow noopener" target="_blank" title=""><strong><u>copper</u></strong></a>, and zinc are gaining traction for their high economic value and recyclability. Mechanical recycling remains the most common method due to its cost efficiency and recyclability. Mechanical recycling remains the most common method due to its cost efficiency and scalability, while hydrometallurgical processes are emerging as advanced alternatives for complex materials.</p>
1252. <p><strong>U.S. Metal Recycling Market Report Highlights</strong></p>
1253. <ul type="disc">
1254. <li style="margin-bottom:8pt;">By metal type, the ferrous metals segment led the U.S. metal recycling market with approximately 60% industry share in 2024, due to its widespread use in the major sectors like automotive, manufacturing, and construction.</li>
1255. <li style="margin-bottom:8pt;">By recycling method, the mechanical process segment emerged as the top-performing segment in the market with approximately 50% industry share in 2024, as it is considered the cost-effective, scalable, and simple yet ideal option</li>
1256. <li style="margin-bottom:8pt;">By source, the post-industrial scrap segment led the market with approximately 40% share in 2024, because it provides cleaner, higher-quality materials directly from manufacturing waste.</li>
1257. <li style="margin-bottom:8pt;">By end user industry, the automotive segment led the market with approximately 30% industry share in 2024, because end-of-life vehicles are one of the largest sources of scrap metals in the U.S.</li>
1258. <li style="margin-bottom:8pt;">By recycling facility type, the integrated mills segment led the U.S. metal recycling market with approximately 45% share in 2024, as the U.S. faces rising e-waste volumes from rapid tech consumption. </li>
1259. </ul>
1260. <p><strong>Benefits of in Metal Recycling Market</strong></p>
1261. <p>Metals, including Critical Raw Materials, are an ideal candidate for a circular economy as they are eternally recyclable, and properly treated, secondary metals do not face downcycling or quality issues. Since they do not lose their intrinsic properties during recycling, metals can be used and re-used multiple times, maintaining their quality and functionality</p>
1262. <p><strong>1.Socio-economic benefits;</strong>  </p>
1263. <p>• The EU produces only about 3% of the primary raw materials required to sustain a growing demand for metals. Consequently, the EU’s metal recycling value chain contributes to reduce EU’s dependency on imported materials.</p>
1264. <p>• The Recycling of metals is labor intensive and creates a wide variety of job opportunities for skilled workers who carry out a range of functions relating to the collection and sorting of EoL products containing metals.</p>
1265. <p><strong>2.International trade</strong></p>
1266. <p>• The Metal waste collected and reprocessed into scrap, compliant with industry specifications, and standards, compete on commodity markets with primary materials. Recyclers are not competing on a level playing field since the market fails to reward the environmental benefits in terms of resource, energy, and CO2 savings resulting from the use of secondary materials.</p>
1267. <p>• The Removing the barriers affecting the internal market for recycling, resulting from complex waste shipment procedures, as well as ensuring free and fair trade of secondary raw materials, is crucial to balance supply and demand and guarantee the proper functioning of recycling markets.</p>
1268. <p><strong>3.Environmental benefits</strong></p>
1269. <p>• The metal recycling industry is a major contributor to both, the circular economy and climate policy, by saving primary resources, energy, and CO2. However, European policy framework has so far failed to reward the environmental benefits of metal recycling which could further boost its circularity.</p>
1270. <p>• The Metals recycling will reduce landfill of metals, which is not only a loss of valuable raw materials, but could also generate an impact on the environment (i.e., leaching into water courses).</p>
1271. <p>• The Metals recycling saves up to 20 times (i.e., between 60-95%) of the energy needed compared to the extraction of those metals from ores whilst preserving the quality. That directly impacts the costs of re-processing those metals into final products.</p>
1272. <p>• The Production of metals from secondary raw materials significantly reduces CO2 emissions compared to their primary production (i.e., mining), and also reduces the derived impact on the water and the land. Using recycled metal instead of finite virgin ores reduces air pollution by 80%, water pollution by 76%, and water use by 40%</p>
1273. <p><strong>Buy Now this Premium Research Report at a Special Price Against the List Price With [Express Delivery] @ </strong><a href="https://www.globenewswire.com/Tracker?data=pTVBlbxZYQRPXLUQlZn7UeglwYqcA1KORWey4aOKBzLBOU5_UadYKWPVXGIDztuQ-cy4CnR6QRZtIaiFq2JxWEHRlkl4bN4ocRAYFKJgHPuZdEMPVzuUyBiZbtmXfYKzAM3Xe9ETXHrqULJdiucvk3zOjCSzGzaMRiMX60Pc0AFCTZEuC8ku9tWWtvMHm736" rel="nofollow noopener" target="_blank" title=""><strong><u>https://www.towardschemandmaterials.com/checkout/5873</u></strong></a></p>
1274. <p><strong>U.S. Metal Recycling Market Report Scope</strong></p>
1275. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
1276. <tr>
1277. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Report Attribute</strong></td>
1278. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Details</strong></td>
1279. </tr>
1280. <tr>
1281. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Market size value in 2026</strong></td>
1282. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>USD 99.76 billion</strong></td>
1283. </tr>
1284. <tr>
1285. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Revenue forecast in 2034</strong></td>
1286. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>USD 121.04 billion</strong></td>
1287. </tr>
1288. <tr>
1289. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Growth rate</strong></td>
1290. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>CAGR of 3.25% from 2024 to 2034</strong></td>
1291. </tr>
1292. <tr>
1293. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>Actual data</strong></td>
1294. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; "><strong>2021 &#8211; 2024</strong></td>
1295. </tr>
1296. <tr>
1297. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Forecast period</td>
1298. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">2025 &#8211; 2034</td>
1299. </tr>
1300. <tr>
1301. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Quantitative units</td>
1302. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Revenue in USD billion, volume in million tons, and CAGR from 2025 to 2034</td>
1303. </tr>
1304. <tr>
1305. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Report coverage</td>
1306. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Revenue forecast, company ranking, competitive landscape, growth factors, and trends</td>
1307. </tr>
1308. <tr>
1309. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Segments covered</td>
1310. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">By Metal Type, By Recycling Method, By Source, By End-User Industry , By Recycling Facility Type</td>
1311. </tr>
1312. <tr>
1313. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">Key companies profiled</td>
1314. <td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: middle ; ">CMC; European Metal Recycling; Novelis; Norsk Hydro ASA; Tata Steel; GFG Alliance; Kimmel Scrap Iron &amp; Metal Co., Inc; Schnitzer Steel Industries, Inc., Sims Metal, Utah Metal Works</td>
1315. </tr>
1316. </table>
1317. <p><strong>For more information, visit the </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrAxYxw-vf6Z-CGjwr27JhoNuL4JAvAU-FbU2KmarvZapckBO9Y858ta54IjRYb5wTEHx00bokPsqcbOU-Xhpl5IwGurvvEpqCfs-0qeqbqC6ooEOdFBxgWRMhd9T3QxrVPA==" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Chemical and Materials</u></strong></a><strong> website or email the team at </strong><a href="https://www.globenewswire.com/Tracker?data=t7pOHoTUxydsyW2gDtnPjqD3Gr1dJqvIulXA-T8hR70MXLsQf4cOGDw-e6wtMafwFAXbjc_e4DBsLv98x4IGiTIBpixgY35uhrHYrBIbbiUPCLUBDmi3jtELeFG0aiUes1x3kB2kIGV0WgTCNBQBvw==" rel="nofollow noopener" target="_blank" title=""><strong><u>sales@towardschemandmaterials.com</u></strong></a><strong>| +1 804 441 9344</strong></p>
1318. <p><strong>Why Is It Important to Recycle Metals?</strong></p>
1319. <p><strong>1. To preserve natural resources.</strong> Recycling metal replaces the need to produce virgin metal. In turn, this preserves precious natural resources like coal and iron ore used in metal production. It’s essential to consider resources like coal, as its combustion is a top contributor to climate change. In 2010, coal accounted for 43% of global greenhouse gas emissions and this climate issue has perpetuated ever since. As it simultaneously uses less energy and cuts down on using natural resources, recycling metals is an environmental activity — and an easy way to take corporate responsibility.</p>
1320. <p><strong>2. To best use raw materials.</strong> Metals are amongst the few raw materials easily recycled without damaging their original properties. This means there isn’t any real reason to create new metal — apart from to meet increased demand. The recycling process can be repeated as many times as needed, even with valuable metals such as aluminium.</p>
1321. <p>The list of recyclable metals is extensive, with only radioactive metals (uranium, plutonium) and toxic metals such as lead and mercury prohibited. There aren’t many disadvantages to recycling metals, but a total waste management company can help you deal with any issues. Scrap metal recycling facilities will always accept a wide range of metals like steel, as operators know the value of metal won’t decrease.</p>
1322. <p><strong>3. To offset your business’s carbon emissions.</strong> There’s an increasing emphasis on companies recycling all raw materials to achieve ambitious “zero to landfill” targets. Recycling metals is an environmental alternative to other forms of disposal, as it cuts down emissions and reduces air pollution. By recycling metals, you’re contributing to your business’s carbon goals. Above all, the recycling process will help eliminate pollution from the atmosphere and encourage others to make the most of metal’s versatile usage.</p>
1323. <p>A tonne of aluminium recycled saves nine tonnes of CO2 emissions from being released into the atmosphere. The Planet Mark environmental foundation confirms that every tonne of aluminium recycled conserves five tonnes of bauxite — the raw material from which aluminium is made.</p>
1324. <p><strong>4. To save money by reducing production costs.</strong> Recycling metals offers financial incentives and there’s no shame in benefiting from these. Most companies recycle on the basis that it’s cheaper to do so, allowing you to drive down production costs (and convert this spend into collection costs). It’s much more affordable to use existing waste metal than to create it from scratch.</p>
1325. <p><strong>5. To meet recycling industry standards.</strong> As people grow more concerned about the environment, the recycling industry is putting additional pressure on businesses to recycle. Companies are expected to recycle materials where possible, with metal recycling being a huge part of this. Needless to say, if you have scrap metal lying around on-site, you should take action. You’re also benefiting the economy by recycling metals as the recycling industry provides employment in waste facilities.</p>
1326. <p>Metal items can be hard to recycle, but the benefits far outweigh any difficulties. The key to recovering all the value from metal is effective segregation and quality control before it finds its way to a metal recycler.</p>
1327. <p><strong>Here Are Some Of The Top Products In The U.S. Metal Recycling Market</strong></p>
1328. <p>1<strong>. Ferrous Scrap Metal- </strong>Recycled iron and steel from automobiles, appliances, construction debris, etc.</p>
1329. <p><strong>2. Non-Ferrous Scrap Metal-</strong> Includes aluminum, copper, brass, stainless steel—high-value recyclables.</p>
1330. <p><strong>3. Rebar (Reinforcing Bar)-</strong> Steel bars used in construction, made from recycled scrap.</p>
1331. <p><strong>4. Steel Beams &amp; Structural Steel-</strong> Produced by mills using recycled metal for construction and infrastructure.</p>
1332. <p><strong>5. Sheet Steel &amp; Coil- </strong>Flat-rolled steel products used in automotive, appliances, and manufacturing.</p>
1333. <p><strong>6. Shredded Scrap (Shredder Feed)-</strong> Processed scrap used as feedstock for electric arc furnaces.</p>
1334. <p><strong> 7. Copper Wire &amp; Tubing-</strong> Recycled and resold for use in electrical and plumbing applications.</p>
1335. <p><strong>8. Aluminum Products-</strong> Recycled aluminum cans, extrusions, and automotive parts.</p>
1336. <p><strong>9. Steel Billets &amp; Rods-</strong> Semi-finished products used for further steel manufacturing.</p>
1337. <p><strong>10. Stainless Steel Scrap-</strong> High-value material used in high-grade steel production.</p>
1338. <p><strong>What Are the Major Trends In The U.S. Metal Recycling Market?</strong></p>
1339. <ul type="disc">
1340. <li style="margin-bottom:8pt;">Shifting toward “green” production processes, such as adoption of electric arc furnaces that rely more on recycled feedstocks rather than virgin metal sources.</li>
1341. <li style="margin-bottom:8pt;">Growing use of digital platforms for scrap trading, improving transparency, efficiency and access to buyers and sellers.</li>
1342. <li style="margin-bottom:8pt;">Increasing regulatory and policy encouragement for recycled content, driven by sustainability goals and environmental standards.</li>
1343. <li style="margin-bottom:8pt;">Rising investor interest in recycling operations and infrastructure as sustainability becomes a core component of corporate strategies.</li>
1344. <li style="margin-bottom:8pt;">Stronger focus on recovering non-ferrous and specialty metals because they carry higher value and are in demand for high tech, electronics, and clean energy application.</li>
1345. </ul>
1346. <p><strong>How Does AI Influence the Growth Of The U.S. Metal Recycling Market In 2025? </strong></p>
1347. <p>In 2025, AI is reshaping the U.S. metal recycling contamination, increasing recovery yields, improving quality of recycled output. AI driven computer vision systems are being used to distinguish different metal type and grades in mixed streams (e.g. aluminium, copper) with high accuracy (as demonstrated by TOMRA’s deep learning solution for aluminium sorting). Robotic arms guided by machine learning are automating pick and place operations in scrap yards, reducing reliance on manual labour and enabling faster throughput. AI also powers predictive analytics and process optimization tools anticipating maintenance needs, optimizing conveyor speeds and workflows, and reducing operational downtime.</p>
1348. <p><strong>U.S. Metal Recycling Market Dynamics</strong></p>
1349. <p><strong>Growth Factors </strong></p>
1350. <p><strong>What’s Powering Quality And Purity In Recycled Metals? </strong></p>
1351. <p>AI driven sorting systems are being integrated into metal recycling plants to distinguish subtle visual features (such as surface texture or shape) and thus separate mixed or alloyed metals more accurately, which raises the purity of output and reduces waste.</p>
1352. <p><strong>Why Is Nonferrous Scrap Flowing Into The U.S.? </strong></p>
1353. <p>Trade tensions and high global prices for nonferrous metals are rerouting scrap exports onwards the U.S. making imported nonferrous metal feedstock more available for domestic recycling operations.</p>
1354. <p><strong>Market Opportunity </strong></p>
1355. <p><strong>What If E-Waste Becomes The New Goldmine? </strong></p>
1356. <p>The rise of electronics usage and the sheer volume of discarded devices open a lucrative avenue for metal recyclers to tap into urban mining extracting critical and rare metal from printed circuit boards, batteries, and other consumer electronics instead of relying solely on bulk scrap.</p>
1357. <p><strong>Could Domestic Refining Of Critical Metals Reshape The Supply Chain? </strong></p>
1358. <p>With the U.S. seeking self-sufficiency strategic metals, opportunities are growing for recycling firms that can integrate advanced refining technologies to recover cobalt, nickel, lithium and rare from industrial waste and battery feedstock, reducing dependence on imports.</p>
1359. <p><strong>Limitations In The U.S. Metal Recycling Market</strong></p>
1360. <ul type="disc">
1361. <li style="margin-bottom:8pt;">Global market changes can cause metal prices to vary, making recycling operations less predictable and affecting profitability.</li>
1362. <li style="margin-bottom:8pt;">Varying state regulations and proposed changes can create compliance uncertainty and operational hurdles for recyclers.</li>
1363. </ul>
1364. <p><strong>What Drives Dominance in The U.S. Metal Recycling Market? </strong></p>
1365. <p>In the U.S. metal recycling market, the automotive industry okays a pivotal role, serving as a significant source of scrap metal. End of life vehicles (ELVs) contribute substantially to the supply of ferrous and non-ferrous metals, including steel, aluminium, and copper. This consistent influx of materials supports established recycling infrastructure, such as shredding and dismantling facilities, assuring a steady flow of recyclable metals. The automotive sector’s integration into the recycling loop not only bolsters material recovery rates but also aligns with sustainability goals by reducing the need for virgin resources. As the demand for recycled metals continues to rise, the automotive industry’s contribution remains integral to the market’s growth and stability.</p>
1366. <p><strong>U.S. Metal Recycling Market Segmentation Insights</strong></p>
1367. <p><strong>Metal Type Insights</strong></p>
1368. <p><strong>Why Are Ferrous Metals Segment Dominating the U.S. Metal Recycling Market? </strong></p>
1369. <p>The ferrous metals segment dominated the U.S. metal recycling market in 2024. Ferrous metals, primarily steel and iron, are highly used in construction, automotive, and heavy machinery, making them abundant in scrap streams. Their widespread availability and high recyclability have established a stable demand for ferrous recycling, supporting extensive collection, sorting, and processing infrastructure. Recycling these metals not only reduces energy consumption compared to primary production but also contributes significantly to environmental sustainability initiatives across the U.S. As industries continue to rely on steel and iron, ferrous metals maintain a prominent role in shaping the market’s current and future dynamics.</p>
1370. <p>The non-ferrous metals segment is projected to grow at the fastest rate during the forecast period. Non-ferrous metals such as aluminium, copper, and zinc are increasingly valuable due to their demand in electronics, automotive lightweight, and renewable energy sectors. These metals are more expensive and technologically critical, which drives efforts to improve collection and advanced recycling methods for better purity and efficiency. As manufacturers seek sustainable alternatives and reduced dependence on virgin metals, non-ferrous recycling presents an opportunity for higher margins and technological innovation. The market’s focus on energy efficiency and circular economy principles further accelerates the adoption and growth of non-ferrous metal recycling.</p>
1371. <p><strong>Recycling Method Insights</strong></p>
1372. <p><strong>Why Is Mechanical Processing Segment Doming In U.S. Metal Recycling Market?</strong></p>
1373. <p>The mechanical processing segment dominated in 204. Mechanical methods, including shredding, sorting, and baling, are widely used due to their cost efficiency and scalability across various metal types. This approach supports large volumes of scrap material, particularly ferrous metals, assuring steady output and operational efficiency. The simplicity and reliability of mechanical processing have allowed recyclers to maintain consistent recovery rates while integrating new sorting technologies.</p>
1374. <p>The hydrometallurgical segment is expected to experience the highest growth rate between 2025 and 2034. Hydrometallurgy involves chemical processes to extract metals from complex or low-grade materials, which is increasingly important for non-ferrous and critical metals. This method allows recyclers to recover metals with higher purity that mechanical processes cannot achieve, opening new opportunities in electronics, batteries, and specialty metal recycling. Growing environmental regulation and the push for sustainable metal recovery further drive the adoption of hydrometallurgical techniques.</p>
1375. <p><strong>Source Insights</strong></p>
1376. <p><strong>Why Are Post-Industrial Scraps Segment Dominating U.S. Metal Recycling Market? </strong></p>
1377. <p>The post-industrial scrap segment dominated in 2024. Post-industrial scrap, generated from manufacturing processes and production waste, is highly reliable and consistent, making it a preferred source for recyclers. Its predicted composition allows efficient sorting and processing, especially for ferrous and non-ferrous metals. Industries such as automotive and construction generate continues streams of post-industrial scrap, ensuring that recyclers have access to high quality feedstock. This steady supply supports operational stability and contributes to sustainability by reducing the need for virgin metal extraction.</p>
1378. <p>The post-consumer scrap segment is projected to expand rapidly in the coming years. Post-consumer scrap, collected from end-of-life products such as electronics, appliances, and packaging, is increasingly targeted due to regulatory incentives and corporate sustainability goals. Advancements in collection systems and sorting technologies make it more feasible to diverse consumer scrap streams efficiently. The growing focus on circular economy practices ensures that post-consumer scrap becomes a critical resource for reducing waste and supporting metal demand.</p>
1379. <p><strong>End User Industry Insights</strong></p>
1380. <p><strong>Why Are Automotive Segment Dominating In U.S. Metal Recycling Market? </strong></p>
1381. <p>The automotive segment dominated in 2024. The automotive industry generates large volumes of end-of-life vehicles and manufacturing scrap, providing a consistent and high quality source of both ferrous and non-ferrous metals. Recyclers rely on automotive scrap to maintain operational efficiency, as it is easier to sort and process compared to mixed consumer scrap. The industry’s, integration into the recycling ecosystem ensures that recovered metals are redirected into the new vehicle production and other applications. The automotive sector’s contributions make it a cornerstone of the market.</p>
1382. <p>The electronics segment is anticipated to grow with the highest CAGR in the studied years. Electronics generate complex and valuable scrap, including copper, aluminium, and rare earth metals, which are in high demand for new devices. Growth in consumer electronics, renewable energy systems, and electric vehicles increases the volume of recoverable metals from electronic waste.</p>
1383. <p><strong>Recycling Facility Type Insights</strong></p>
1384. <p><strong>Why Are Integrated Mills Segment Dominating in U.S. Metal Recycling Market? </strong></p>
1385. <p>The integrated mills segment dominated in 2024. Integrated mills, which combine multiple recycling operations including shredding, sorting, and remelting, offer higher efficiency and centralized control over metal recovery. These facilities handle large volumes of scrap, particularly from automotive and industrial sources, assuring steady production and consistent quality. Their established distribution networks and operational expertise make them a preferred choice for recyclers seeking reliability and scale.</p>
1386. <p>The specialized plants segment is predicted to witness growth over the period 2025 to 2034. Specialized plants focus on high value hard to recycle metals such as lithium, cobalt, and rare earth elements from batteries and electronics. Advanced technologies and targeted processes allow these facilities to recover metals that traditional mills cannot energy and electronics, specialized plants are becoming essential for supplying recycled metals.</p>
1387. <p><strong>More Insights in Towards Chemical and Materials:</strong></p>
1388. <ul type="disc">
1389. <li><strong>Copper Foil Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg3T24H8tfl4sHtyJW8bs7JPuHfxABQaQu6ckz75Nl-cChHYLAyyP2-fMq9TMuoMZjKLqAHXt9iKPiLEgLMOSp9LsfzT5Q9XnOzaK7FbmGJNMD5axXxMo3iadrSiL4Muanae-vNwh4MycGXo91asH60cLOR3Uwtwzzrq9N8u_YWuE" rel="nofollow noopener" target="_blank" title=""><strong><u>copper foil market</u></strong></a> volume is calculated at 387.50 kilo tons in 2024, grew to USD 415.07 kilo tons in 2025 and is predicted to hit around 770.50 kilo tons by 2034, expanding at healthy CAGR of 7.11% between 2025 and 2034.</li>
1390. <li><strong>Mechanical &amp; Chemical Recycling of Polyethylene Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg5otRHJD8Fy7kfJlePA06o_CJ1gKELnKeRl07s2Vmey3rmcOG0RvbsLCyopStD90WRlndzmxrCR6Pan2nSEAZtV60ddcsvEUgc-vBiZ5WWLVT7zVnyJR3IjulDPkl5-3c-vGCjjEDWztjI_nrjI_P8foBq6rpd8gE1T8RYTkujIdLsjMrEhF64A1hW5q8hVUW4YWBRgzeA6QF4eBbR_ke-lHvTm37WPJoFDjqoQ_-4cAZufzYO37AOAQDcAEWuTKprXAf5YUkB3NxPZccKd6OYM=" rel="nofollow noopener" target="_blank" title=""><strong><u>mechanical &amp; chemical recycling of polyethylene market</u></strong></a> was valued at approximately USD 17.35 billion in 2024 and is projected to grow at a CAGR of 10.29% from 2025 to 2034, reaching a value of USD 46.20 billion by 2034.</li>
1391. <li><strong>Microplastic Recycling Market ; </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg0xpAI56vbE2vdsB3qziQ1ZtVdNrJ5skzBFEM-6vAxS0KP7BhkHS7K6SOKryZfgxHcn8qkl93JrOgGgBx3cFG63bkCUbmx7MLYA87H0S9qSKZujy9DoQbeI0JEDp_Q_A1UxKLmaLlj90gMC9WceOKwRNX542-DUrIcSgXD4UsiTi6O-oLxvZB4MEx8S4JJt4rA==" rel="nofollow noopener" target="_blank" title=""><strong><u>microplastic recycling market</u></strong></a> size was reached at USD 325.19 million in 2024 and is expected to be worth around USD 817.00 million by 2034, growing at a compound annual growth rate (CAGR) of 9.65% over the forecast period 2025 to 2034. </li>
1392. <li><strong>Mechanical Recycling of Plastics Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg1lipDR2aVKHNoP_doKvk9bGjz2qXOitrzz8oBubWg-V5JkG6QQIioSV3l1pNH9hmrpUj0tksLyq3_unLJnmsx1FFEYhdBOegm6yiiANS7GIy2AYS3KMazQZ2fmXioxPU3us1cOcQHZstIBHUYWpGLsGz14bi-hwY9Xb1JrswwSHayPDVrt6EKiON1sBxDbGA__x_dYIdT0N_0PwWG22ryw=" rel="nofollow noopener" target="_blank" title=""><strong><u>Mechanical Recycling Of Plastics Market</u></strong></a> is expected to reach a volume of approximately 54.87 million tons in 2025, with a forecasted increase to 120.26 million tons by 2034, growing at a CAGR of 9.11% from 2025 to 2034.</li>
1393. <li><strong>Aluminum Oxide Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg98xJp66KuxlA_eGIQ_zzn_86FXKsTLrSVGUYLggpFghWtTbfDVll5ytH3MofATVh1Ko6rnzv4bvkXU2dsCQ5n6fIPTiskOXMsC5o3rw1dCoEqhVjkdAT8Zjcrpi-M_MvfH1e_HjazoBJUcHE0_fHI6g3Xrv856iDoVHI8wfmEj3" rel="nofollow noopener" target="_blank" title=""><strong><u>aluminum oxide market</u></strong></a> volume was reached at  160.12 million tons in 2024 and is expected to be worth around 215.45 million tons by 2034, growing at a compound annual growth rate (CAGR) of 3.01% over the forecast period from 2025 to 2034</li>
1394. <li><strong>Aluminum Trihydrate (ATH) Market  ; </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67egwmw3MqTH2bA-5iAXaQNeCya1MhSUBlZrRg7vRUUflRqsiUy9ZZMxioNJuovSlvjMVpO4ZXkEUcqX5j4FRX0TXLR3q_dDc69BkuzgPgxcllUEf2GhujNBdl3v_XuXZDAavolOTdrBf9UWgTyykqaUv8P3lns3vjI_MCdRARuC5UJRQhhGoJoamEQfmP-i3WNDw==" rel="nofollow noopener" target="_blank" title=""><strong><u>aluminum trihydrate (ATH) market</u></strong></a> volume was reached at 2850.21 kilo tons in 2024 and is expected to be worth around 4653.45 kilo tons by 2034, growing at a compound annual growth rate (CAGR) of 5.02% over the forecast period 2025 to 2034. </li>
1395. <li><strong>Aluminum Foil Market  : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg9CvWMyPVn2yYk356eE9U9dUGtd8ctYHg3E4bpuHR95OvNr6tHppO-azhKWeMOqRejEg9ggO9SzzW5nC_4HFMiXLu3j6xJsw4zyALxqM2PsySXfwqbkCeonSYxlL8XLYUFrbxB1EUfD2KaXfS4-k99CyVXnmz_cEmJvuKh0aJlxE" rel="nofollow noopener" target="_blank" title=""><strong><u>aluminum foil market</u></strong></a> size was reached at USD 29.33 billion in 2024 and is expected to be worth around USD 48.46 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.15% over the forecast period 2025 to 2034.</li>
1396. <li><strong>Aluminum Composite Materials Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg1tehRe7kG8e_K9oNqQD87b0c1IGXPAJgmNZnqhYCD-jnx5bKjdImB4ZMH5K86SEHMIUSeQMIdz6JixNAK8d8RPfBZtD0dRCZ73gRkmKEnjzSKPz5ZRNfGKvN2fpxLOxq_bBC25SSquB-CCHn2bIyRFg8SY4litZrsMmEEuDgNxmf0vO0GnwdC1lNppZPOiuVMBVdG-MOimHmAVXt_b2KmU=" rel="nofollow noopener" target="_blank" title=""><strong><u>aluminum composite materials market</u></strong></a> size is calculated at USD 3.84 billion in 2024, grew to USD 4.14 billion in 2025, and is projected to reach around USD 8.18 billion by 2034. The market is expanding at a CAGR of 7.85% between 2025 and 2034.</li>
1397. <li><strong>Flat Steel Market : </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg8Z8j6CphxdLuasH5CDCrJEmnCJoB20yDh3E1j4l2y1Dl9UGyoFSLJaaqFKxxt1822k-KzuttijfucOYfaa1wVGmHfUzzmDELHmBtXhN6cY4xPlgFqhoc4DAGOlgEPEWytjZzoF1iuuRuFhxk-7vOI5MchdyyEmbJVNpWvvqkOAn" rel="nofollow noopener" target="_blank" title=""><strong><u>flat steel market</u></strong></a> size accounted for USD 687.55 billion in 2024 and is predicted to increase from USD 724.33 billion in 2025 to approximately USD 1,157.84 billion by 2034, expanding at a CAGR of 5.35% from 2025 to 2034.</li>
1398. <li><strong>Green Steel Market ; </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67egyhH4To3Su8XACz7zdBa9eT8xrsGJo-E9mZZZPKVNtGEZZJyyDrR6uZhtJToU5ZbFwgAoVsFXrtRNMAXLpf487Z2n-SB1kF5DkhNMMZNPZA2KlajdksFozmpJ-ti_DXqJaiFQFRaH7gqKeRKBY8sjibx10IPFWColBBt1GR9UNtS" rel="nofollow noopener" target="_blank" title=""><strong><u>green steel-market</u></strong></a> size was valued at USD 718.55 billion in 2024, grew to USD 763.10 billion in 2025, and is expected to hit around USD 1,311.30 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.20% over the forecast period from 2025 to 2034.</li>
1399. <li><strong>Hot Rolled Coil (HRC) Steel Market ; </strong>The global <a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg3U8gnKS1MWwQ0xPfbwTKRYOuvTXzXw9qV9aYnd9taeOR_GgYZiopGB5s7_5T83S1sHtawJMv4zrQUX1AwxMLEXRctBPymjBut75pmn-BP-KxizC5P_8EoloszUbpcaETlZJyLvQWL_I3Z3C-w8t6HFA1ZDDQkgCA4HEAfg3zwABvuyhJfyBgP7g7cmiIic7f9XmILjWA1D4deAnrjOg4Ig=" rel="nofollow noopener" target="_blank" title=""><strong><u>hot rolled coil (HRC) steel market</u></strong></a> size accounted for USD 355.42 billion in 2024, grew to USD 375.86 billion in 2025, and is expected to be worth around USD 621.65 billion by 2034, poised to grow at a CAGR of 5.75% between 2025 and 2034.</li>
1400. </ul>
1401. <p><strong>U.S. Metal Recycling Market Top Key Companies:</strong></p>
1402. <ul type="disc">
1403. <li style="margin-bottom:8pt;">Schnitzer Steel Industries, Inc.</li>
1404. <li style="margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg5Z7hDvEb1RfxsCZWjrwmioQaEK9sPpYU1lztfFrb_NV-jsEAw5QvyJCOXQ8HuViDZ0GTmdIWZVYPQDU7S0jDLC2SpyOxP5eehb21HlVHTji" rel="nofollow noopener" target="_blank" title=""><strong><u>Nucor Corporation</u></strong></a></li>
1405. <li style="margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg8HjIF-2WDFVWa_S3GY0O_zWmNqTR_LQ9IcXsBpA0L1J9k_Bq3b8sTHR7kGhAx8sUxWrHmX6VWwn2P0c0XqMT3fekn4g9iSqsWPMypbW9rru1E_Zm5BPPYNpILWMz2dZVg==" rel="nofollow noopener" target="_blank" title=""><strong><u>Commercial Metals Company</u></strong></a></li>
1406. <li style="margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg4tu-onBJd_AIuypB3_BaCrQHA-qUyh3hEad_P9lWYAL1G2OMlt9zOh7NR_0QWcgIrY2Hit7u8-IbZ3XmbM1daS-ZCyCQacEwDPjeLwhnngUdbup6Kmfqx8qvyQGXyJpfA==" rel="nofollow noopener" target="_blank" title=""><strong><u>Alter Trading Corporation</u></strong></a></li>
1407. <li style="margin-bottom:8pt;">Sims Metal Management</li>
1408. <li style="margin-bottom:8pt;"><a href="https://www.globenewswire.com/Tracker?data=Gbl8ALxJ4EbN2a_3o67eg28yj8HcYfs04HtEr9Q3IxdPOmHzEBNOCg6kyFdaRBYYeL4PdAoyQyLD9moaRoUurlpiFkwgD4d_oBo9EtFi4WqFfBPN7XYCfEjxXiYFxNv4" rel="nofollow noopener" target="_blank" title=""><strong><u>Radius Recycling</u></strong></a></li>
1409. <li style="margin-bottom:8pt;">Metal Management Inc.</li>
1410. <li style="margin-bottom:8pt;">OmniSource Corporation</li>
1411. <li style="margin-bottom:8pt;">Tube City IMS</li>
1412. <li style="margin-bottom:8pt;">Philip Metals Inc.</li>
1413. <li style="margin-bottom:8pt;">Hugo Neu Corporation</li>
1414. <li style="margin-bottom:8pt;">Ferrous Processing &amp; Trading Corporation</li>
1415. <li style="margin-bottom:8pt;">Sadoff Iron &amp; Metal Company</li>
1416. <li style="margin-bottom:8pt;">Yaffe Companies, Inc.</li>
1417. <li style="margin-bottom:8pt;">Louis Padnos Iron &amp; Metal Company</li>
1418. <li style="margin-bottom:8pt;">Adams Steel, Inc.</li>
1419. <li style="margin-bottom:8pt;">Pacific Coast Recycling, Inc.</li>
1420. <li style="margin-bottom:8pt;">Azcon Corporation</li>
1421. <li style="margin-bottom:8pt;">Tennessee Valley Recycling</li>
1422. <li style="margin-bottom:8pt;">Ellis Metals, Inc.</li>
1423. </ul>
1424. <p><strong>Recent Developments </strong></p>
1425. <ul type="disc">
1426. <li style="margin-bottom:8pt;"><strong>In March 2025</strong>, in s significant industry consolidation, Toyota Tsusho America has acquired Radius Recycling for $1.34 billion, marking a 115% premium over Radius’s stock price. This acquisition is poised to enhance Toyota Tsusho’s capabilities in the U.S. recycling sector, particularly in automotive applications, by integrating Radius’s established infrastructure and expertise.</li>
1427. </ul>
1428. <p><strong>U.S. Metal Recycling Market Report Segmentation</strong></p>
1429. <p>This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. For this study, Towards Chemical and Materials has segmented the global U.S. Metal Recycling Market</p>
1430. <p><strong>By Metal Type</strong></p>
1431. <ul type="disc">
1432. <li style="margin-bottom:8pt;">Ferrous Metals</li>
1433. <li style="margin-bottom:8pt;">Steel</li>
1434. <li style="margin-bottom:8pt;">Carbon Steel</li>
1435. <li style="margin-bottom:8pt;">Stainless Steel</li>
1436. <li style="margin-bottom:8pt;">Alloy Steel</li>
1437. <li style="margin-bottom:8pt;">Iron</li>
1438. <li style="margin-bottom:8pt;">Cast Iron</li>
1439. <li style="margin-bottom:8pt;">Wrought Iron</li>
1440. <li style="margin-bottom:8pt;">Non-Ferrous Metals</li>
1441. <li style="margin-bottom:8pt;">Aluminum</li>
1442. <li style="margin-bottom:8pt;">Copper</li>
1443. <li style="margin-bottom:8pt;">Lead</li>
1444. <li style="margin-bottom:8pt;">Zinc</li>
1445. <li style="margin-bottom:8pt;">Nickel</li>
1446. <li style="margin-bottom:8pt;">Precious Metals (Gold, Silver, Platinum Group Metals)</li>
1447. </ul>
1448. <p><strong>By Recycling Method</strong></p>
1449. <ul type="disc">
1450. <li style="margin-bottom:8pt;">Mechanical Processing (Shredding, Shearing, Baling, Granulation)</li>
1451. <li style="margin-bottom:8pt;">Pyrometallurgical Processing (Smelting, Refining)</li>
1452. <li style="margin-bottom:8pt;">Hydrometallurgical Processing (Leaching, Electrowinning)</li>
1453. <li style="margin-bottom:8pt;">Biotechnological Processing (Bioleaching, Bioremediation)</li>
1454. </ul>
1455. <p><strong>By Source</strong></p>
1456. <ul type="disc">
1457. <li style="margin-bottom:8pt;">Post-Consumer Scrap (End-of-Life Vehicles, Household Appliances, Electronics)</li>
1458. <li style="margin-bottom:8pt;">Post-Industrial Scrap (Manufacturing Waste, Construction &amp; Demolition Debris)</li>
1459. <li style="margin-bottom:8pt;">Obsolete Scrap (Discarded Industrial Equipment, Retired Infrastructure Materials)</li>
1460. </ul>
1461. <p><strong>By End-User Industry</strong></p>
1462. <ul type="disc">
1463. <li style="margin-bottom:8pt;">Automotive</li>
1464. <li style="margin-bottom:8pt;">Construction</li>
1465. <li style="margin-bottom:8pt;">Electronics</li>
1466. <li style="margin-bottom:8pt;">Aerospace</li>
1467. <li style="margin-bottom:8pt;">Packaging</li>
1468. <li style="margin-bottom:8pt;">Energy</li>
1469. <li style="margin-bottom:8pt;">Consumer Goods</li>
1470. </ul>
1471. <p><strong>By Recycling Facility Type</strong></p>
1472. <ul type="disc">
1473. <li style="margin-bottom:8pt;">Integrated Mills (Mini Mills, Electric Arc Furnace Mills)</li>
1474. <li style="margin-bottom:8pt;">Recycling Centers (Material Recovery Facilities, Scrap Yards)</li>
1475. <li style="margin-bottom:8pt;">Specialized Processing Plants (Aluminum Refineries, Copper Smelters)</li>
1476. </ul>
1477. <p><strong>Immediate Delivery Available | Buy This Premium Research Report@ </strong><a href="https://www.globenewswire.com/Tracker?data=pTVBlbxZYQRPXLUQlZn7UeglwYqcA1KORWey4aOKBzLBOU5_UadYKWPVXGIDztuQ-cy4CnR6QRZtIaiFq2JxWKLll_sYO-qppOHcJoZjp_9hCfIvhYFaEmFWqKlh2RJ1pvUGniWivBbxW_0A_S-fO3YCKargAdDoNCF49XOoz8zL3dgCa6Ei8ALNLDij6-iL" rel="nofollow noopener" target="_blank" title=""><strong><u>https://www.towardschemandmaterials.com/checkout/5873</u></strong></a></p>
1478. <p><strong>About Us</strong></p>
1479. <p>Towards Chemical and Materials is a leading global consulting firm specializing in providing comprehensive and strategic research solutions across the chemical and materials industries. With a highly skilled and experienced consultant team, we offer a wide range of services designed to empower businesses with valuable insights and actionable recommendations.</p>
1480. <p><strong>Our Trusted Data Partners</strong></p>
1481. <p><a href="https://www.globenewswire.com/Tracker?data=FIUKQl_X5Vh2VL_7Kx_ELB4bAkgOOINR-_1b0BtvvmuhXE5zlnh3nZeY7ru5KdsVhnj-IDz2cpSxSDt-GRA9EcxZjqWNSubLm56PdWGZxc8-RsR-pTgsOuMoQLqHJhCM" rel="nofollow noopener" target="_blank" title=""><strong><u>Precedence Research</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=tMiCfxCwUCOQq7oLQghkpcPc4S31cpqfG3XXLqjG0h1W1MH_AHtlFaCAAvvkcMETnT5mRYfWv2J8m2dZsAvFOj2BnDWZpMwmhxDQKplQIZo=" rel="nofollow noopener" target="_blank" title=""><strong><u>Statifacts</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrAxBgZ4510AHxcuV_993Tl6_yf5XgbjLWaU8kJjmONf0nkPtL6GOYEeqNfznN7G1L2UjKx7S5dHfT0l67DSyyw8Y=" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Packaging</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrAy1pzry0GaN3FVW5MruppqijRCZHtYnhua0tTIf_mheMajvSPxiwFF8lae3VYGPV4Ed2Y_ypHrsy0bMCzsqo5lRiXTiBK2nHyYO05SjWQcsa" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Healthcare</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrA2h8fsPUceAYtQ_uCCIDYXeKM5ufTjnmuCEnzS2oUAU1ordTXAoZp6HEGMht67n4HbROvdZrW76xzbEKjnIsCCleiTvKuTxuv7N7ebph4Hxd" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Food and Beverages</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrA3y9XYG9_wok3_biJODhb27NiWsN9u3uk28igPPfgWEYEE2mZzsTLK5wKdxBKiMTEKjCXwyRfmR7VMJjYOUJp_sI3Lx9tQ3YHQpPFEr1fdwi" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Automotive</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=FlVk2fDLUPsBn1vQkQQrAw9CJDkH6J405ntNqPPtIliEaxj6xIXmliZEdfocItBkcR5H1IF0fSMSexxaP7nQiV0hLLGA8bxi_xsieZHl_vLXN6eODaxEIuwT_MLWXXJR" rel="nofollow noopener" target="_blank" title=""><strong><u>Towards Consumer Goods</u></strong></a><strong> | </strong><a href="https://www.globenewswire.com/Tracker?data=M2DmOWa1z4GqFS51XXadIodCYGrgvd2_0brUD0SFbQhAfzSKXAIXnRqTInrdoCyRo17jjSDgjkW81kcH-QzrADj8WkkA15H1H4SBPS3xLgE=" rel="nofollow noopener" target="_blank" title=""><strong><u>Nova One Advisor</u></strong></a><strong> | </strong></p>
1482. <p><strong>For Latest Update Follow Us: </strong><a href="https://www.globenewswire.com/Tracker?data=pTVBlbxZYQRPXLUQlZn7UQrzRRQK0EJrYniA6Jr2utX3apQQqPThvtnvsIRC0LyNtzhE6z9RqTovRXradlUWvOJd88Ln9DtF-D04COh7Qaqet-oS9_L-qo4hS4JpInzcEA9yw-Y3MYHA7AQIW8TnetW7YhVSWjWg1VwETeYAfQq09WlRn-W0IIcpEL-B5L4_gvx2ZePKOnqzj9XP_lafMQ==" rel="nofollow noopener" target="_blank" title=""><strong><u>https://www.linkedin.com/company/towards-chem-and-materials/</u></strong></a></p>
1483. <p><strong>USA: +1 804 441 9344</strong></p>
1484. <p><strong>APAC: +61 485 981 310 or +91 87933 22019</strong></p>
1485. <p><strong>Europe: +44 7383 092 044</strong></p>
1486. <p><strong>Email: </strong><a href="https://www.globenewswire.com/Tracker?data=t7pOHoTUxydsyW2gDtnPjqD3Gr1dJqvIulXA-T8hR702Mxx9DzcOAwg581FH1a0VZb-rivBaAtQbNiLxU7o_BIEAUyG_gs-HsqOucNI1LN55HuaMkGuH_QlZ-KQPb8rlXyWfAtboH57kbz9YagJi5A==" rel="nofollow noopener" target="_blank" title=""><strong><u>sales@towardschemandmaterials.com</u></strong></a></p>
1487. <p><strong>Web: </strong><a href="https://www.globenewswire.com/Tracker?data=pTVBlbxZYQRPXLUQlZn7UeglwYqcA1KORWey4aOKBzLBOU5_UadYKWPVXGIDztuQIKg07BtOJ4jc9p1GRS91O8E8EViS7rPrXE0h-pTnFMbgcZ5d8ZZLJbeBRcrmQqWPNcWJM7NDto9j6Hmt4KXH1w==" rel="nofollow noopener" target="_blank" title=""><strong><u>https://www.towardschemandmaterials.com/</u></strong></a></p>
1488. <p><img alt="" src='https://ml.globenewswire.com/media/Y2Q1ZDcxMjAtZmYzYS00Y2VmLWEwZGItNWE0YjIwZjhlOTE3LTEyMTM4NDktMjAyNS0xMC0xMy1lbg==/tiny/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
1489. ]]></content:encoded>
1493. </item>
1494. <item>
1495. <title>Global Pet Insurance Market Set to Surpass USD 29.80 Billion by 2030 &#124; MarketsandMarkets™</title>
1496. <link>https://singaporeoutlook.com/global-pet-insurance-market-set-to-surpass-usd-29-80-billion-by-2030-marketsandmarkets-30157/</link>
1498. <dc:creator><![CDATA[Globenewswire]]></dc:creator>
1499. <pubDate>Mon, 13 Oct 2025 14:30:00 +0000</pubDate>
1500. <category><![CDATA[Brand Post]]></category>
1501. <guid isPermaLink="false">https://www.globenewswire.com/news-release/2025/10/13/3165629/0/en/Global-Pet-Insurance-Market-Set-to-Surpass-USD-29-80-Billion-by-2030-MarketsandMarkets.html3165629</guid>
1502.  
1503. <description><![CDATA[Industry growth fueled by consumer demand, escalating veterinary expenses, and digital-first insurance innovation Delray Beach, FL, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global pet insurance market, valued at US$12.51 billion in 2024, stood at US$14.35 billion in 2025 and is projected to advance at a resilient CAGR of 15.7% from 2025 to 2030, culminating [&#8230;]]]></description>
1504. <content:encoded><![CDATA[<p><em>Industry growth fueled by consumer demand, escalating veterinary expenses, and digital-first insurance innovation</em></p>
1505. <p>Delray Beach, FL, Oct. 13, 2025 (GLOBE NEWSWIRE) &#8212; The global <a href="https://www.globenewswire.com/Tracker?data=aZJUdWeHH0yLBgwhdvZpPnOmzvtID5XP-VdFNvBvJAbJhI6gHSfHWOOsJfxfjzhnUgMdf1BbcS-60AaN1xPmwMueE0xneFZDgF3GLvrsy9W1tz7AO2FuXUdk1_xVklF1ox4tSC4wwyOgs45MDzGnKZONBaM3xLlCwLjRv2XtqskUZd_ngBVU904_yvlbrE5fGlZPYPuYkNKFAvOGc1yMdaloccBM_7hnHgimWofVJJcpsjgfZJG0QQUZKwXNXD4dB8JGU5WZnNpHhc9ETSeZkrQpUWVrpy52tDK_AYkaZUA=" rel="nofollow noopener" target="_blank" title=""><b>pet insurance market</b></a>, valued at US$12.51 billion in 2024, stood at US$14.35 billion in 2025 and is projected to advance at a resilient CAGR of 15.7% from 2025 to 2030, culminating in a forecasted valuation of US$29.80 billion by the end of the period. This acceleration reflects a structural shift in how pet owners worldwide approach animal healthcare and financial protection.</p>
1506. <p><b>Download PDF Brochure: </b><a href="https://www.globenewswire.com/Tracker?data=8LWztPtll8dXBiERvTFRjADI3g6n3gsmjBNQEaCS4T4b2nRZEQM-VxTUvLmzlud9Y-KYEOSYGxkWi5RSCsnxm3t2I0HidqTWyjzX-X2eMHxeFKGF2dMwvGKCxdnCmgYPFdtPDNu1061VZtPhkK-Ayg9DTMOHPrkBmFiIDGwRljVlKeXpjw6mgaqh4l92t9FRR-OR-BvyedLTsLAGAUSilde3LcXAS0LAPE1VGcSg0AdFV5nlMTBSPmIUTf8epBMRGaafyDQ8ognTijVaC8VJTf65E2a4AwlYOXZcJlbb0NeFYuN052oVeSmlrHdD97Sr" rel="nofollow noopener" target="_blank" title=""><b>https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=884</b></a></p>
1507. <p><b>What is Driving Market Growth?</b><br />At the core of this expansion is the rise in pet ownership, particularly among urban and high-income households where pets are increasingly treated as family members. Owners are seeking comprehensive insurance policies that cover not only accidents and illnesses but also preventive care. Rising veterinary expenses—spanning diagnostics, surgeries, and chronic disease management—have further heightened the demand for financial safeguards.</p>
1508. <p><b>Why Does It Matter Now?</b><br />The timing is critical: as veterinary costs climb and healthcare innovations extend pet lifespans, owners face growing financial exposure. Employers are also integrating pet coverage into voluntary benefits packages, signaling recognition of pets’ importance in employee well-being and retention strategies. For insurers and corporate partners, this creates new growth opportunities through bundled offerings, embedded models, and insurtech-led digital platforms.</p>
1509. <p><b>Where Are the Opportunities?</b></p>
1510. <ul type="disc">
1511. <li style="margin-top:0cm; margin-bottom:0cm;">Embedded insurance: Integration at point-of-purchase—whether at veterinary clinics, adoption agencies, or retail platforms—is unlocking new distribution channels and lowering adoption barriers.</li>
1512. <li style="margin-top:0cm; margin-bottom:0cm;">AI and machine learning: Insurers are leveraging advanced analytics to personalize coverage, expedite claims, and improve underwriting efficiency.</li>
1513. <li style="margin-top:0cm; margin-bottom:0cm;">Emerging markets: Rising middle-class pet ownership in Asia-Pacific is set to deliver the highest CAGR globally, creating a new frontier for expansion.</li>
1514. </ul>
1515. <p><b>Request Sample Pages : </b><a href="https://www.globenewswire.com/Tracker?data=8LWztPtll8dXBiERvTFRjADI3g6n3gsmjBNQEaCS4T5CVrRpT7oibJw7erEz6awbMSk6hOfcYaYuNYTIuBTG2Wo-2RMdKWlQDWCEBcIjxm26ZaDStPBvW5byWpNxWp3OXVxJzAhAga3ovJg6jw3ZOdLQzCz9oww52jVVSvM3SxxlvXpy4pEkHV9g7wHmzJRI_MyDOOFwj3AcJi5SqJyB0nRvcrqHiBWcaGafEtSaq7wDJ7CH052mg-054AH1orlLoZ7nDXbu9Yd0QUBtx2qtZ3r1eJ4N2DugQIdHzauNveVpfcyzRFi8SejPejQ4g4GE" rel="nofollow noopener" target="_blank" title=""><b>https://www.marketsandmarkets.com/requestsampleNew.asp?id=884</b></a></p>
1516. <p><b>Who Are the Market Leaders?</b><br />The competitive landscape features Trupanion (US), Nationwide (US), Pet Plan Limited (UK), Anicom Holdings, Inc. (Japan), and Healthy Paws (US) among the top five global players. Other significant participants include Pets Best, Pumpkin, Spot, Figo, Agria, ASPCA, Embrace, and Getsafe. These companies are actively expanding portfolios, launching new products, and forming cross-industry partnerships to capture market share.</p>
1517. <p><b>How Is the Market Evolving?</b></p>
1518. <ul type="disc">
1519. <li style="margin-top:0cm; margin-bottom:0cm;">Claims Processing Challenges: Despite growth, inefficiencies in claims reimbursement remain a significant hurdle, impacting customer trust and satisfaction.</li>
1520. <li style="margin-top:0cm; margin-bottom:0cm;">Policy Exclusions: The exclusion of pre-existing conditions continues to deter adoption among owners of older or chronically ill pets.</li>
1521. <li style="margin-top:0cm; margin-bottom:0cm;">Regional Dynamics: Europe currently commands the largest market share, driven by strong cultural emphasis on animal welfare and established insurance frameworks. In contrast, Asia-Pacific will record the fastest growth, reflecting both economic development and increasing pet adoption rates.</li>
1522. </ul>
1523. <p><b>Recent Strategic Developments</b></p>
1524. <ul type="disc">
1525. <li style="margin-top:0cm; margin-bottom:0cm;">Healthy Paws (US) partnered with Combined Insurance (June 2025) to include pet insurance in employer benefit packages.</li>
1526. <li style="margin-top:0cm; margin-bottom:0cm;">Pumpkin Insurance (US) launched PumpkinNow (April 2025), enabling near-instant reimbursement of veterinary expenses.</li>
1527. <li style="margin-top:0cm; margin-bottom:0cm;">Pets Best (US) integrated with Bindable (October 2024), enhancing digital distribution.</li>
1528. <li style="margin-top:0cm; margin-bottom:0cm;">Trupanion (US) entered Germany and Switzerland (September 2024) to tap into a market of over 29 million pets.</li>
1529. <li style="margin-top:0cm; margin-bottom:0cm;">Nationwide (US) launched Unum Pet Insurance (May 2024), expanding its employee benefits suite.</li>
1530. </ul>
1531. <p><b>Strategic Insights for Executives</b><br />For insurers, the message is clear: speed, transparency, and integration will define the next phase of competition. Employers and benefits providers have an opportunity to differentiate talent strategies by offering pet insurance as a wellness benefit. Meanwhile, investors and industry stakeholders should note the market’s trajectory mirrors broader insurance sector transformations, where digital-first distribution and consumer-centric design are non-negotiable growth levers.</p>
1532. <p>For more information, <a href="https://www.globenewswire.com/Tracker?data=0zSYGvGdUnVyIdr9bbf3lCsK1p7w5YEt8_SKnLTidVktiKsmceoG-WMOlLbiXwigtDwyBLZhl_fY9KJr6tf0oQK8ip60SJraMq98POBl3883QBQYOCkaB4pGeIE5cdJYdJiifTg3CuZFkhSc3h93FEK3tV1Xkp-Ny7_WuwN5txlAlw1V4Sw8QFt4a5fUeF3ymfodY0dP4QKZbkkEY-P-wJK4WEjQfFx675yIk18VFDpTRc36Q1iDsmLN936QK0DNbkFrg5eIvtEN1KSTcoxACg==" rel="nofollow noopener" target="_blank" title=""><b>Inquire Now!</b></a></p>
1533. <p><b>Discover Connected Healthcare Market Opportunities:</b><br /><a href="https://www.globenewswire.com/Tracker?data=EgqH0j7vW388x9cIMaW_alkO4ClI-pa4sSFVMI5t5IhxWGlEp3-VkA1yGovMpNehZiGovqtjsSpacWAH6iDB80eeKjUQtQN3j_sQwNNul4dVRNWfQgu76-yRai1UeEv7YVVILf9hIWuIVS1h4linBIWiEyjtooNlSOeL0gXrUo6aMTaWuhmcZEKCB7UzkBRWYBQsf4VfITD-OqBui1IQ_X-jfzgy5gIGqpZEg1FFjDpHcTlLkXkgb95gBs4KRUuRt5U9dA-Cb5CyPaM3BiCxoZ6W52Eyn0C0o5_mgY2sQbehSVTQDUPfbqA1we_vbMna" rel="nofollow noopener" target="_blank" title="Veterinary Diagnostics Market">Veterinary Diagnostics Market</a><br /><a href="https://www.globenewswire.com/Tracker?data=Z_aes6DwGB40h85NTpjdKkSI9n9aa2m9_ZDnkuUMAECMSFR5wf762jboNsFlcpE_5VaWnVc96Stu_iDwZ8PDW7-QR_Xj-RW_dh5w1lo9t5OFl9KGdbkFF4hXznMEvEnm_za4GJBm2XtnhkGcHXp74NvSPI3P_e7ZAX6tB7HlAx-23xuxvGCvyNxTSSfKq0uWp3FHAGybX5ROnxVk5wnvrN6Z0Drz1sIytukipNzWi2dzHp38RwVRDjx5_X034X-leQ7hI2eGiLz33-yC1FErauWqrY_RaOX0KjmEXwMFIHrcQOe2tuT9hp7sVhW1tIWk0UveoMZDhmJMQJFKdlK_6w==" rel="nofollow noopener" target="_blank" title="Companion Animal Diagnostics Market">Companion Animal Diagnostics Market</a><br /><a href="https://www.globenewswire.com/Tracker?data=EgqH0j7vW388x9cIMaW_avPR2RKGZIJ4PpJLY5GqzS4bEfy3zrpGVdEElR0Na4ejxNv6o7TIDOsWpzaWxHyEshbXgV0rqpSC74c2xCYy4UHLZ3DLP5-A0Fp8wFvQz4qnfHK4N-K4d0Ep2dNA6BJNZ014ijPb-iZwcgjmvR7q9rlhAkglik04k62LsJOPs1xf0p7X7Mjv4wfn29m3vRJJg8wWw6tZDqZO7FgOPaD44PWABYxn877Mlb0yEj0fsgw7UXv9_ObRvqRFBuq9B2aYjofJs3hmtImt40OMD9mrpT0Flin_cPWTNYZ1ZdOF7H8r-_WcnSvNG7UABksRMJ1qhDC9mFnbeVTPdbErPi8r8rdBFtj9dfSZTvKjjLqL5GSB" rel="nofollow noopener" target="_blank" title="Veterinary Infectious Disease Diagnostics Market">Veterinary Infectious Disease Diagnostics Market</a><br /><a href="https://www.globenewswire.com/Tracker?data=EgqH0j7vW388x9cIMaW_ah9IGf7uIifn25DaaTy81o2NLfzHcMg0IzqE5kA4e7G6_-dr37JbIm3SnucFbnE3pUof0hLeXRNafewGvzPc5woZg0dk8-swBdMfj0Pt4V0Re3tKj3zzXfyv8e9DN9zIzGMOQGMSZmBjRyGkIaZslV6a-65nyyR3g2mRk_o_f_Pv7-QKdWf6RykP5wsVfUbtu6Og1__ZeAZKKaDaDuYMjLVXwOEBdmXmZasDePmVK8PsDMESjaUIwlQmQU-gbOV0XMUHy0qpP7w7NJIxIl8pvDCaf-hcjIy8KhGR-qNZ-nHEuYUSmIfkRsShnb5WwqGqpw==" rel="nofollow noopener" target="_blank" title="Veterinary Ultrasound Market">Veterinary Ultrasound Market</a><br /><a href="https://www.globenewswire.com/Tracker?data=EgqH0j7vW388x9cIMaW_auh2wIPIR0ReAFX4ou1QLwsE55NbYDupnDMIbxA0XrdBVu4BE4-CimuhyM21SllEheYoApgep31vX06w6C0dYWZAnNWEW_diBOP96I-nqy3__crM_DkWjBGWgsAasIou7_3kIQhfKJc_eqqo9MQLjX-3xx_PYRib9Q56bCZG_NCGbaVHY_S_zPxy-_3IWVGiyFVtDg4U4tBwagK3C8nBeNyuewLqEI2Hsl1d2Pp70De_DeSBygECEU2_PYhjGfZEUDyRkna6JQYSHRxFcAXqO7HJsnGi-k6fq833Vv3hfxwL_VzibXQz09N2NzkdkrxvsA==" rel="nofollow noopener" target="_blank" title="Veterinary Reference Laboratory Market">Veterinary Reference Laboratory Market</a></p>
1534. <p>Get access to the latest updates on <a href="https://www.globenewswire.com/Tracker?data=3dTeOc0JPUpwo88WFGndnRslw8cYd5BtAZRqsUJMjALD4rwwRRSn_8TjHbpxGt7CDKywF3zQIA_hvFaklDIOOsLG7Yz8-vVI4TxdeN2Y2rq6ZWhoo43zuAT8SlAxCewMZwrqOCgYD4kha4zWwd_WvsDRn4iOr6PsqtKy2wgUh_ixE5v8FSgbSL_vBmPL9t1uSOg36W4RSp3u_NHk1z8eXBte02B8g97btOVKW4H3h8eBRy_ULS92OuQF_eINxkdP2SvVyUNW1Hmy8X9ZT7VOkLAETu1rUH6CsfPdogsOLWkBxE7N025KX_PK69moeKmL" rel="nofollow noopener" target="_blank" title=""><b>Top Companies in Pet Insurance</b></a> and <a href="https://www.globenewswire.com/Tracker?data=VTGTQNQtsYEWAfe_d4dDXosp3rABOXYgR8n1VWgEOCBN5cP62bEB_IoUFvR71aIiUb72WLAz-qP1pGb3PtnC1KJOx58Kwz2R0EMoFfgluanKYjxJZiIo7Lfv1ye9XMpYaaKXmrkCjdtlI_sY1F8Is4Rc4juLiPNhPSOEaXooQ0fmy8KN-vDnONwFgVD3Zm7szpK3CWJHE277CaV17H6wITCe6qWDZUKsYokg0tYTQFDSWFFE3E7PatGcEY2xfzbO1MMrSOqU2R2h7ZdzTvTogMSJtOQ30adQBJc22VHoeXc=" rel="nofollow noopener" target="_blank" title=""><b>Pet Insurance Market Size</b></a></p>
1535. <pre>CONTACT: About MarketsandMarkets&#x2122; MarketsandMarkets&#x2122; has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets&#x2122; is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore&#x2122;, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets&#x2122;.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets&#x2122; INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.com</pre>
1536. <p><img alt="" src='https://ml.globenewswire.com/media/YTFhYzdkNTMtYmNhYS00MTY4LTg1YjEtZWM2MGZjOGJhZGU0LTEyMDYwNjctMjAyNS0xMC0xMy1lbg==/tiny/MarketsandMarkets-Research-Pvt.png' referrerpolicy='no-referrer-when-downgrade' /> Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.</p>
1537. ]]></content:encoded>
1541. </item>
1542. </channel>
1543. </rss>
1544.  

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

1. Download the "valid RSS" banner.

2. Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)

3. Add this HTML to your page (change the image src attribute if necessary):

   <a href="http://www.feedvalidator.org/check.cgi?url=https%3A//singaporeoutlook.com/feed/"><img src="valid-rss-rogers.png" alt="[Valid RSS]" title="Validate my RSS feed" /></a>

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//singaporeoutlook.com/feed/

Home · About · News · Docs · Terms